Compounds and methods for the diagnosis and treatment of ehrlichia infection

Abstract

Compounds and methods for the diagnosis and treatment of Ehrlichia infection, in particular human granulocytic ehrlichiosis, are disclosed. The compounds provided include polypeptides that contain at least one antigenic portion of an Ehrlichia antigen and DNA sequences encoding such polypeptides. Pharmaceutical compositions and vaccines comprising such polypeptides or DNA sequences are also provided. Diagnostic kits containing such polypeptides or DNA sequences and a suitable detection reagent may be used for the detection of Ehrlichia infection in patients and biological samples. Antibodies directed against such polypeptides are also provided.

Description

TECHNICAL FIELD

The present invention relates generally to the detection and treatment of Ehrlichia infection. In particular, the invention is related to polypeptides comprising an Ehrlichia antigen and the use of such polypeptides for the serodiagnosis and treatment of Human granulocytic ehrlichiosis (HGE).

BACKGROUND OF THE INVENTION

Human granulocytic ehrlichiosis (HGE) is an illness caused by a rodent bacterium which is generally transmitted to humans by the same tick that is responsible for the transmission of Lyme disease and babesiosis, thereby leading to the possibility of co-infection with Lyme disease, babesiosis and HGE from a single tick bite. The bacterium that causes HGE is believed to be quite widespread in parts of the northeastern United States and has been detected in parts of Europe. While the number of reported cases of HGE infection is increasing rapidly, infection with Ehrlichia, including co-infection with Lyme disease, often remains undetected for extended periods of time. HGE is a potentially fatal disease, with the risk of death increasing if appropriate treatment is delayed beyond the first few days after symptoms occur. In contrast, deaths from Lyme disease and babesiosis are relatively rare.

The preferred treatments for HGE, Lyme disease and babesiosis are different, with penicillins, such as doxycycline and amoxicillin, being most effective in treating Lyme disease, anti-malarial drugs being preferred for the treatment of babesiosis and tetracycline being preferred for the treatment of ehrlichiosis. Accurate and early diagnosis of Ehrlichia infection is thus critical but methods currently employed for diagnosis are problematic.

All three tick-borne illnesses share the same flu-like symptoms of muscle aches, fever, headaches and fatigue, thus making clinical diagnosis difficult. Microscopic analysis of blood samples may provide false-negative results when patients are first seen in the clinic. The only tests currently available for the diagnosis of HGE infection are indirect fluorescent antibody staining methods for total immunoglobulins to Ehrlichia causative agents and polymerase chain reaction (PCR) amplification tests. Such methods are time-consuming, labor-intensive and expensive. There thus remains a need in the art for improved methods for the detection of Ehrlichia infection, particularly as related to HGE. The present invention fulfills this need and further provides other related advantages.

SUMMARY OF THE INVENTION

The present invention provides compositions and methods for the diagnosis and treatment of Ehrlichia infection and, in particular, for the diagnosis and treatment of HGE. In one aspect, polypeptides are provided comprising an immunogenic portion of an Ehrlichia antigen, particularly one associated with HGE, or a variant of such an antigen that differs only in conservative substitutions and/or modifications. In one embodiment, the antigen comprises an amino acid sequence encoded by a DNA sequence selected from the group consisting of (a) sequences recited in SEQ ID NO: 1-3, 5, 7, 16, 20, 34, 39-49; (b) the complements of said sequences; and (c) sequences that hybridize to a sequence of (a) or (b) under moderately stringent conditions.

In another aspect, the present invention provides an antigenic epitope of an Ehrlichia antigen comprising an amino acid sequence selected from the group consisting of sequences recited in SEQ ID NO: 30 and 51, together with polypeptides comprising at least two such antigenic epitopes, the epitopes being contiguous.

In a related aspect, DNA sequences encoding the above polypeptides, recombinant expression vectors comprising one or more of these DNA sequences and host cells transformed or transfected with such expression vectors are also provided.

In another aspect, the present invention provides fusion proteins comprising either a first and a second inventive polypeptide, a first and a second inventive antigenic epitope, or, alternatively, an inventive polypeptide and an inventive antigenic epitope.

In further aspects of the subject invention, methods and diagnostic kits are provided for detecting Ehrlichia infection in a patient. In one embodiment, the method comprises: (a) contacting a biological sample with at least one of the above polypeptides, antigenic epitopes or fusion proteins; and (b) detecting in the sample the presence of antibodies that bind to the polypeptide, antigenic epitope or fusion protein, thereby detecting Ehrlichia infection in the biological sample. Suitable biological samples include whole blood, sputum, serum, plasma, saliva, cerebrospinal fluid and urine. The diagnostic kits comprise one or more of the above polypeptides, antigenic epitopes or fusion proteins in combination with a detection reagent.

The present invention also provides methods for detecting Ehrlichia infection comprising: (a) obtaining a biological sample from a patient; (b) contacting the sample with at least two oligonucleotide primers in a polymerase chain reaction, at least one of the oligonucleotide primers being specific for a DNA sequence encoding the above polypeptides; and (c) detecting in the sample a DNA sequence that amplifies in the presence of the oligonucleotide primers. In one embodiment, the oligonucleotide primer comprises at least about 10 contiguous nucleotides of a DNA sequence encoding the above polypeptides.

In a further aspect, the present invention provides a method for detecting Ehrlichia infection in a patient comprising: (a) obtaining a biological sample from the patient; (b) contacting the sample with an oligonucleotide probe specific for a DNA sequence encoding the above polypeptides; and (c) detecting in the sample a DNA sequence that hybridizes to the oligonucleotide probe. In one embodiment, the oligonucleotide probe comprises at least about 15 contiguous nucleotides of a DNA sequence encoding the above polypeptides.

In yet another aspect, the present invention provides antibodies, both polyclonal and monoclonal, that bind to the polypeptides described above, as well as methods for their use in the detection of Ehrlichia infection.

In further aspects, the present invention provides methods for detecting either Ehrlichia infection, Lyme disease or B. microti infection in a patient. Such inventive methods comprise (a) obtaining a biological sample from the patient; (b) contacting the sample with (i) at least one of the inventive polypeptides, antigenic epitopes or fusion proteins, (ii) a known Lyme disease antigen and (iii) a known B. microti antigen; and (b) detecting in the sample the presence of antibodies that bind to the inventive polypeptide, antigenic epitope or fusion protein, the known Lyme disease antigen or the known B. microti antigen, thereby detecting either Ehrlichia infection, Lyme disease or B. microti infection in the patient.

Within other aspects, the present invention provides pharmaceutical compositions that comprise one or more of the above polypeptides or antigenic epitopes, or a DNA molecule encoding such polypeptides, and a physiologically acceptable carrier. The invention also provides vaccines comprising one or more of the inventive polypeptides or antigenic epitopes and a non-specific immune response enhancer, together with vaccines comprising one or more DNA sequences encoding such polypeptides and a non-specific immune response enhancer.

In yet another aspect, methods are provided for inducing protective immunity in a patient, comprising administering to a patient an effective amount of one or more of the above pharmaceutical compositions or vaccines.

These and other aspects of the present invention will become apparent upon reference to the following detailed description and attached drawings. All references disclosed herein are hereby incorporated by reference in their entirety as if each was incorporated individually.

BRIEF DESCRIPTION OF THE DRAWINGS AND SEQUENCE IDENTIFIERS

FIG. 1 shows the results of Western blot analysis of representative Ehrlichia antigens of the present invention.

FIGS. 2A and B show the reactivity of purified recombinant Ehrlichia antigens HGE-1 and HGE-3, respectively, with sera from HGE-infected patients, babesiosis-infected patients, Lyme-disease infected patients and normal donors as determined by Western blot analysis.

SEQ ID NO:1 is the determined DNA sequence of HGE-1.
SEQ ID NO:2 is the determined DNA sequence of HGE-3.
SEQ ID NO:3 is the determined DNA sequence of HGE-6.
SEQ ID NO:4 is the determined 5′ DNA sequence of HGE-7.
SEQ ID NO:5 is the determined DNA sequence of HGE-12.
SEQ ID NO:6 is the determined DNA sequence of HGE-23.
SEQ ID NO:7 is the determined DNA sequence of HGE-24.
SEQ ID NO:8 is the predicted protein sequence of HGE-1.
SEQ ID NO:9 is the predicted protein sequence of HGE-3.
SEQ ID NO:10 is the predicted protein sequence of HGE-6.
SEQ ID NO:11 is the predicted protein sequence of HGE-7.
SEQ ID NO:12 is the predicted protein sequence of HGE-12.
SEQ ID NO:13 is the predicted protein sequence of HGE-23.
SEQ ID NO:14 is the predicted protein sequence of HGE-24.
SEQ ID NO:15 is the determined 5′ DNA sequence of HGE-2.
SEQ ID NO:16 is the determined DNA sequence of HGE-9.
SEQ ID NO:17 is the determined DNA sequence of HGE-14.
SEQ ID NO:18 is the determined 5′ DNA sequence of HGE-15.
SEQ ID NO:19 is the determined 5′ DNA sequence of HGE-16.
SEQ ID NO:20 is the determined 5′ DNA sequence of HGE-17.
SEQ ID NO:21 is the determined 5′ DNA sequence of HGE-18.
SEQ ID NO:22 is the determined 5′ DNA sequence of HGE-25.
SEQ ID NO:23 is the predicted protein sequence of HGE-2.
SEQ ID NO:24 is the predicted protein sequence of HGE-9.
SEQ ID NO:25 is the predicted protein sequence of HGE-14.
SEQ ID NO:26 is the predicted protein sequence of HGE-18.
SEQ ID NO:27 is the predicted protein sequence from the reverse complement of
HGE-14.
SEQ ID NO:28 is the predicted protein sequence from the reverse complement of
HGE-15.
SEQ ID NO:29 is the predicted protein sequence from the reverse complement of
HGE-18.
SEQ ID NO:30 is a 41 amino acid repeat sequence from HGE-14.
SEQ ID NO:31 is the determined DNA sequence of HGE-11.
SEQ ID NO:32 is the predicted protein sequence of HGE-11.
SEQ ID NO:33 is the predicted protein sequence from the reverse complement of
HGE-11.
SEQ ID NO:34 is the determined DNA sequence of HGE-13.
SEQ ID NO:35 is the predicted protein sequence of HGE-13.
SEQ ID NO:36 is the determined DNA sequence of HGE-8.
SEQ ID NO:37 is the predicted protein sequence of HGE-8.
SEQ ID NO:38 is the predicted protein sequence from the reverse complement of
HGE-8.
SEQ ID NO:39 is the extended DNA sequence of HGE-2.
SEQ ID NO:40 is the extended DNA sequence of HGE-7.
SEQ ID NO:41 is the extended DNA sequence of HGE-8.
SEQ ID NO:42 is the extended DNA sequence of HGE-11.
SEQ ID NO:43 is the extended DNA sequence of HGE-14.
SEQ ID NO:44 is the extended DNA sequence of HGE-15.
SEQ ID NO:45 is the extended DNA sequence of HGE-16.
SEQ ID NO:46 is the extended DNA sequence of HGE-18.
SEQ ID NO:47 is the extended DNA sequence of HGE-23.
SEQ ID NO:48 is the extended DNA sequence of HGE-25.
SEQ ID NO:49 is the determined 3′ DNA sequence of HGE-17.
SEQ ID NO:50 is the extended predicted protein sequence of HGE-2.
SEQ ID NO:51 is the amino acid repeat sequence of HGE-2.
SEQ ID NO:52 is a second predicted protein sequence of HGE-7.
SEQ ID NO:53 is a third predicted protein sequence of HGE-7.
SEQ ID NO:54 is a second predicted protein sequence of HGE-8.
SEQ ID NO:55 is a third predicted protein sequence of HGE-8.
SEQ ID NO:56 is a fourth predicted protein sequence of HGE-8.
SEQ ID NO:57 is a fifth predicted protein sequence of HGE-8.
SEQ ID NO:58 is a second predicted protein sequence of HGE-11.
SEQ ID NO:59 is a third predicted protein sequence of HGE-11.
SEQ ID NO:60 is a second predicted protein sequence from the reverse complement
of HGE-14.
SEQ ID NO:61 is a third predicted protein sequence from the reverse complement of
HGE-14.
SEQ ID NO:62 is a first predicted protein sequence of HGE-15.
SEQ ID NO:63 is a second predicted protein sequence of HGE-15.
SEQ ID NO:64 is a second predicted protein sequence from the reverse complement
of HGE-15.
SEQ ID NO:65 is the predicted protein sequence of HGE-16.
SEQ ID NO:66 is a first predicted protein sequence from the reverse complement of
HGE-17.
SEQ ID NO:67 is a second predicted protein sequence from the reverse complement
of HGE-17.
SEQ ID NO:68 is a second predicted protein sequence from the reverse complement
of HGE-18.
SEQ ID NO:69 is a third predicted protein sequence from the reverse complement of
HGE-18.
SEQ ID NO:70 is a fourth predicted protein sequence from the reverse complement of
HGE-18.
SEQ ID NO:71 is a second predicted protein sequence of HGE-23.
SEQ ID NO:72 is a third predicted protein sequence of HGE-23.
SEQ ID NO:73 is the predicted protein sequence of HGE-25.
SEQ ID NO:74-79 are primers used in the preparation of a fusion protein containing
HGE-9, HGE-3 and HGE-1.

DETAILED DESCRIPTION OF THE INVENTION

As noted above, the present invention is generally directed to compositions and methods for the diagnosis and treatment of Ehrlichia infection, in particular HGE. In one aspect, the compositions of the subject invention include polypeptides that comprise at least one immunogenic portion of an Ehrlichia antigen, or a variant of such an antigen that differs only in conservative substitutions and/or modifications.

As used herein, the term “polypeptide” encompasses amino acid chains of any length, including full length proteins (i.e., antigens), wherein the amino acid residues are linked by covalent peptide bonds. Thus, a polypeptide comprising an immunogenic portion of one of the above antigens may consist entirely of the immunogenic portion, or may contain additional sequences. The additional sequences may be derived from the native Ehrlichia antigen or may be heterologous, and such sequences may (but need not) be immunogenic.

An “immunogenic portion” of an antigen is a portion that is capable of reacting with sera obtained from an Ehrlichia-infected individual (i.e., generates an absorbance reading with sera from infected individuals that is at least three standard deviations above the absorbance obtained with sera from uninfected individuals, in a representative ELISA assay described herein). Such immunogenic portions generally comprise at least about 5 amino acid residues, more preferably at least about 10, and most preferably at least about 20 amino acid residues. Methods for preparing and identifying immunogenic portions of antigens of known sequence are well known in the art and include those summarized in Paul, Fundamental Immunology, 3 rd ed., Raven Press, 1993, pp. 243-247. Polypeptides comprising at least an immunogenic portion of one or more Ehrlichia antigens as described herein may generally be used, alone or in combination, to detect HGE in a patient.

The compositions and methods of the present invention also encompass variants of the above polypeptides and DNA molecules. Such variants include, but are not limited to, naturally occurring allelic variants of the inventive sequences.

A polypeptide “variant,” as used herein, is a polypeptide that differs from the recited polypeptide only in conservative substitutions and/or modifications, such that the antigenic properties of the polypeptide are retained. Such variants may generally be identified by modifying one of the above polypeptide sequences, and evaluating the antigenic properties of the modified polypeptide using, for example, the representative procedures described herein. Polypeptide variants preferably exhibit at least about 70%, more preferably at least about 90% and most preferably at least about 95% identity to the identified polypeptides. The identity of polypeptides may be determined by comparing sequences using computer algorithms well known to those of skill in the art, such as Megalign, using default parameters.

As used herein, a “conservative substitution” is one in which an amino acid is substituted for another amino acid that has similar properties, such that one skilled in the art of peptide chemistry would expect the secondary structure and hydropathic nature of the polypeptide to be substantially unchanged. In general, the following groups of amino acids represent conservative changes: (1) ala, pro, gly, glu, asp, gln, asn, ser, thr; (2) cys, ser, tyr, thr; (3) val, ile, leu, met, ala, phe; (4) lys, arg, his; and (5) phe, tyr, trp, his.

Variants may also, or alternatively, contain other modifications, including the deletion or addition of amino acids that have minimal influence on the antigenic properties, secondary structure and hydropathic nature of the polypeptide. For example, a polypeptide may be conjugated to a signal (or leader) sequence at the N-terminal end of the protein which co-translationally or post-translationally directs transfer of the protein. The polypeptide may also be conjugated to a linker or other sequence for ease of synthesis, purification or identification of the polypeptide (e.g., poly-His), or to enhance binding of the polypeptide to a solid support. For example, a polypeptide may be conjugated to an immunoglobulin Fc region.

A nucleotide “variant” is a sequence that differs from the recited nucleotide sequence in having one or more nucleotide deletions, substitutions or additions. Such modifications may be readily introduced using standard mutagenesis techniques, such as oligonucleotide-directed site-specific mutagenesis as taught, for example, by Adelman et al. ( DNA, 2:183, 1983). Nucleotide variants may be naturally occurring allelic variants, or non-naturally occurring variants. Variant nucleotide sequences preferably exhibit at least about 70%, more preferably at least about 80% and most preferably at least about 90% identity to the recited sequence. The identity of nucleotide sequences may be determined by comparing sequences using computer algorithms well known to those of skill in the art, such as Megalign, using default parameters.

In specific embodiments, the subject invention discloses polypeptides comprising at least an immunogenic portion of an Ehrlichia antigen (or a variant of such an antigen), that comprises one or more of the amino acid sequences encoded by (a) a DNA sequence selected from the group consisting of SEQ ID NO: 1-3, 5, 7, 16, 20, 34, 39-49, (b) the complements of such DNA sequences or (c) DNA sequences substantially homologous to a sequence in (a) or (b).

The Ehrlichia antigens provided by the present invention include variants that are encoded by DNA sequences which are substantially homologous to one or more of the DNA sequences specifically recited herein. “Substantial homology,” as used herein, refers to DNA sequences that are capable of hybridizing under moderately stringent conditions. Suitable moderately stringent conditions include prewashing in a solution of 5×SSC, 0.5% SDS, 1.0 mM EDTA (pH 8.0); hybridizing at 50° C.-65° C., 5×SSC, overnight or, in the event of cross-species homology, at 45° C. with 0.5×SSC; followed by washing twice at 65° C. for 20 minutes with each of 2×, 0.5× and 0.2×SSC containing 0.1% SDS. Such hybridizing DNA sequences are also within the scope of this invention, as are nucleotide sequences that, due to code degeneracy, encode an immunogenic polypeptide that is encoded by a hybridizing DNA sequence.

In general, Ehrlichia antigens, and DNA sequences encoding such antigens, may be prepared using any of a variety of procedures. For example, DNA molecules encoding Ehrlichia antigens may be isolated from an Ehrlichia genomic or cDNA expression library by screening with sera from HGE-infected individuals as described below in Example 1, and sequenced using techniques well known to those of skill in the art. DNA molecules encoding Ehrlichia antigens may also be isolated by screening an appropriate Ehrlichia expression library with anti-sera (e.g., rabbit) raised specifically against Ehrlichia antigens.

Antigens may be induced from such clones and evaluated for a desired property, such as the ability to react with sera obtained from an HGE-infected individual as described herein. Alternatively, antigens may be produced recombinantly, as described below, by inserting a DNA sequence that encodes the antigen into an expression vector and expressing the antigen in an appropriate host. Antigens may be partially sequenced using, for example, traditional Edman chemistry. See Edman and Berg, Eur. J. Biochem. 80:116-132, 1967.

DNA sequences encoding antigens may also be obtained by screening an appropriate Ehrlichia cDNA or genomic DNA library for DNA sequences that hybridize to degenerate oligonucleotides derived from partial amino acid sequences of isolated antigens. Degenerate oligonucleotide sequences for use in such a screen may be designed and synthesized, and the screen may be performed, as described (for example) in Sambrook et al., Molecular Cloning: A Laboratory Manual , Cold Spring Harbor Laboratories, Cold Spring Harbor, N.Y. (and references cited therein). Polymerase chain reaction (PCR) may also be employed, using the above oligonucleotides in methods well known in the art, to isolate a nucleic acid probe from a cDNA or genomic library. The library screen may then be performed using the isolated probe.

Synthetic polypeptides having fewer than about 100 amino acids, and generally fewer than about 50 amino acids, may be generated using techniques well known in the art. For example, such polypeptides may be synthesized using any of the commercially available solid-phase techniques, such as the Merrifield solid-phase synthesis method, where amino acids are sequentially added to a growing amino acid chain. See Merrifield, J. Am. Chem. Soc. 85:2149-2146, 1963. Equipment for automated synthesis of polypeptides is commercially available from suppliers such as Perkin Elmer/Applied BioSystems Division, Foster City, Calif., and may be operated according to the manufacturer's instructions.

Immunogenic portions of Ehrlichia antigens may be prepared and identified using well known techniques, such as those summarized in Paul, Fundamental Immunology, 3d ed., Raven Press, 1993, pp. 243-247 and references cited therein. Such techniques include screening polypeptide portions of the native antigen for immunogenic properties. The representative ELISAs described herein may generally be employed in these screens. An immunogenic portion of a polypeptide is a portion that, within such representative assays, generates a signal in such assays that is substantially similar to that generated by the full length antigen. In other words, an immunogenic portion of an Ehrlichia antigen generates at least about 20%, and preferably about 100%, of the signal induced by the full length antigen in a model ELISA as described herein.

Portions and other variants of Ehrlichia antigens may be generated by synthetic or recombinant means. Variants of a native antigen may generally be prepared using standard mutagenesis techniques, such as oligonucleotide-directed site-specific mutagenesis. Sections of the DNA sequence may also be removed using standard techniques to permit preparation of truncated polypeptides.

Recombinant polypeptides containing portions and/or variants of a native antigen may be readily prepared from a DNA sequence encoding the polypeptide using a variety of techniques well known to those of ordinary skill in the art. For example, supernatants from suitable host/vector systems which secrete recombinant protein into culture media may be first concentrated using a commercially available filter. Following concentration, the concentrate may be applied to a suitable purification matrix such as an affinity matrix or an ion exchange resin. Finally, one or more reverse phase HPLC steps can be employed to further purify a recombinant protein.

Any of a variety of expression vectors known to those of ordinary skill in the art may be employed to express recombinant polypeptides as described herein. Expression may be achieved in any appropriate host cell that has been transformed or transfected with an expression vector containing a DNA molecule that encodes a recombinant polypeptide. Suitable host cells include prokaryotes, yeast and higher eukaryotic cells. Preferably, the host cells employed are E. coli , yeast or a mammalian cell line, such as COS or CHO. The DNA sequences expressed in this manner may encode naturally occurring antigens, portions of naturally occurring antigens, or other variants thereof.

In another aspect, the present invention provides antigenic epitopes of an Ehrlichia antigen or epitope repeat sequences, as well as polypeptides comprising at least two such contiguous antigenic epitopes. As used herein, an “epitope” is a portion of an antigen that reacts with sera from Ehrlichia-infected individuals (i.e. an epitope is specifically bound by one or more antibodies present in such sera). As discussed above, epitopes of the antigens described in the present application may be generally identified using techniques well known to those of skill in the art.

In specific embodiments, antigenic epitopes of the present invention comprise an amino acid sequence selected from the group consisting of sequence recited in SEQ ID NO: 30 and 51. As discussed in more detail below, antigenic epitopes provided herein may be employed in the diagnosis and treatment of Ehrlichia infection, either alone or in combination with other Ehrlichia antigens or antigenic epitopes. Antigenic epitopes and polypeptides comprising such epitopes may be prepared by synthetic means, as described generally above and in detail in Example 3.

In general, regardless of the method of preparation, the polypeptides and antigenic epitopes disclosed herein are prepared in an isolated, substantially pure, form. Preferably, the polypeptides and antigenic epitopes are at least about 80% pure, more preferably at least about 90% pure and most preferably at least about 99% pure.

In a further aspect, the present invention provides fusion proteins comprising either a first and a second inventive polypeptide, a first and a second inventive antigenic epitope, or an inventive polypeptide and an antigenic epitope of the present invention, together with variants of such fusion proteins. The fusion proteins of the present invention may also include a linker peptide between the polypeptides or antigenic epitopes.

A DNA sequence encoding a fusion protein of the present invention may be constructed using known recombinant DNA techniques to assemble separate DNA sequences encoding, for example, the first and second polypeptides, into an appropriate expression vector. The 3′ end of a DNA sequence encoding the first polypeptide is ligated, with or without a peptide linker, to the 5′ end of a DNA sequence encoding the second polypeptide so that the reading frames of the sequences are in phase to permit mRNA translation of the two DNA sequences into a single fusion protein that retains the biological activity of both the first and the second polypeptides.

A peptide linker sequence may be employed to separate the first and the second polypeptides by a distance sufficient to ensure that each polypeptide folds into its secondary and tertiary structures. Such a peptide linker sequence is incorporated into the fusion protein using standard techniques well known in the art. Suitable peptide linker sequences may be chosen based on the following factors: (1) their ability to adopt a flexible extended conformation; (2) their inability to adopt a secondary structure that could interact with functional epitopes on the first and second polypeptides; and (3) the lack of hydrophobic or charged residues that might react with the polypeptide functional epitopes. Preferred peptide linker sequences contain Gly, Asn and Ser residues. Other near neutral amino acids, such as Thr and Ala may also be used in the linker sequence. Amino acid sequences which may be usefully employed as linkers include those disclosed in Maratea et al., Gene 40:39-46, 1985; Murphy et al., Proc. Natl. Acad. Sci. USA 83:8258-8562, 1986; U.S. Pat. No. 4,935,233 and U.S. Pat. No. 4,751,180. The linker sequence may be from 1 to about 50 amino acids in length. As an alternative to the use of a peptide linker sequence (when desired), one can utilize non-essential N-terminal amino acid regions (when present) on the first and second polypeptides to separate the functional domains and prevent steric hindrance.

In another aspect, the present invention provides methods for using the polypeptides and antigenic epitopes described above to diagnose Ehrlichia infection, in particular HGE. In this aspect, methods are provided for detecting Ehrlichia infection in a biological sample, using one or more of the above polypeptides and antigenic epitopes, either alone or in combination. For clarity, the term “polypeptide” will be used when describing specific embodiments of the inventive diagnostic methods. However, it will be clear to one of skill in the art that the antigenic epitopes and fusion proteins of the present invention may also be employed in such methods.

As used herein, a “biological sample” is any antibody-containing sample obtained from a patient. Preferably, the sample is whole blood, sputum, serum, plasma, saliva, cerebrospinal fluid or urine. More preferably, the sample is a blood, serum or plasma sample obtained from a patient. The polypeptides are used in an assay, as described below, to determine the presence or absence of antibodies to the polypeptide(s) in the sample, relative to a predetermined cut-off value. The presence of such antibodies indicates previous sensitization to Ehrlichia antigens which may be indicative of HGE.

In embodiments in which more than one polypeptide is employed, the polypeptides used are preferably complementary (i.e., one component polypeptide will tend to detect infection in samples where the infection would not be detected by another component polypeptide). Complementary polypeptides may generally be identified by using each polypeptide individually to evaluate serum samples obtained from a series of patients known to be infected with HGE. After determining which samples test positive (as described below) with each polypeptide, combinations of two or more polypeptides may be formulated that are capable of detecting infection in most, or all, of the samples tested.

A variety of assay formats are known to those of ordinary skill in the art for using one or more polypeptides to detect antibodies in a sample. See, e.g., Harlow and Lane, Antibodies: A Laboratory Manual , Cold Spring Harbor Laboratory, 1988, which is incorporated herein by reference. In a preferred embodiment, the assay involves the use of polypeptide immobilized on a solid support to bind to and remove the antibody from the sample. The bound antibody may then be detected using a detection reagent that contains a reporter group. Suitable detection reagents include antibodies that bind to the antibody/polypeptide complex and free polypeptide labeled with a reporter group (e.g., in a semi-competitive assay). Alternatively, a competitive assay may be utilized, in which an antibody that binds to the polypeptide is labeled with a reporter group and allowed to bind to the immobilized antigen after incubation of the antigen with the sample. The extent to which components of the sample inhibit the binding of the labeled antibody to the polypeptide is indicative of the reactivity of the sample with the immobilized polypeptide.

The solid support may be any solid material known to those of ordinary skill in the art to which the antigen may be attached. For example, the solid support may be a test well in a microtiter plate, or a nitrocellulose or other suitable membrane. Alternatively, the support may be a bead or disc, such as glass, fiberglass, latex or a plastic material such as polystyrene or polyvinylchloride. The support may also be a magnetic particle or a fiber optic sensor, such as those disclosed, for example, in U.S. Pat. No. 5,359,681.

The polypeptides may be bound to the solid support using a variety of techniques known to those of ordinary skill in the art. In the context of the present invention, the term “bound” refers to both noncovalent association, such as adsorption, and covalent attachment (which may be a direct linkage between the antigen and functional groups on the support or may be a linkage by way of a cross-linking agent). Binding by adsorption to a well in a microtiter plate or to a membrane is preferred. In such cases, adsorption may be achieved by contacting the polypeptide, in a suitable buffer, with the solid support for a suitable amount of time. The contact time varies with temperature, but is typically between about 1 hour and 1 day. In general, contacting a well of a plastic microtiter plate (such as polystyrene or polyvinylchloride) with an amount of polypeptide ranging from about 10 ng to about 1 μg, and preferably about 100 ng, is sufficient to bind an adequate amount of antigen.

Covalent attachment of polypeptide to a solid support may generally be achieved by first reacting the support with a bifunctional reagent that will react with both the support and a functional group, such as a hydroxyl or amino group, on the polypeptide. For example, the polypeptide may be bound to supports having an appropriate polymer coating using benzoquinone or by condensation of an aldehyde group on the support with an amine and an active hydrogen on the polypeptide (see, e.g., Pierce Immunotechnology Catalog and Handbook, 1991, at A12-A13).

In certain embodiments, the assay is an enzyme linked immunosorbent assay (ELISA). This assay may be performed by first contacting a polypeptide antigen that has been immobilized on a solid support, commonly the well of a microtiter plate, with the sample, such that antibodies to the polypeptide within the sample are allowed to bind to the immobilized polypeptide. Unbound sample is then removed from the immobilized polypeptide and a detection reagent capable of binding to the immobilized antibody-polypeptide complex is added. The amount of detection reagent that remains bound to the solid support is then determined using a method appropriate for the specific detection reagent.

More specifically, once the polypeptide is immobilized on the support as described above, the remaining protein binding sites on the support are typically blocked. Any suitable blocking agent known to those of ordinary skill in the art, such as bovine serum albumin (BSA) or Tween 20™ (Sigma Chemical Co., St. Louis, Mo.) may be employed. The immobilized polypeptide is then incubated with the sample, and antibody is allowed to bind to the antigen. The sample may be diluted with a suitable dilutent, such as phosphate-buffered saline (PBS) prior to incubation. In general, an appropriate contact time (i.e., incubation time) is that period of time that is sufficient to detect the presence of antibody within an HGE-infected sample. Preferably, the contact time is sufficient to achieve a level of binding that is at least 95% of that achieved at equilibrium between bound and unbound antibody. Those of ordinary skill in the art will recognize that the time necessary to achieve equilibrium may be readily determined by assaying the level of binding that occurs over a period of time. At room temperature, an incubation time of about 30 minutes is generally sufficient.

Unbound sample may then be removed by washing the solid support with an appropriate buffer, such as PBS containing 0.1% Tween 20™. Detection reagent may then be added to the solid support. An appropriate detection reagent is any compound that binds to the immobilized antibody-polypeptide complex and that can be detected by any of a variety of means known to those in the art. Preferably, the detection reagent contains a binding agent (such as, for example, Protein A, Protein G, immunoglobulin, lectin or free antigen) conjugated to a reporter group. Preferred reporter groups include enzymes (such as horseradish peroxidase), substrates, cofactors, inhibitors, dyes, radionuclides, luminescent groups, fluorescent groups and biotin. The conjugation of binding agent to reporter group may be achieved using standard methods known to those of ordinary skill in the art. Common binding agents may also be purchased conjugated to a variety of reporter groups from many commercial sources (e.g., Zymed Laboratories, San Francisco, Calif., and Pierce, Rockford, Ill.).

The detection reagent is then incubated with the immobilized antibody-polypeptide complex for an amount of time sufficient to detect the bound antibody. An appropriate amount of time may generally be determined from the manufacturer's instructions or by assaying the level of binding that occurs over a period of time. Unbound detection reagent is then removed and bound detection reagent is detected using the reporter group. The method employed for detecting the reporter group depends upon the nature of the reporter group. For radioactive groups, scintillation counting or autoradiographic methods are generally appropriate. Spectroscopic methods may be used to detect dyes, luminescent groups and fluorescent groups. Biotin may be detected using avidin, coupled to a different reporter group (commonly a radioactive or fluorescent group or an enzyme). Enzyme reporter groups may generally be detected by the addition of substrate (generally for a specific period of time), followed by spectroscopic or other analysis of the reaction products.

To determine the presence or absence of anti-Ehrlichia antibodies in the sample, the signal detected from the reporter group that remains bound to the solid support is generally compared to a signal that corresponds to a predetermined cut-off value. In one preferred embodiment, the cut-off value is the average mean signal obtained when the immobilized antigen is incubated with samples from an uninfected patient. In general, a sample generating a signal that is three standard deviations above the predetermined cut-off value is considered positive for HGE. In an alternate preferred embodiment, the cut-off value is determined using a Receiver Operator Curve, according to the method of Sackett et al., Clinical Epidemiology: A Basic Science for Clinical Medicine , Little Brown and Co., 1985, pp. 106-107. Briefly, in this embodiment, the cut-off value may be determined from a plot of pairs of true positive rates (i.e., sensitivity) and false positive rates (100%-specificity) that correspond to each possible cut-off value for the diagnostic test result. The cut-off value on the plot that is the closest to the upper left-hand corner (i.e., the value that encloses the largest area) is the most accurate cut-off value, and a sample generating a signal that is higher than the cut-off value determined by this method may be considered positive. Alternatively, the cut-off value may be shifted to the left along the plot, to minimize the false positive rate, or to the right, to minimize the false negative rate. In general, a sample generating a signal that is higher than the cut-off value determined by this method is considered positive for HGE.

In a related embodiment, the assay is performed in a rapid flow-through or strip test format, wherein the antigen is immobilized on a membrane, such as nitrocellulose. In the flow-through test, antibodies within the sample bind to the immobilized polypeptide as the sample passes through the membrane. A detection reagent (e.g., protein A-colloidal gold) then binds to the antibody-polypeptide complex as the solution containing the detection reagent flows through the membrane. The detection of bound detection reagent may then be performed as described above. In the strip test format, one end of the membrane to which polypeptide is bound is immersed in a solution containing the sample. The sample migrates along the membrane through a region containing detection reagent and to the area of immobilized polypeptide. Concentration of detection reagent at the polypeptide indicates the presence of anti-Ehrlichia antibodies in the sample. Typically, the concentration of detection reagent at that site generates a pattern, such as a line, that can be read visually. The absence of such a pattern indicates a negative result. In general, the amount of polypeptide immobilized on the membrane is selected to generate a visually discernible pattern when the biological sample contains a level of antibodies that would be sufficient to generate a positive signal in an ELISA, as discussed above. Preferably, the amount of polypeptide immobilized on the membrane ranges from about 25 ng to about 1 μg, and more preferably from about 50 ng to about 500 ng. Such tests can typically be performed with a very small amount (e.g., one drop) of patient serum or blood.

Of course, numerous other assay protocols exist that are suitable for use with the polypeptides and antigenic epitopes of the present invention. The above descriptions are intended to be exemplary only.

The inventive polypeptides may be employed in combination with known Lyme disease and/or B. microli antigens to diagnose the presence of either Ehrlichia infection, Lyme disease and/or B. microti infection, using either the assay formats described herein or other assay protocols. One example of an alternative assay protocol which may be usefully employed in such methods is a Western blot, wherein the proteins present in a biological sample are separated on a gel, prior to exposure to a binding agent. Such techniques are well known to those of skill in the art. Lyme disease antigens which may be usefully employed in such methods are well known to those of skill in the art and include, for example, those described by Magnarelli, L. et al. (J. Clin. Microbiol., 1996 34:237-240), Magnarelli, L. (Rheum. Dis. Clin. North Am., 1989, 15:735-745) and Cutler, S. J. (J. Clin. Pathol., 1989, 42:869-871). B. microti antigens which may be usefully employed in the inventive methods include those described in U.S. patent application Ser. No. 08/845,258, filed Apr. 24, 1997, the disclosure of which is hereby incorporated by reference.

In yet another aspect, the present invention provides antibodies to the polypeptides and antigenic epitopes of the present invention. Antibodies may be prepared by any of a variety of techniques known to those of ordinary skill in the art. See, e.g., Harlow and Lane, Antibodies: A Laboratory Manual , Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., 1988. In one such technique, an immunogen comprising the antigenic polypeptide or epitope is initially injected into any of a wide variety of mammals (e.g., mice, rats, rabbits, sheep and goats). The polypeptides and antigenic epitopes of this invention may serve as the immunogen without modification. Alternatively, particularly for relatively short polypeptides, a superior immune response may be elicited if the polypeptide is joined to a carrier protein, such as bovine serum albumin or keyhole limpet hemocyanin. The immunogen is injected into the animal host, preferably according to a predetermined schedule incorporating one or more booster immunizations, and the animals are bled periodically. Polyclonal antibodies specific for the polypeptide or antigenic epitope may then be purified from such antisera by, for example, affinity chromatography using the polypeptide coupled to a suitable solid support.

Monoclonal antibodies specific for the antigenic polypeptide or epitope of interest may be prepared, for example, using the technique of Kohler and Milstein, Eur. J. Immunol. 6:511-519, 1976, and improvements thereto. Briefly, these methods involve the preparation of immortal cell lines capable of producing antibodies having the desired specificity (i.e., reactivity with the polypeptide or antigenic epitope of interest). Such cell lines may be produced, for example, from spleen cells obtained from an animal immunized as described above. The spleen cells are then immortalized by, for example, fusion with a myeloma cell fusion partner, preferably one that is syngeneic with the immunized animal. A variety of fusion techniques may be employed. For example, the spleen cells and myeloma cells may be combined with a nonionic detergent for a few minutes and then plated at low density on a selective medium that supports the growth of hybrid cells, but not myeloma cells. A preferred selection technique uses HAT (hypoxanthine, aminopterin, thymidine) selection. After a sufficient time, usually about 1 to 2 weeks, colonies of hybrids are observed. Single colonies are selected and tested for binding activity against the polypeptide or antigenic epitope. Hybridomas having high reactivity and specificity are preferred.

Monoclonal antibodies may be isolated from the supernatants of growing hybridoma colonies. In addition, various techniques may be employed to enhance the yield, such as injection of the hybridoma cell line into the peritoneal cavity of a suitable vertebrate host, such as a mouse. Monoclonal antibodies may then be harvested from the ascites fluid or the blood. Contaminants may be removed from the antibodies by conventional techniques, such as chromatography, gel filtration, precipitation, and extraction. The polypeptides or antigenic epitopes of this invention may be used in the purification process in, for example, an affinity chromatography step.

Antibodies may be used in diagnostic tests to detect the presence of Ehrlichia antigens using assays similar to those detailed above and other techniques well known to those of skill in the art, thereby providing a method for detecting Ehrlichia infection in a patient.

Diagnostic reagents of the present invention may also comprise DNA sequences encoding one or more of the above polypeptides, or one or more portions thereof For example, at least two oligonucleotide primers may be employed in a polymerase chain reaction (PCR) based assay to amplify Ehrlichia-specific cDNA derived from a biological sample, wherein at least one of the oligonucleotide primers is specific for a DNA molecule encoding a polypeptide of the present invention. The presence of the amplified cDNA is then detected using techniques well known in the art, such as gel electrophoresis. Similarly, oligonucleotide probes specific for a DNA molecule encoding a polypeptide of the present invention may be used in a hybridization assay to detect the presence of an inventive polypeptide in a biological sample.

As used herein, the term “oligonucleotide primer/probe specific for a DNA molecule” means an oligonucleotide sequence that has at least about 80%, preferably at least about 90% and more preferably at least about 95%, identity to the DNA molecule in question. Oligonucleotide primers and/or probes which may be usefully employed in the inventive diagnostic methods preferably have at least about 10-40 nucleotides. In a preferred embodiment, the oligonucleotide primers comprise at least about 10 contiguous nucleotides of a DNA molecule encoding one of the polypeptides disclosed herein. Preferably, oligonucleotide probes for use in the inventive diagnostic methods comprise at least about 15 contiguous oligonucleotides of a DNA molecule encoding one of the polypeptides disclosed herein. Techniques for both PCR based assays and hybridization assays are well known in the art (see, for example, Mullis et al. Ibid; Ehrlich, Ibid). Primers or probes may thus be used to detect Ehrlichia-specific sequences in biological samples. DNA probes or primers comprising oligonucleotide sequences described above may be used alone or in combination with each other.

In another aspect, the present invention provides methods for using one or more of the above polypeptides, antigenic epitopes or fusion proteins (or DNA molecules encoding such polypeptides) to induce protective immunity against Ehrlichia infection in a patient. As used herein, a “patient” refers to any warm-blooded animal, preferably a human. A patient may be afflicted with a disease, or may be free of detectable disease and/or infection. In other words, protective immunity may be induced to prevent or treat Ehrlichia infection, specifically HGE.

In this aspect, the polypeptide, antigenic epitope, fusion protein or DNA molecule is generally present within a pharmaceutical composition or a vaccine. Pharmaceutical compositions may comprise one or more polypeptides, each of which may contain one or more of the above sequences (or variants thereof), and a physiologically acceptable carrier. Vaccines may comprise one or more of the above polypeptides and a non-specific immune response enhancer, such as an adjuvant or a liposome (into which the polypeptide is incorporated). Such pharmaceutical compositions and vaccines may also contain other Ehrlichia antigens, either incorporated into a combination polypeptide or present within a separate polypeptide.

Alternatively, a vaccine may contain DNA encoding one or more polypeptides, antigenic epitopes or fusion proteins as described above, such that the polypeptide is generated in situ. In such vaccines, the DNA may be present within any of a variety of delivery systems known to those of ordinary skill in the art, including nucleic acid expression systems, bacterial and viral expression systems. Appropriate nucleic acid expression systems contain the necessary DNA sequences for expression in the patient (such as a suitable promoter and terminating signal). Bacterial delivery systems involve the administration of a bacterium (such as Bacillus-Calmette-Guerrin) that expresses an immunogenic portion of the polypeptide on its cell surface. In a preferred embodiment, the DNA may be introduced using a viral expression system (e.g., vaccinia or other pox virus, retrovirus, or adenovirus), which may involve the use of a non-pathogenic (defective), virus. Techniques for incorporating DNA into such expression systems are well known to those of ordinary skill in the art. The DNA may also be “naked,” as described, for example, in Ulmer et al., Science 259:1745-1749, 1993 and reviewed by Cohen, Science 259:1691-1692, 1993. The uptake of naked DNA may be increased by coating the DNA onto biodegradable beads, which are efficiently transported into the cells.

In a related aspect, a DNA vaccine as described above may be administered simultaneously with or sequentially to either a polypeptide of the present invention or a known Ehrlichia antigen. For example, administration of DNA encoding a polypeptide of the present invention, either “naked” or in a delivery system as described above, may be followed by administration of an antigen in order to enhance the protective immune effect of the vaccine.

Routes and frequency of administration, as well as dosage, will vary from individual to individual. In general, the pharmaceutical compositions and vaccines may be administered by injection (e.g., intracutaneous, intramuscular, intravenous or subcutaneous), intranasally (e.g., by aspiration) or orally. Between 1 and 3 doses may be administered for a 1-36 week period. Preferably, 3 doses are administered, at intervals of 3-4 months, and booster vaccinations may be given periodically thereafter. Alternate protocols may be appropriate for individual patients. A suitable dose is an amount of polypeptide or DNA that, when administered as described above, is capable of raising an immune response in an immunized patient sufficient to protect the patient from HGE for at least 1-2 years. In general, the amount of polypeptide present in a dose (or produced in situ by the DNA in a dose) ranges from about 1 pg to about 100 mg per kg of host, typically from about 10 pg to about 1 μg, and preferably from about 100 pg to about 1 μg. Suitable dose sizes will vary with the size of the patient, but will typically range from about 0.1 mL to about 5 mL.

While any suitable carrier known to those of ordinary skill in the art may be employed in the pharmaceutical compositions of this invention, the type of carrier will vary depending on the mode of administration. For parenteral administration, such as subcutaneous injection, the carrier preferably comprises water, saline, alcohol, a fat, a wax or a buffer. For oral administration, any of the above carriers or a solid carrier, such as mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, glucose, sucrose, and magnesium carbonate, may be employed. Biodegradable microspheres (e.g., polylactic galactide) may also be employed as carriers for the pharmaceutical compositions of this invention. Suitable biodegradable microspheres are disclosed, for example, in U.S. Pat. Nos. 4,897,268 and 5,075,109.

Any of a variety of adjuvants may be employed in the vaccines of this invention to nonspecifically enhance the immune response. Most adjuvants contain a substance designed to protect the antigen from rapid catabolism, such as aluminum hydroxide or mineral oil, and a nonspecific stimulator of immune responses, such as lipid A, Bortadella pertussis or Mycobacterium tuberculosis . Suitable adjuvants are commercially available as, for example, Freund's Incomplete Adjuvant and Freund's Complete Adjuvant (Difco Laboratories, Detroit, Mich.) and Merck Adjuvant 65 (Merck and Company, Inc., Rahway, N.J.). Other suitable adjuvants include alum, biodegradable microspheres, monophosphoryl lipid A and quil A.

The following Examples are offered by way of illustration and not by way of limitation.

EXAMPLE 1

Isolation of DNA Sequences Encoding Ehrlichia Antigens

This example illustrates the preparation of DNA sequences encoding Ehrlichia antigens by screening an Ehrlichia genomic expression library, prepared using genomic DNA from the Ehrlichia species that is the causative agent of HGE, with sera obtained from mice infected with the HGE agent.

Ehrlichia genomic DNA was isolated from infected human HL60 cells and sheared by sonication. The resulting randomly sheared DNA was used to construct an Ehrlichia genomic expression library (approximately 0.5-4.0 kbp inserts) with EcoRI adaptors and a Lambda ZAP II/EcoRI/CIAP vector (Stratagene, La Jolla, Calif.). The unamplified library (6.5×10 6 /ml) was screened with an E. coli lysate-absorbed Ehrlichia mouse serum pool, as described in Sambrook et al., Molecular Cloning: A Laboratory Manual , Cold Spring Harbor Laboratories, Cold Spring Harbor, N.Y., 1989. Positive plaques were visualized and purified with goat-anti-mouse alkaline phosphatase. Phagemid from the plaques was rescued and DNA sequence for positive clones was obtained using forward, reverse, and specific internal primers on a Perkin Elmer/Applied Biosystems Inc. Automated Sequencer Model 373A (Foster City, Calif.).

Of the eighteen antigens isolated using this technique, seven (hereinafter referred to as HGE-1, HGE-3, HGE-6, HGE-7, HGE-12, HGE-23 and HGE-24) were found to be related. The determined DNA sequences for HGE-1, HGE-3, HGE-6, HGE-12, HGE-23 and HGE-24 are shown in SEQ ID NO: 1-3 and 5-7, respectively, with the 5′ DNA sequence for HGE-7 being provided in SEQ ID NO: 4. The deduced amino acid sequences for HGE-1, HGE-3, HGE-6, HGE-7, HGE-12, HGE-23 and HGE-24 are provided in SEQ ID NO: 8-14, respectively. Comparison of these sequences with known sequences in the gene bank using the DNA STAR system, revealed some degree of homology to the Anaplasma marginale major surface protein.

Of the remaining eleven isolated antigens, no significant homologies were found to HGE-2, HGE-9, HGE-14, HGE-15, HGE-16, HGE-17, HGE-18 and HGE-25. The determined full-length DNA sequences for HGE-9 and HGE-14 are provided in SEQ ID NO: 16 and 17, respectively, with the determined 5′ DNA sequences for HGE-2, HGE-15, HGE-16, HGE-17, HGE-18 and HGE-25 being shown in SEQ ID NO: 15, and 18-22, respectively. The corresponding predicted amino acid sequences for HGE-2, HGE-9, HGE-14 and HGE-18 are provided in SEQ ID NO: 23-26, respectively. The reverse complements of HGE-14, HGE-15 and HGE-18 were found to contain open reading frames which encode the amino acid sequences shown in SEQ ID NO: 27, 28 and 29, respectively. The predicted amino acid sequence from the reverse complement strand of HGE-14 (SEQ ID NO: 27) was found to contain a 41 amino acid repeat, provided in SEQ ID NO: 30.

The determined DNA sequence for the isolated antigen HGE-11 is provided in SEQ ID NO: 31, with the predicted amino acid sequences being provided in SEQ ID NO: 32 and 33. Comparison of these sequences with known sequence in the gene bank, revealed some homology between the amino acid sequence of SEQ ID NO: 32 and that of bacterial DNA-directed RNA polymerase beta subunit rpoB (Monastyrskaya, G. S. et al., 1990 , Bioorg. Khim. 6:1106-1109), and further between the amino acid sequence of SEQ ID NO: 33 and that of bacterial DNA-directed RNA polymerase beta′ subunit rpoC (Borodin A. M. et al, 1988 Bioorg. Khim. 14:1179-1182).

The determined 5′ DNA sequence for the antigen HGE-13 is provided in SEQ ID NO: 34. The opposite strand for HGE-13 was found to contain an open reading frame which encodes the amino acid sequence provided in SEQ ID NO: 35. This sequence was found to have some homology to bacterial 2,3-biphosphoglycerate-independent phosphoglycerate mutase (Leyva-Vazquez, M. A. and Setlow, P., 1994 J. Bacteriol. 176:3903-3910).

The determined partial nucleotide sequence for the isolated antigen HGE-8 (SEQ ID NO: 36) was found to include, on the reverse complement of the 5′ end, two open reading frames encoding the amino acid sequences provided in SEQ ID NO: 37 and 38. The amino acid sequences of SEQ ID NO: 37 and 38 were found to show some homology to prokaryotic and eukaryotic dihydrolipamide succinyltransferase (Fleischmann R. D. et al, 1995 Science 269:496-512) and methionine aminopeptidase (Chang, Y. H., 1992 J. Biol. Chem. 267:8007-8011), respectively.

Subsequent studies resulted in the determination of extended DNA sequences for HGE-2, HGE-7, HGE-8, HGE-11, HGE-14, HGE-15, HGE-16, HGE-18, HGE-23 and HGE-25 (SEQ ID NO: 39-48, respectively) and in the determination of the 3′ sequence for HGE-17 (SEQ ID NO: 49). The complement of the extended HGE-2 DNA sequence was found to contain an open reading frame which encodes for a 61.4 kDa protein (SEQ ID NO: 50) having three copies of a 125 amino acid repeat (SEQ ID NO: 51). The extended DNA sequence of HGE-7 was found to contain two open reading frames encoding for the amino acid sequences shown in SEQ ID NO: 52 and 53. The extended DNA sequence of HGE-8 was found to contain four open reading frames encoding the proteins of SEQ ID NO: 54-57. Each of these four proteins was found to show some similarity to known proteins, however, to the best of the inventors' knowledge, none have previously been identified in Ehrlichia.

The extended DNA sequence of HGE-11 was found to contain two open reading frames encoding for the amino acid sequences provided in SEQ ID NO: 58 and 59. These two proteins were found to show some homology to the bacterial DNA-directed RNA polymerase beta subunits rpoB and rpo C, respectively. The reverse complement of the extended DNA sequence of HGE-14 was found to contain two open reading frames, with one encoding the amino acid sequence provided in SEQ ID NO: 60. The second open reading frame encodes the amino acid sequence provided in SEQ ID NO: 61, which contains the amino acid sequence provided in SEQ ID NO: 27. The extended DNA sequence of HGE-15 was found to contain two open reading frames encoding for the sequences provided in SEQ ID NO: 62 and 63, with a third open reading frame encoding the sequence of SEQ ID NO: 64 being located on the reverse complement. The extended DNA sequence of HGE-16 was found to contain an open reading frame encoding the amino acid sequence of SEQ ID NO: 65. The reverse complement of the 3′ DNA sequence of HGE-17 was found to contain two open reading frames encoding the amino acid sequences of SEQ ID NO: 66 and 67.

The reverse complement of the extended DNA sequence of HGE-18 was found to contain three open reading frames encoding the amino acid sequences of SEQ ID NO: 68-70. The sequence of SEQ ID NO: 70 was found to show some homology to bacterial DNA helicase. The extended DNA sequence of HGE-23 was found to contain two open reading frames encoding for the sequences of SEQ ID NO:71 and 72. Both of these sequences, together with those of SEQ ID NO:52 and 53, were found to share some homology with the Anaplasma marginale major surface protein. The predicted amino acid sequence for the extended DNA sequence of HGE-25 is provided in SEQ ID NO:73. This sequence was found to show some similarity to that of SEQ ID NO:64 (HGE-15). No significant homologies were found to the sequences of HGE-2, HGE-14, HGE-15, HGE-16, HGE-17 and HGE-25 (SEQ ID NO: 50, 60-67 and 73).

EXAMPLE 2

Use of Representative Antigens for Serodiagnosis of HGE Infection

The diagnostic properties of representative Ehrlichia antigens were determined by Western blot analysis as follows.

Antigens were induced as pBluescript SK-constructs (Stratagene), with 2 mM IPTG for three hours (T3), after which the resulting proteins from time 0 (T0) and T3 were separated by SDS-PAGE on 15% gels. Separated proteins were then transferred to nitrocellulose and blocked for 1 hr in 1% BSA in 0.1% Tween 20™/PBS. Blots were then washed 3 times in 0.1% Tween 20™/PBS and incubated with either an HGE patient serum pool (1:200) or an Ehrlichia-infected mouse serum pool for a period of 2 hours. After washing in 0.1% Tween 20™/PBS 3 times, blots were incubated with a second antibody (goat-anti-human IgG conjugated to alkaline phosphatase (AP) or goat-anti-mouse IgG-AP, respectively) for 1 hour. Immunocomplexes were visualized with NBT/BCIP (Gibco BRL) after washing with Tween 20™/PBS three times and AP buffer (100 mM Tris-HCl, 100 mM Na Cl, 5 mM MgCl 2 , pH 9.5) two times.

As shown in FIG. 1 , resulting bands of reactivity with serum antibody were seen at 37 kDa for HGE-1 and HGE-3 for both the mouse serum pool and the human serum pool. Protein size standards, in kDa (Gibco BRL, Gaithersburg, Md.), are shown to the left of the blots.

Western blots were performed on partially purified HGE-1 and HGE-3 recombinant antigen with a series of patient sera from HGE patients, patients with Lyme disease, babesiosis patients or from normal donors. Specifically, purified antigen (4 μg) was separated by SDS-PAGE on 12% gels. Protein was then transferred to nitrocellulose membrane for immunoblot analysis. The membrane was first blocked with PBS containing 1% Tween 20™ for 2 hours. Membranes were then cut into strips and incubated with individual sera (1/500) for two hours. The strips were washed 3 times in PBS/0.1% Tween 20™ containing 0.5 M NaCl prior to incubating with Protein A-horseradish peroxidase conjugate (1/20,000) in PBS/0.1% Tween 20™/0.5 M NaCl for 45 minutes. After further washing three times in PBS/0.1% Tween 20™/0.5 M NaCl, ECL chemiluminescent substrate (Amersham, Arlington Heights, Ill.) was added for 1 min. Strips were then reassembled and exposed to Hyperfilm ECL (Amersham) for 5-30 seconds.

Lanes 1-6 of FIG. 2A show the reactivity of purified recombinant HGE-1 (MW 37 kD) with sera from six HGE-infected patients, of which all were clearly positive. In contrast, no immunoreactivity with HGE-1 was seen with sera from patients with either babesiosis (lanes 7-11), or Lyme disease (lanes 12-16), or with sera from normal individuals (lanes 17-21). As shown in FIG. 2B , HGE-3 (MW 37 kD) was found to react with sera from all six HGE patients (lanes 22-27), while cross-reactivity was seen with sera from two of the five babesiosis patients and weak cross-reactivity was seen with sera from two of the five Lyme disease patients. This apparent cross-reactivity may represent the ability of the antigen HGE-3 to detect low antibody titer in patients co-infected with HGE. No immunoreactivity of HGE-3 was seen with sera from normal patients.

Table 1 provides representative data from studies of the reactivity of HGE-1, HGE-3 and HGE-9 with both IgG and IgM in sera from patients with acute (A) or convalescent (C) HGE, determined as described above. The antibody titer for each patient, as determined by immunofluorescence, is also provided.

	TABLE 1
	IgG	IgM
Patient	HGE
ID	titer	HGE-1	HGE-9	HGE-3	HGE-1	HGE-9	HGE-3
1 (A)	128	0.346	0.154	0.423	0.067	0.028	0.022
2 (A)	1024	1.539	1.839	0.893	2.75	3.256	1.795
3 (A)	<16	0.412	0.16	0.659	0.043	0.088	0.047
4 (A)	<16	0.436	0.072	0.472	0.017	0.032	0.064
5 (C)	256	0.322	0.595	0.694	0.229	0.345	0.269
6 (A)	512	1.509	2.042	1.241	0.721	0.695	0.313
7 (C)	512	0.508	1.019	0.777	0.45	0.777	0.29
8 (C)	128	0.635	0.979	1.684	0.729	2.079	0.729
9 (C)	256	0.408	0.74	0.679	0.052	0.11	0.062
10 (A)	64	0.579	0.133	0.239	−0.002	0.015	0.126
11 (A)	256	0.13	0.066	1.002	−0.018	0.003	0.047
12 (A)	16	0.347	0.249	0.727	0.135	0.071	0.113
14 (A)	1024	2.39	3.456	2.635	1.395	1.52	0.55

These results indicate that HGE-9 is able to complement the serological reactivity of HGE-1 and HGE-3, leading to increased sensitivity in the serodiagnosis of HGE-infection in convalescent and acute patient sera, as shown, for example, with patients 5, 8, 11 and 12 in Table 1.

EXAMPLE 3

Preparation and Characterization of Ehrlichia Fusion Proteins

A fusion protein containing the Ehrlichia antigens HGE-9, HGE-3 and HGE-1 is prepared as follows.

Each of the DNA constructs HGE-9, HGE-3 and HGE-1 are modified by PCR in order to facilitate their fusion and the subsequent expression of the fusion protein. HGE-9, HGE-3 and HGE-1 DNA was used to perform PCR using the primers PDM-225 and PDM-226 (SEQ ID NO: 74 and 75), PDM-227 and PDM-228 (SEQ ID NO: 76 and 77), and PDM-229 and PDM-209 (SEQ ID NO: 78 and 79), respectively. In each case, the DNA amplification is performed using 10 μl of 10×Pfu buffer (Stratagene), 1 μl of 12.5 mM dNTPs, 2 μl each of the PCR primers at 10 μM concentration, 82 μl water, 2 μl Pfu DNA polymerase (Stratagene, La Jolla, Calif.) and 1 μl DNA at 110 ng/μl. Denaturation at 96° C. is performed for 2 min, followed by 40 cycles of 96° C. for 20 sec, 60° C. for 15 sec and 72° C. for 5 min, and lastly by 72° C. for 5 min.

The HGE-9 PCR fragment is cloned into pPDM HIS at the Eco 72 I sites along with a three-way ligation of HGE-3 or HGE-1 by cutting with Pvu I. HGE-3 is cloned into pPDM HIS which has been cut with Eco 72I/Xho I. HGE-1 is cloned into pPDM HIS which has been cut with Eco 72I/Eco RI. PCR is performed on the ligation mix of each fusion with the primers PDM-225, PDM-228 and PDM-209 using the conditions provided above. These PCR products are digested with Eco RI (for HGE-1) or Xho I (for HGE-3) and cloned into pPDM HIS which is digested with Eco RI (or Xho I) and Eco 72I. The fusion construct is confirmed by DNA sequencing.

The expression construct is transformed to BLR pLys S E. coli (Novagen, Madison, Wis.) and grown overnight in LB broth with kanamycin (30 μg/ml) and chloramphenicol (34 μg/ml). This culture (12 ml) is used to inoculate 500 ml 2XYT with the same antibiotics and the culture is induced with IPTG. Four hours post-induction, the bacteria are harvested and sonicated in 20 mM Tris (8.0), 100 mM NaCl, 0.1% DOC, followed by centrifugation at 26,000×g. The resulting pellet is resuspended in 8 M urea, 20 mM Tris (8.0), 100 mM NaCl and bound to Ni NTA agarose resin (Qiagen, Chatsworth, Calif.). The column is washed several times with the above buffer then eluted with an imidazole gradient (50 mM, 100 mM, 500 mM imidazole is added to 8 M urea, 20 mM Tris (8.0), 100 mM NaCl). The eluates containing the protein of interest are then dialyzed against 10 mM Tris (8.0).

One of skill in the art will appreciate that the order of the individual antigens within the fusion protein may be changed and that comparable or enhanced activity could be expected provided each of the epitopes is still functionally available. In addition, truncated forms of the proteins containing active epitopes may be used in the construction of fusion proteins.

EXAMPLE 4

Preparation of Synthetic Polypeptides

Polypeptides may be synthesized on a Millipore 9050 peptide synthesizer using FMOC chemistry with HPTU (O-Benzotriazole-N,N,N′,N′-tetramethyluronium hexafluorophosphate) activation. A Gly-Cys-Gly sequence may be attached to the amino terminus of the peptide to provide a method of conjugating or labeling of the peptide. Cleavage of the peptides from the solid support may be carried out using the following cleavage mixture: trifluoroacetic acid:ethanedithiol:thioanisole:water:phenol (40:1:2:2:3). After cleaving for 2 hours, the peptides may be precipitated in cold methyl-t-butyl-ether. The peptide pellets may then be dissolved in water containing 0.1% trifluoroacetic acid (TFA) and lyophilized prior to purification by C18 reverse phase HPLC. A gradient of 0-60% acetonitrile (containing 0.1% TFA) in water (containing 0.1% TFA) may be used to elute the peptides. Following lyophilization of the pure fractions, the peptides may be characterized using electrospray mass spectrometry and by amino acid analysis.

Although the present invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, changes and modifications can be carried out without departing from the scope of the invention which is intended to be limited only by the scope of the appended claims.

73 1345 base pairs nucleic acid single linear DNA (genomic) Ehrlichia 1TTGAGCTTGA GATTGGTTAC GAGCGCTTCA AGACCAAGGG TATTAGAGAT AGTGGTAGTA 60AGGAAGATGA AGCTGATACA GTATATCTAC TAGCTAAGGA GTTAGCTTAT GATGTTGTTA 120CTGGTCAGAC TGATAACCTT GCCGCTGCTC TTGCCAAAAC CTCCGGTAAG GATATTGTTC 180AGTTTGCTAA GGCGGTGGAG ATTTCTCATT CCGAGATTGA TGGCAAGGTT TGTAAGACGA 240AGTCGGCGGG AACTGGAAAA AATCCGTGTG ATCATAGCCA AAAGCCGTGT AGTACGAATG 300CGTATTATGC GAGGAGAACG CAGAAGAGTA GGAGTTCGGG AAAAACGTCT TTATGCGGGG 360ACAGTGGGTA TAGCGGGCAG GAGCTAATAA CGGGTGGGCA TTATAGCAGT CCAAGCGTAT 420TCCGGAATTT TGTCAAAGAC ACACTACAAG GAAATGGTAG TGAGAACTGG CCTACATCTA 480CTGGAGAAGG AAGTGAGAGT AACGACAACG CCATAGCCGT TGCTAAGGAC CTAGTAAATG 540AACTTACTCC TGAAGAACGA ACCATAGTGG CTGGGTTACT TGCTAAAATT ATTGAAGGAA 600GCGAGGTTAT TGAGATTAGG GCCATCTCTT CGACTTCAGT TACAATGAAT ATTTGCTCAG 660ATATCACGAT AAGTAATATC TTAATGCCGT ATGTTTGTGT TGGTCCAGGG ATGAGCTTTG 720TTAGTGTTGT TGATGGTCAC ACTGCTGCAA AGTTTGCATA TCGGTTAAAG GCAGGTCTGA 780GTTATAAATT TTCGAAAGAA GTTACAGCTT TTGCAGGTGG TTTTTACCAT CACGTTATAG 840GAGATGGTGT TTATGATGAT CTGCCATTGC GGCATTTATC TGATGATATT AGTCCTGTGA 900AACATGCTAA GGAAACCGCC ATTGCTAGAT TCGTCATGAG GTACTTTGGC GGGGAATTTG 960GTGTTAGGCT CGCTTTTTAA GGTTGCGACC TAAAAGCACT TAGCTCGCCT TCACTCCCCC 1020TTAAGCAATA TGATGCACAT TTGTTGCCCT ACAAATCTAA TATAAGGTTT GTTGCCTATA 1080CTCGTGCCGA ATTCGGCACG AGGAGGAAGC TGAACTCACC CATCAGTCTC TCTCATCCGT 1140TGGCCACCTG CTGTCCCCAC CCACCCACCA AACTGGTGCT TTTAATGGAA TCAGCTTTAA 1200AAAGAAAAAA ATCCTCCAAG TAACAAAGCA CCCTATAATT ATTCCGCAGC TCCTTGTCCT 1260CGGTAATTTT AGGCTTGTGC TGCTATCATT ACACATTACA TGGAGTTAGG GAGTCATAGC 1320TCTTGTGTGG CCAATCAGTG ATACA 1345 1132 base pairs nucleic acid single linear cDNA 2ATTTCTATAT TGGTTTGGAT TACAGTCCAG CGTTTAGCAA GATAAGAGAT TTTAGTATAA 60GGGAGAGTAA CGGAGAGACA AAGGCAGTAT ATCCATACTT AAAGGATGGA AAGAGTGTAA 120AGCTAGAGTC ACACAAGTTT GACTGGAACA CACCTGATCC TCGGATTGGG TTTAAGGACA 180ACATGCTTGT AGCTATGGAA GGTAGTGTTG GTTATGGTAT TGGTGGTGCC AGGGTTGAGC 240TTGAGATTGG TTACGAGCGC TTCAAGACCA AGGGTATTAG AGATAGTGGT AGTAAGGAAG 300ATGAAGCTGA TACAGTATAT CTACTAGCTA AGGAGTTAGC TTATGATGTT GTTACTGGAC 360AGACTGATAA CCTTGCTGCT GCTCTTGCTA AGACCTCGGG GAAAGACATC GTTCAGTTTG 420CTAAGGCGGT TGGGGTTTCT CATCCTAGTA TTGATGGGAA GGTTTGTAAG ACGAAGGCGG 480ATAGCTCGAA GAAATTTCCG TTATATAGTG ACGAAACGCA CACGAAGGGG GCAAATGAGG 540GGAGAACGTC TTTGTGCGGT GACAATGGTA GTTCTACGAT AACAACCAGT GGTACGAATG 600TAAGTGAAAC TGGGCAGGTT TTTAGGGATT TTATCAGGGC AACGCTGAAA GAGGATGGTA 660GTAAAAACTG GCCAACTTCA AGCGGCACGG GAACTCCAAA ACCTGTCACG AACGACAACG 720CCAAAGCCGT AGCTAAAGAC CTAGTACAGG AGCTAACCCC TGAAGAAAAA ACCATAGTAG 780CAGGGTTACT AGCTAAGACT ATTGAAGGGG GTGAAGTTGT TGAGATCAGG GCGGTTTCTT 840CTACTTCCGT AATGGTCAAT GCTTGTTATG ATCTTCTTAG TGAAGGTTTA GGTGTTGTTC 900CTTATGCTTG TGTTGGTCTC GGTGGTAACT TCGTGGGCGT GGTTGATGGA ATTCATTACA 960CAAACCATCT TTAACTCTGA ATACCCTAGT TAAGGTAAGT GAAGTAACTA GGCAAATTAG 1020TGCTGCACCA CTCGTGAAAC AAACTACGAT CAGCGATTCA CCATACTTAG TAGGTCCGTA 1080CAGTGGCTTT ACGCTCTTAC CCATCATGAA AAATACTTGC TATCTAGGAA TC 1132 554 base pairs nucleic acid single linear DNA (genomic) Ehrlichia 3CTACTAGCTA AGGAGTTAGC TTATGATGTT GTTACTGGGC AGACTGATAA CCTTGCTGCT 60GCTCTTGCCA AGACTTCTGG TAAAGATATT GTTCAGTTTG CTAAGACTCT TAATATTTCT 120CACTCTAATA TCGATGGGAA GGTTTGTAGG AGGGAAAAGC ATGGGAGTCA AGGTTTGACT 180GGAACCAAAG CAGGTTCGTG TGATAGTCAG CCACAAACGG CGGGTTTCGA TTCCATGAAA 240CAAGGTTTGA TGGCAGCTTT AGGCGAACAA GGCGCTGAAA AGTGGCCCAA AATTAACAAT 300GGTGGCCACG CAACAATTTA TAGTAGTAGC GCAGGTCCAG GAAATGCGTA TGCTAGAGAT 360GCATCTACTA CGGTAGCTAC AGACCTAACA AAGCTCACTA CTGAAGAAAA AACCATAGTA 420GCAGGGTTAC TAGCTAGAAC TATTGAAGGG GGTGAAGTTG TTGAGATTAG GGCAGTTTCT 480TCTACTTCTG TGATGGTTAA TGCTTGTTAT GATCTTCTTA GTGAAGGTTT AGGTGTTGTA 540CCTTATGCTT GTGT 554 559 base pairs nucleic acid single linear DNA (genomic) Ehrlichia 4ATGCTGTGAA AATTACTAAC TCCACTATCG ATGGGAAGGT TTGTAATGGT AGTAGAGAGA 60AGGGGAATAG TGCTGGGAAC AACAACAGTG CTGTGGCTAC CTACGCGCAG ACTCACACAG 120CGAATACATC AACGTCACAG TGTAGCGGTC TAGGGACCAC TGTTGTCAAA CAAGGTTATG 180GAAGTTTGAA TAAGTTTGTT AGCCTGACGG GGGTTGGTGA AGGTAAAAAT TGGCCTACAG 240GTAAGATACA CGACGGTAGT AGTGGTGTCA AAGATGGTGA ACAGAACGGG AATGCCAAAG 300CCGTAGCTAA AGACCTAGTA GATCTTAATC GTGACGAAAA AACCATAGTA GCAGGATTAC 360TAGCTAAAAC TATTGAAGGG GGTGAAGTTG TTGAGATCAG GGCGGTTTCT TCTACTTCTG 420TGATGGTTAA TGCTTGTTAT GATCTTCTTA GTGAAGGTTT AGGCGTTGTT CCTTACGCTT 480GTGTCGGTCT CGGAGGTAAC TTCGTGGGCG TTGTTGATGG GCATATCACT CCTAAGCTTG 540CTTATAGATT AAAGGCTGG 559 201 base pairs nucleic acid single linear DNA (genomic) Ehrlichia 5AGCGCTTCAA GACCAAGGGT ATTAGAGATA GTGGTAGTAA GGAAGATGAA GCTGATACAG 60TATATCTACT AGCTAAGGAG TTAGCTTATG ATGTTGTTAC TGGACAGACT GATAACCTTG 120CCGCTGCTCT TGCTAAAACC TCGGGGAAAG ACTTTGTTCA GTTTGCTAAG GCCGTGGAGA 180TTTCTAATTC TACGATTGGG G 201 467 base pairs nucleic acid single linear DNA (genomic) Ehrlichia 6GGTATATCGA TAGCCTACGT AGTCACTCCT TATTATTAAA AAGGAAGACC AAGGGTATTA 60GAGATAGTGG AAGTAAGGAA GATGAAGCAG ATACAGTATA TCTACTAGCT AAGGAGTTAG 120CTTATGATGT TGTTACTGGG CAGACTGATA ACCTTGCCGC TGCTCTTGCC AAAACCTCCG 180GTAAGGACTT TGTTAAATTT GCCAATGCTG TTGTTGGAAT TTCTCACCCC GATGTTAATA 240AGAAGGTTTG TGCGACGAGG AAGGACAGTG GTGGTACTAG ATATGCGAAG TATGCTGCCA 300CGACTAATAA GAGCAGCAAC CCTGAAACCT CACTGTGTGG AGACGAAGGT GGCTCGAGCG 360GCACGAATAA TACACAAGAG TTTCTTAAGG AATTTGTAGC CCAAACCCTA GTAGAAAATG 420AAAGTAAAAA CTGGCCTACT TCAAGCGGGA CTGGGTTGAA GACTAAC 467 530 base pairs nucleic acid single linear DNA (genomic) Ehrlichia 7AAGATGAAGC TGATACAGTA TATCTACTGG CTAAGGAGTT AGCTTATGAT GTTGTTACTG 60GACAGACTGA TAAGCTTACT GCTGCTCTTG CTAAGACCTC CGGGAAGGAC TTTGTTCAGT 120TTGCTAAGGC GGTTGGGGTT TCTCATCCTA ATATCGATGG GAAGGTTTGT AAGACTACGC 180TAGGGCACAC GAGTGCGGAT AGCTACGGTG TGTATGGGGA GTTAACAGGC CAGGCGAGTG 240CGAGTGAGAC ATCGTTATGT GGTGGTAAGG GTAAAAATAG TAGTGGTGGT GGAGCTGCTC 300CCGAAGTTTT AAGGGACTTT GTAAAGAAAT CTCTGAAAGA TGGGGGCCAA AACTGGCCAA 360CATCTAGGGC GACCGAGAGT TCACCTAAGA CTAAATCTGA AACTAACGAC AATGCAAAAG 420CTGTCGCTAA AGACCTAGTA GACCTTAATC CTGAAGAAAA AACCATAGTA GCAGGGTTAC 480TAGCTAAAAC TATTGAAGGT GGGGAAGTTG TAGAAATCAG AGCAGTTTCT 530 325 amino acids amino acid single linear protein Ehrlichia 8Glu Leu Glu Ile Gly Tyr Glu Arg Phe Lys Thr Lys Gly Ile Arg Asp1 5 10 15Ser Gly Ser Lys Glu Asp Glu Ala Asp Thr Val Tyr Leu Leu Ala Lys 20 25 30Glu Leu Ala Tyr Asp Val Val Thr Gly Gln Thr Asp Asn Leu Ala Ala 35 40 45Ala Leu Ala Lys Thr Ser Gly Lys Asp Ile Val Gln Phe Ala Lys Ala 50 55 60Val Glu Ile Ser His Ser Glu Ile Asp Gly Lys Val Cys Lys Thr Lys65 70 75 80Ser Ala Gly Thr Gly Lys Asn Pro Cys Asp His Ser Gln Lys Pro Cys 85 90 95Ser Thr Asn Ala Tyr Tyr Ala Arg Arg Thr Gln Lys Ser Arg Ser Ser 100 105 110Gly Lys Thr Ser Leu Cys Gly Asp Ser Gly Tyr Ser Gly Gln Glu Leu 115 120 125Ile Thr Gly Gly His Tyr Ser Ser Pro Ser Val Phe Arg Asn Phe Val 130 135 140Lys Asp Thr Leu Gln Gly Asn Gly Ser Glu Asn Trp Pro Thr Ser Thr145 150 155 160Gly Glu Gly Ser Glu Ser Asn Asp Asn Ala Ile Ala Val Ala Lys Asp 165 170 175Leu Val Asn Glu Leu Thr Pro Glu Glu Arg Thr Ile Val Ala Gly Leu 180 185 190Leu Ala Lys Ile Ile Glu Gly Ser Glu Val Ile Glu Ile Arg Ala Ile 195 200 205Ser Ser Thr Ser Val Thr Met Asn Ile Cys Ser Asp Ile Thr Ile Ser 210 215 220Asn Ile Leu Met Pro Tyr Val Cys Val Gly Pro Gly Met Ser Phe Val225 230 235 240Ser Val Val Asp Gly His Thr Ala Ala Lys Phe Ala Tyr Arg Leu Lys 245 250 255Ala Gly Leu Ser Tyr Lys Phe Ser Lys Glu Val Thr Ala Phe Ala Gly 260 265 270Gly Phe Tyr His His Val Ile Gly Asp Gly Val Tyr Asp Asp Leu Pro 275 280 285Leu Arg His Leu Ser Asp Asp Ile Ser Pro Val Lys His Ala Lys Glu 290 295 300Thr Ala Ile Ala Arg Phe Val Met Arg Tyr Phe Gly Gly Glu Phe Gly305 310 315 320Val Arg Leu Ala Phe 325 323 amino acids amino acid single linear protein 9Phe Tyr Ile Gly Leu Asp Tyr Ser Pro Ala Phe Ser Lys Ile Arg Asp 1 5 10 15Phe Ser Ile Arg Glu Ser Asn Gly Glu Thr Lys Ala Val Tyr Pro Tyr 20 25 30Leu Lys Asp Gly Lys Ser Val Lys Leu Glu Ser His Lys Phe Asp Trp 35 40 45Asn Thr Pro Asp Pro Arg Ile Gly Phe Lys Asp Asn Met Leu Val Ala 50 55 60Met Glu Gly Ser Val Gly Tyr Gly Ile Gly Gly Ala Arg Val Glu Leu65 70 75 80Glu Ile Gly Tyr Glu Arg Phe Lys Thr Lys Gly Ile Arg Asp Ser Gly 85 90 95Ser Lys Glu Asp Glu Ala Asp Thr Val Tyr Leu Leu Ala Lys Glu Leu 100 105 110Ala Tyr Asp Val Val Thr Gly Gln Thr Asp Asn Leu Ala Ala Ala Leu 115 120 125Ala Lys Thr Ser Gly Lys Asp Ile Val Gln Phe Ala Lys Ala Val Gly 130 135 140Val Ser His Pro Ser Ile Asp Gly Lys Val Cys Lys Thr Lys Ala Asp145 150 155 160Ser Ser Lys Lys Phe Pro Leu Tyr Ser Asp Glu Thr His Thr Lys Gly 165 170 175Ala Asn Glu Gly Arg Thr Ser Leu Cys Gly Asp Asn Gly Ser Ser Thr 180 185 190Ile Thr Thr Ser Gly Thr Asn Val Ser Glu Thr Gly Gln Val Phe Arg 195 200 205Asp Phe Ile Arg Ala Thr Leu Lys Glu Asp Gly Ser Lys Asn Trp Pro 210 215 220Thr Ser Ser Gly Thr Gly Thr Pro Lys Pro Val Thr Asn Asp Asn Ala225 230 235 240Lys Ala Val Ala Lys Asp Leu Val Gln Glu Leu Thr Pro Glu Glu Lys 245 250 255Thr Ile Val Ala Gly Leu Leu Ala Lys Thr Ile Glu Gly Gly Glu Val 260 265 270Val Glu Ile Arg Ala Val Ser Ser Thr Ser Val Met Val Asn Ala Cys 275 280 285Tyr Asp Leu Leu Ser Glu Gly Leu Gly Val Val Pro Tyr Ala Cys Val 290 295 300Gly Leu Gly Gly Asn Phe Val Gly Val Val Asp Gly Ile His Tyr Thr305 310 315 320Asn His Leu 185 amino acids amino acid single linear protein Ehrlichia 10Leu Leu Ala Lys Glu Leu Ala Tyr Asp Val Val Thr Gly Gln Thr Asp1 5 10 15Asn Leu Ala Ala Ala Leu Ala Lys Thr Ser Gly Lys Asp Ile Val Gln 20 25 30Phe Ala Lys Thr Leu Asn Ile Ser His Ser Asn Ile Asp Gly Lys Val 35 40 45Cys Arg Arg Glu Lys His Gly Ser Gln Gly Leu Thr Gly Thr Lys Ala 50 55 60Gly Ser Cys Asp Ser Gln Pro Gln Thr Ala Gly Phe Asp Ser Met Lys65 70 75 80Gln Gly Leu Met Ala Ala Leu Gly Glu Gln Gly Ala Glu Lys Trp Pro 85 90 95Lys Ile Asn Asn Gly Gly His Ala Thr Ile Tyr Ser Ser Ser Ala Gly 100 105 110Pro Gly Asn Ala Tyr Ala Arg Asp Ala Ser Thr Thr Val Ala Thr Asp 115 120 125Leu Thr Lys Leu Thr Thr Glu Glu Lys Thr Ile Val Ala Gly Leu Leu 130 135 140Ala Arg Thr Ile Glu Gly Gly Glu Val Val Glu Ile Arg Ala Val Ser145 150 155 160Ser Thr Ser Val Met Val Asn Ala Cys Tyr Asp Leu Leu Ser Glu Gly 165 170 175Leu Gly Val Val Pro Tyr Ala Cys Val 180 185 185 amino acids amino acid single linear protein Ehrlichia 11Ala Val Lys Ile Thr Asn Ser Thr Ile Asp Gly Lys Val Cys Asn Gly1 5 10 15Ser Arg Glu Lys Gly Asn Ser Ala Gly Asn Asn Asn Ser Ala Val Ala 20 25 30Thr Tyr Ala Gln Thr His Thr Ala Asn Thr Ser Thr Ser Gln Cys Ser 35 40 45Gly Leu Gly Thr Thr Val Val Lys Gln Gly Tyr Gly Ser Leu Asn Lys 50 55 60Phe Val Ser Leu Thr Gly Val Gly Glu Gly Lys Asn Trp Pro Thr Gly65 70 75 80Lys Ile His Asp Gly Ser Ser Gly Val Lys Asp Gly Glu Gln Asn Gly 85 90 95Asn Ala Lys Ala Val Ala Lys Asp Leu Val Asp Leu Asn Arg Asp Glu 100 105 110Lys Thr Ile Val Ala Gly Leu Leu Ala Lys Thr Ile Glu Gly Gly Glu 115 120 125Val Val Glu Ile Arg Ala Val Ser Ser Thr Ser Val Met Val Asn Ala 130 135 140Cys Tyr Asp Leu Leu Ser Glu Gly Leu Gly Val Val Pro Tyr Ala Cys145 150 155 160Val Gly Leu Gly Gly Asn Phe Val Gly Val Val Asp Gly His Ile Thr 165 170 175Pro Lys Leu Ala Tyr Arg Leu Lys Ala 180 185 66 amino acids amino acid single linear protein Ehrlichia 12Arg Phe Lys Thr Lys Gly Ile Arg Asp Ser Gly Ser Lys Glu Asp Glu1 5 10 15Ala Asp Thr Val Tyr Leu Leu Ala Lys Glu Leu Ala Tyr Asp Val Val 20 25 30Thr Gly Gln Thr Asp Asn Leu Ala Ala Ala Leu Ala Lys Thr Ser Gly 35 40 45Lys Asp Phe Val Gln Phe Ala Lys Ala Val Glu Ile Ser Asn Ser Thr 50 55 60Ile Gly65 155 amino acids amino acid single linear protein Ehrlichia 13Tyr Ile Asp Ser Leu Arg Ser His Ser Leu Leu Leu Lys Arg Lys Thr1 5 10 15Lys Gly Ile Arg Asp Ser Gly Ser Lys Glu Asp Glu Ala Asp Thr Val 20 25 30Tyr Leu Leu Ala Lys Glu Leu Ala Tyr Asp Val Val Thr Gly Gln Thr 35 40 45Asp Asn Leu Ala Ala Ala Leu Ala Lys Thr Ser Gly Lys Asp Phe Val 50 55 60Lys Phe Ala Asn Ala Val Val Gly Ile Ser His Pro Asp Val Asn Lys65 70 75 80Lys Val Cys Ala Thr Arg Lys Asp Ser Gly Gly Thr Arg Tyr Ala Lys 85 90 95Tyr Ala Ala Thr Thr Asn Lys Ser Ser Asn Pro Glu Thr Ser Leu Cys 100 105 110Gly Asp Glu Gly Gly Ser Ser Gly Thr Asn Asn Thr Gln Glu Phe Leu 115 120 125Lys Glu Phe Val Ala Gln Thr Leu Val Glu Asn Glu Ser Lys Asn Trp 130 135 140Pro Thr Ser Ser Gly Thr Gly Leu Lys Thr Asn145 150 155 176 amino acids amino acid single linear protein Ehrlichia 14Asp Glu Ala Asp Thr Val Tyr Leu Leu Ala Lys Glu Leu Ala Tyr Asp1 5 10 15Val Val Thr Gly Gln Thr Asp Lys Leu Thr Ala Ala Leu Ala Lys Thr 20 25 30Ser Gly Lys Asp Phe Val Gln Phe Ala Lys Ala Val Gly Val Ser His 35 40 45Pro Asn Ile Asp Gly Lys Val Cys Lys Thr Thr Leu Gly His Thr Ser 50 55 60Ala Asp Ser Tyr Gly Val Tyr Gly Glu Leu Thr Gly Gln Ala Ser Ala65 70 75 80Ser Glu Thr Ser Leu Cys Gly Gly Lys Gly Lys Asn Ser Ser Gly Gly 85 90 95Gly Ala Ala Pro Glu Val Leu Arg Asp Phe Val Lys Lys Ser Leu Lys 100 105 110Asp Gly Gly Gln Asn Trp Pro Thr Ser Arg Ala Thr Glu Ser Ser Pro 115 120 125Lys Thr Lys Ser Glu Thr Asn Asp Asn Ala Lys Ala Val Ala Lys Asp 130 135 140Leu Val Asp Leu Asn Pro Glu Glu Lys Thr Ile Val Ala Gly Leu Leu145 150 155 160Ala Lys Thr Ile Glu Gly Gly Glu Val Val Glu Ile Arg Ala Val Ser 165 170 175 1185 base pairs nucleic acid single linear DNA (genomic) Ehrlichia 15GAAACAGCAT TGCTAGATTT CGTTGAACAA TTTGCTAATT TGCAACTAAA GCACTCATGA 60TAAAGCTTGA TAGTATTTTA GAGGATAGTA GGCAATATGG TTTAGGGGAT TTCTTCGCAT 120ACTTGTTATC ATCGTCCTTA TTTGTGCTTA GTTGGTCGGA TATTTGTGCA AGTTGTTGTA 180AAATATGCAT ATTGTATGTA TAGGTGTGCA AGATATCATC TCTTTAGGTG TATCGTGTAG 240CACTTAAACA AATGCTGGTG AACGTAGAGG GATTAAAGGA GGATTTGCGT ATATGTATGG 300TATAGATATA GAGCTAAGTG ATTACAGAAT TGGTAGTGAA ACCATTTCCA GTGGAGATGA 360TGGCTACTAC GAAGGATGTG CTTGTGACAA AGATGCCAGC ACTAATGCGT ACTCGTATGA 420CAAGTGTAGG GTAGTACGGG GAACGTGGAG ACCGAGCGAA CTGGTTTTAT ATGTTGGTGA 480TGAGCATGTG GCATGTAGAG ATGTTGCTTC GGGTATGCAT CATGGTAATT TGCCAGGGGA 540AGGTGTATTT TATAGAGGCA GAAGCGGGCA GAGCTGCTAC TGCTGAAGGT GGTGTTTATA 600CTACCGTTGT GGAGGCATTA TCGCTGGTGC AAGAGGAAGA GGGTACAGGT ATGTACTTGA 660TAAACGCACC AGAAAAAGCG GTCGTAAGGT TTTTCAAGAT AGAAAAGAGT GCAGCAGAGG 720AACCTCAAAC AGTAGATCCT AGTGTAGTTG AGTCAGCAAC AGGGTCGGGT GTAGATACGC 780AAGAAGAACA AGAAATAGAT CAAGAAGCAC CAGCAATTGA AGAAGTTGAG ACAGAAGAGC 840AAGAAGTTAT TCTGGAAGAA GGTACTTTGA TAGATCTTGA GCAACCTGTA GCGCAAGTAC 900CTGTAGTAGC TGAAGCAGAA TTACCTGGTG TTGAAGCTGC AGAAGCGATT GTACCATCAC 960TAGAAGAAAA TAAGCTTCAA GAAGTGGTAG TTGCTCCAGA AGCGCAACAA CTAGAATCAG 1020CTCCTGAAGT TTCTGCGCCA GCACAACCTG AGTCTACAGT TCTTGGTGTT GCTGAAGGTG 1080ATCTAAAGTC TGAAGTATCT GTAGAAGCTA ATGCTGATGT ACGCAAAAAG AAGTAATCTC 1140TGGTCCACRA GAGCAAGAAA TTGCAGAAGC ACTAGAGGGA ACTGA 1185 1131 base pairs nucleic acid single linear DNA (genomic) Ehrlichia 16ATAAAGGGGC TCCAGCAACG CAGAGAGATG CTTATGGTAA GACGGCTTTA CATATAGCAG 60CTGCTAATGG TGACGGTAAG CTATATAAGT TAATTGCGAA AAAATGCCCA GATAGCTGTC 120AAGCACTCCT TTCTCATATG GGAGATACAG CGTTACATGA GGCTTTATAT TCTGATAAGG 180TTACAGAAAA ATGCTTTTTA AAGATGCTTA AAGAGTCTCG AAAGCATTTG TCAAACTCAT 240CTTTCGGAGA CTTGCTTAAT ACTCCTCAAG AAGCAAATGG TGACACGTTA CTGCATCTGG 300CTGCATCGCG TGGTTTCGGT AAAGCATGTA AAATACTACT AAAGTCTGGG GCGTCAGTAT 360CAGTCGTGAA TGTAGAGGGA AAAACACCGG TAGATGTTGC GGATCCATCA TTGAAAACTC 420GTCCGTGGTT TTTTGGAAAG TCCGTTGTCA CAATGATGGC TGAACGTGTT CAAGTTCCTG 480AAGGGGGATT CCCACCATAT CTGCCGCCTG AAAGTCCAAC TCCTTCTTTA GGATCTATTT 540CAAGTTTTGA GAGTGTCTCT GCGCTATCAT CCTTGGGTAG TGGCCTAGAT ACTGCAGGAG 600CTGAGGAGTC TATCTACGAA GAAATTAAGG ATACAGCAAA AGGTACAACG GAAGTTGAAA 660GCACATATAC AACTGTAGGA GCTGAGGAGT CTATCTACGA AGAAATTAAG GATACAGCAA 720AAGGTACAAC GGAAGTTGAA AGCACATATA CAACTGTAGG AGCTGAAGGT CCGAGAACAC 780CAGAAGGTGA AGATCTGTAT GCTACTGTGG GAGCTGCAAT TACTTCCGAG GCGCAAGCAT 840CAGATGCGGC GTCATCTAAG GGAGAAAGGC CGGAATCCAT TTATGCTGAT CCATTTGATA 900TAGTGAAACC TAGGCAGGAA AGGCCTGAAT CTATCTATGC TGACCCATTT GCTGCGGAAC 960GAACATCTTC TGGAGTAACG ACATTTGGCC CTAAGGAAGA GCCGATTTAT GCAACAGTGA 1020AAAAGGGTCC TAAGAAGAGT GATACTTCTC AAAAAGAAGG AACAGCTTCT GAAAAAGTCG 1080GCTCAACAAT AACTGTGATT AAGAAGAAAG TGAAACCTCA GGTTCCAGCT A 1131 800 base pairs nucleic acid single linear DNA (genomic) Ehrlichia 17AATGCGCTCC ACATAACTAG CATAACGTTT TCAGCAACGG CAGATCTTCA TATATAAGCA 60CTGAACACCT ACGTTCCAAG ATCATGCTCT TCGCGCCTGT TTACTTGGTG GCTCAGAGTC 120ATCATCACTA GGAGTTCGTG GTCTGTGAGA GCTAACTTGT GCTTCTTCCA GCGTATAACT 180AGCACCTCCC AATCCTGATG CTGAAGGTTG ATCCCACGAA TAAGGCATAA TCCCTTGATC 240CTGAGGTGGC ACATAGGGAG CTTGTGATCT TCCCATTCCA GTACTAGTAC CTCCTAGCCC 300AGATGTTGAG AATTGGCTAG ATGGATAAGG AACATTCTCT AGGACACGTA GTATAATATG 360AGGGGGGGGG GGAACGAGTT GAGCTCCCTG TCCGGCAGTA CCTCCCAATC CTGATGTTGA 420GGGTTGATCC CATGATGTTG AGGGTTGATC CCACGATGTT GAAGGTTGTG CATACGAATA 480GGGCATCATC CCTGGATCAT GTGGTGGAAT ATGCGAAGCT TGTTGACTTC CCATTCCAGC 540GGCACTTCCT AACCCTGATG TTGAGGGTTG ATCCCACGAT GTTGAATGTT GTGCATACGA 600ATAGGGCATC ATCCCTGGAT CATGTGGTGG AATATGCGAA GCTTGTTGAC TTCCCATTCC 660AGCGGCACTT CCTAACCCTG ATGTTGAGGG TTGATCCCAC GATGTTGAAG GTTGTGCATA 720CGAATAGGGC ATCATCCCTG GATCATGTGG TGGAATATGC GAAGCTTGTT GACTTCCCGT 780TCCAGCGGCA CTTCCTAACC 800 1011 base pairs nucleic acid single linear DNA (genomic) Ehrlichia 18AATGTATACA GTCTCAGATT CAGAATCTAT AACTTCTTTC GTTACTCCAC CAATGTTAAT 60GGCGAATATC TCATCGACTA AGCGTTCAGG ATACTTGCTA TCATTGTCGG TAGAGCCATC 120TGACTTTTTT ACCGTGACAT TCTTTTTAAA AGAAACTCCA TTTACAACGG ACAATTCAGT 180GCCATTTTGT AGCTTCGAGC GCAACTCCAC AGCAAATTCA CGTATTTTCT TCATACGTAA 240TGCACTCTTC CATTCTTCAG TAAGAATAGA CCTGCTTTCT TCAAGTGTCC TTGGTCTTGG 300AGGCACTACT TCAGTAACAA GAACGCCGAA ATAAGCGTCA CCATTGCTAA CCAGATGAGA 360CGGTTTTCCT ACGGCAGATG AAAACGCCAA AGTAGTAAAG GCGTTTATAC CAAGCTGCAA 420CGGAAAGTCT TTCACTAAGT TGCCAGATTT ATCGAGCCCA TGCATATCAA AATTCGTCAA 480AACACCACTG ATCCGCGCAC CAAACATATC CTTTAGTTCA TTCAGCAATG CCCCGCGGCT 540GATCATATCG TTTGCTTTTT TCACATTGCT AACTAGCAAC TCACCTGCCT TTTGCCTTCT 600AATATTTGAA GATATCTTCT CTTTCAGCTT TTCTAGGTCT TCCTTAGTGA TCTCATGCTT 660CCTTATTACC TTCATGATAT GCCAGCCGAC AACGCTACGG AACATTTCAC TGACTTCTCC 720TTCATTTAGT GCAAACACCA CATTTCGCAC ACCTACCGGA AGAACATCCT TAGAGATATT 780ATTGAGTGCA ATATCCTCTA TGGTGTAGCC AGCATCACTA ACCAATTCCT CAAAAGACTT 840ACCCTCTTGG TAAGCTTTGT AAGCTAGCTC AGCTTCATTT TTGTCTGTAA ATACTAAATT 900TAGAACATCT CTTTGATCAT GTAGTTCACT GTTTTTAATC TCAACGTCTA CCTTCTTGAT 960CCGAAACAAT GACATCAGCA AGCAAGTCGT CTTCTGCCAT GATTATATGA T 1011 513 base pairs nucleic acid single linear DNA (genomic) Ehrlichia 19GCAAATATTT TTCTTGGTGC CGCCCTAAAA GCCTGAAAAA TTTAAAGAAA TGTTACTGCT 60CTAGTCATTC ATAAAATGCA AATAGCCTAC AGAAGGAGTA TTTACTGCTA TAGGCTTGAA 120AGTGCAATCG TTATTTACTA TTTTTTATAC ATATCGCAGT ACAGAGATTT TACGCGCTAC 180GCCTGTGCAT CATAGCCGTA TTGCATCAAT AAATTGTCGT TGCTACGCGG GAAAGCTGCT 240TAGCGCTTGA CCATTTTTCA TACACATTGT ACCATCATAG CGAGTGTGGT GCTCATGAGA 300GTGCGTAGTG TTGCCGCCGG TTTCTCATGT TATAATCTTG CTGCCGTTTT GTGCAGAAGG 360AGGAGTAGTC TCGTTTTTTT CCAAAAGACA ATGTGCTGGA GTGTCCCGGT GAGCCTCAAG 420GTTCTTGTGG GATTTGTGTG GGCTGTTGTA TAAATACCAC GTTCGAAGCT GTCCTAGTGT 480ATTCAGCATA TGTTGAGGAA GTTGTTGCTA TGA 513 464 base pairs nucleic acid single linear DNA (genomic) Ehrlichia 20AGTCATTGAG TCGAGGGTAG TCTTGTGGAT CCCTGATAAA TGTTCTAAAA TTTAAAACAA 60CACTAGAGTT TTGATCACAT GTTGGTTGTC AGAAAAAAAA TGTCAAAAAA TTTACCAGGG 120CTTTTTGAAA TGCCTAGATT TTCCATTTCT CAATGAAACT TGTTTGATCA TGACTATTCC 180AGCTAATGGA GCAGTGTGAT GTAGAGGAAG GAGCCACTGA GGGTATGTGG GGTGTTAGAC 240TGGATCATCA TTCTTCAAGG CGTGTTCCTT GGAATGCCTG GGAGGAGAGC AATTTTCTAT 300TAAAATTTAA TTCGCCTCCT TCCAAATATG GTTCCCTGGA CGATTTAGCA AATAGCATTC 360CTTTTTTGGA GATTCAAAAA GCACATTAGC ATTGAGGATT GCTACAGTAA AGAAATCTGC 420CTAACTTTGT TTTATCCAGT ATTGCCTAAA ATTATTGGAC CACT 464 527 base pairs nucleic acid single linear DNA (genomic) Ehrlichia 21CCTATGGCAG CTCTAAACTC GGCACGACTG GTTTCTACAA GAGATTGGTC GACATTAAAC 60CATGCGAAAT CATTGCGATC AATTCTTCCT TCTTTTTCCT GTATAGCACT ACAGACTTCC 120TCTGCACTAG AAGCCACTCG TGTCCCGATG CGTACGTCAC GGATGCAAAG CCCCAGGTCT 180TTTACGCTGC CGGGTGTGTC TATATCTTCC ACAACATAAT CAACGCAAGC GTGAATATGG 240ATACCAGAAA CAGAGGTAAC CCTGTATACT AAATGCTCTT CCAAAACATG TTGATTAACA 300GGTAAGCGCC TAGCACTATC ACCATTATCA GCAACAACGC CTTCATGCGC AACGTAATGA 360GCAGCGAGCT CAACTGGCAG AGATGACCCA CTACTGTTAC TCAAGATACT AGATAAGAGT 420ACCCGGAGAT TTTCTGTGTT TACACCAGTT TTCTCCACAA TATTTGCAGC ATGCTTCGGC 480TGTGACCTTA AGATTTCACG TATTTCATCG GAGTGTTGTA TGAAAAT 527 464 base pairs nucleic acid single linear DNA (genomic) Ehrlichia 22TTCACCTGGC CAAATCTTAT TGGATCTTCA GGACAAAGAC CAAGAATCTG CTTCTCCAAG 60AAGCATTCTC TGACCCCCAC CTACCTATCT GACTCTTAGC TTAGATTCCT AATGGTGTGA 120GTGTGTCAGA GCCTTTACTT AGTCTAAGCG TAACTGTAAA AACATCTTTT CAAAAGTCTC 180TGCATGACTG TCTAGGTCTC ACCTATCACA CTGTAAGCAT CTGGAAAACA AAGCCACTGA 240GTCTTCCTTT TACCAAAAAG GCCTAGCCTT GTTTTTGACA AATGGCAAGA ACACATTAGA 300TGTTTGTTGA GAGAACAAAA GGAGAGAACT CATTATGAAA CTCTGGACAA CATTTATATA 360CCTCTCTACA TTTTTTGTGT TGGAGGTTAG TTTTCTTTTC TAATAATTTG ATTTCTTTGG 420ATACATCGAG GCAATACACT TAAGAAGCAA GAAGATTGGG GGCC 464 233 amino acids amino acid single linear protein Ehrlichia 23Tyr Gly Glu Arg Gly Asp Arg Ala Asn Trp Phe Tyr Met Leu Val Met1 5 10 15Ser Met Trp His Val Glu Met Leu Leu Arg Val Cys Ile Met Val Ile 20 25 30Cys Gln Gly Lys Val Tyr Phe Ile Glu Ala Glu Ala Gly Arg Ala Ala 35 40 45Thr Ala Glu Gly Gly Val Tyr Thr Thr Val Val Glu Ala Leu Ser Leu 50 55 60Val Gln Glu Glu Glu Gly Thr Gly Met Tyr Leu Ile Asn Ala Pro Glu65 70 75 80Lys Ala Val Val Arg Phe Phe Lys Ile Glu Lys Ser Ala Ala Glu Glu 85 90 95Pro Gln Thr Val Asp Pro Ser Val Val Glu Ser Ala Thr Gly Ser Gly 100 105 110Val Asp Thr Gln Glu Glu Gln Glu Ile Asp Gln Glu Ala Pro Ala Ile 115 120 125Glu Glu Val Glu Thr Glu Glu Gln Glu Val Ile Leu Glu Glu Gly Thr 130 135 140Leu Ile Asp Leu Glu Gln Pro Val Ala Gln Val Pro Val Val Ala Glu145 150 155 160Ala Glu Leu Pro Gly Val Glu Ala Ala Glu Ala Ile Val Pro Ser Leu 165 170 175Glu Glu Asn Lys Leu Gln Glu Val Val Val Ala Pro Glu Ala Gln Gln 180 185 190Leu Glu Ser Ala Pro Glu Val Ser Ala Pro Ala Gln Pro Glu Ser Thr 195 200 205Val Leu Gly Val Ala Glu Gly Asp Leu Lys Ser Glu Val Ser Val Glu 210 215 220Ala Asn Ala Asp Val Arg Lys Lys Lys225 230 376 amino acids amino acid single linear protein Ehrlichia 24Lys Gly Ala Pro Ala Thr Gln Arg Asp Ala Tyr Gly Lys Thr Ala Leu1 5 10 15His Ile Ala Ala Ala Asn Gly Asp Gly Lys Leu Tyr Lys Leu Ile Ala 20 25 30Lys Lys Cys Pro Asp Ser Cys Gln Ala Leu Leu Ser His Met Gly Asp 35 40 45Thr Ala Leu His Glu Ala Leu Tyr Ser Asp Lys Val Thr Glu Lys Cys 50 55 60Phe Leu Lys Met Leu Lys Glu Ser Arg Lys His Leu Ser Asn Ser Ser65 70 75 80Phe Gly Asp Leu Leu Asn Thr Pro Gln Glu Ala Asn Gly Asp Thr Leu 85 90 95Leu His Leu Ala Ala Ser Arg Gly Phe Gly Lys Ala Cys Lys Ile Leu 100 105 110Leu Lys Ser Gly Ala Ser Val Ser Val Val Asn Val Glu Gly Lys Thr 115 120 125Pro Val Asp Val Ala Asp Pro Ser Leu Lys Thr Arg Pro Trp Phe Phe 130 135 140Gly Lys Ser Val Val Thr Met Met Ala Glu Arg Val Gln Val Pro Glu145 150 155 160Gly Gly Phe Pro Pro Tyr Leu Pro Pro Glu Ser Pro Thr Pro Ser Leu 165 170 175Gly Ser Ile Ser Ser Phe Glu Ser Val Ser Ala Leu Ser Ser Leu Gly 180 185 190Ser Gly Leu Asp Thr Ala Gly Ala Glu Glu Ser Ile Tyr Glu Glu Ile 195 200 205Lys Asp Thr Ala Lys Gly Thr Thr Glu Val Glu Ser Thr Tyr Thr Thr 210 215 220Val Gly Ala Glu Glu Ser Ile Tyr Glu Glu Ile Lys Asp Thr Ala Lys225 230 235 240Gly Thr Thr Glu Val Glu Ser Thr Tyr Thr Thr Val Gly Ala Glu Gly 245 250 255Pro Arg Thr Pro Glu Gly Glu Asp Leu Tyr Ala Thr Val Gly Ala Ala 260 265 270Ile Thr Ser Glu Ala Gln Ala Ser Asp Ala Ala Ser Ser Lys Gly Glu 275 280 285Arg Pro Glu Ser Ile Tyr Ala Asp Pro Phe Asp Ile Val Lys Pro Arg 290 295 300Gln Glu Arg Pro Glu Ser Ile Tyr Ala Asp Pro Phe Ala Ala Glu Arg305 310 315 320Thr Ser Ser Gly Val Thr Thr Phe Gly Pro Lys Glu Glu Pro Ile Tyr 325 330 335Ala Thr Val Lys Lys Gly Pro Lys Lys Ser Asp Thr Ser Gln Lys Glu 340 345 350Gly Thr Ala Ser Glu Lys Val Gly Ser Thr Ile Thr Val Ile Lys Lys 355 360 365Lys Val Lys Pro Gln Val Pro Ala 370 375 148 amino acids amino acid single linear protein Ehrlichia 25Tyr Glu Gly Gly Gly Glu Arg Val Glu Leu Pro Val Arg Gln Tyr Leu1 5 10 15Pro Ile Leu Met Leu Arg Val Asp Pro Met Met Leu Arg Val Asp Pro 20 25 30Thr Met Leu Lys Val Val His Thr Asn Arg Ala Ser Ser Leu Asp His 35 40 45Val Val Glu Tyr Ala Lys Leu Val Asp Phe Pro Phe Gln Arg His Phe 50 55 60Leu Thr Leu Met Leu Arg Val Asp Pro Thr Met Leu Lys Val Val His65 70 75 80Thr Asn Arg Ala Ser Ser Leu Asp His Val Val Glu Tyr Ala Lys Leu 85 90 95Val Asp Phe Pro Phe Gln Arg His Phe Leu Thr Leu Met Leu Arg Val 100 105 110Asp Pro Thr Met Leu Lys Val Val His Thr Asn Arg Ala Ser Ser Leu 115 120 125Asp His Val Val Glu Tyr Ala Lys Leu Val Asp Phe Pro Phe Gln Arg 130 135 140His Phe Leu Thr145 89 amino acids amino acid single linear protein Ehrlichia 26Tyr Gly Ser Ser Lys Leu Gly Thr Thr Gly Phe Tyr Lys Arg Leu Val1 5 10 15Asp Ile Lys Pro Cys Glu Ile Ile Ala Ile Asn Ser Ser Phe Phe Phe 20 25 30Leu Tyr Ser Thr Thr Asp Phe Leu Cys Thr Arg Ser His Ser Cys Pro 35 40 45Asp Ala Tyr Val Thr Asp Ala Lys Pro Gln Val Phe Tyr Ala Ala Gly 50 55 60Cys Val Tyr Ile Phe His Asn Ile Ile Asn Ala Ser Val Asn Met Asp65 70 75 80Thr Arg Asn Arg Gly Asn Pro Val Tyr 85 238 amino acids amino acid single linear protein Ehrlichia 27Leu Gly Ser Ala Ala Gly Thr Gly Ser Gln Gln Ala Ser His Ile Pro1 5 10 15Pro His Asp Pro Gly Met Met Pro Tyr Ser Tyr Ala Gln Pro Ser Thr 20 25 30Ser Trp Asp Gln Pro Ser Thr Ser Gly Leu Gly Ser Ala Ala Gly Met 35 40 45Gly Ser Gln Gln Ala Ser His Ile Pro Pro His Asp Pro Gly Met Met 50 55 60Pro Tyr Ser Tyr Ala Gln Pro Ser Thr Ser Trp Asp Gln Pro Ser Thr65 70 75 80Ser Gly Leu Gly Ser Ala Ala Gly Met Gly Ser Gln Gln Ala Ser His 85 90 95Ile Pro Pro His Asp Pro Gly Met Met Pro Tyr Ser Tyr Ala Gln Pro 100 105 110Ser Thr Ser Trp Asp Gln Pro Ser Thr Ser Trp Asp Gln Pro Ser Thr 115 120 125Ser Gly Leu Gly Gly Thr Ala Gly Gln Gly Ala Gln Leu Val Pro Pro 130 135 140Pro Pro His Ile Ile Leu Arg Val Leu Glu Asn Val Pro Tyr Pro Ser145 150 155 160Ser Gln Phe Ser Thr Ser Gly Leu Gly Gly Thr Ser Thr Gly Met Gly 165 170 175Arg Ser Gln Ala Pro Tyr Val Pro Pro Gln Asp Gln Gly Ile Met Pro 180 185 190Tyr Ser Trp Asp Gln Pro Ser Ala Ser Gly Leu Gly Gly Ala Ser Tyr 195 200 205Thr Leu Glu Glu Ala Gln Val Ser Ser His Arg Pro Arg Thr Pro Ser 210 215 220Asp Asp Asp Ser Glu Pro Pro Ser Lys Gln Ala Arg Arg Ala225 230 235 334 amino acids amino acid single linear protein Ehrlichia 28Ser Trp Gln Lys Thr Thr Cys Leu Leu Met Ser Leu Phe Arg Ile Lys1 5 10 15Lys Val Asp Val Glu Ile Lys Asn Ser Glu Leu His Asp Gln Arg Asp 20 25 30Val Leu Asn Leu Val Phe Thr Asp Lys Asn Glu Ala Glu Leu Ala Tyr 35 40 45Lys Ala Tyr Gln Glu Gly Lys Ser Phe Glu Glu Leu Val Ser Asp Ala 50 55 60Gly Tyr Thr Ile Glu Asp Ile Ala Leu Asn Asn Ile Ser Lys Asp Val65 70 75 80Leu Pro Val Gly Val Arg Asn Val Val Phe Ala Leu Asn Glu Gly Glu 85 90 95Val Ser Glu Met Phe Arg Ser Val Val Gly Trp His Ile Met Lys Val 100 105 110Ile Arg Lys His Glu Ile Thr Lys Glu Asp Leu Glu Lys Leu Lys Glu 115 120 125Lys Ile Ser Ser Asn Ile Arg Arg Gln Lys Ala Gly Glu Leu Leu Val 130 135 140Ser Asn Val Lys Lys Ala Asn Asp Met Ile Ser Arg Gly Ala Leu Leu145 150 155 160Asn Glu Leu Lys Asp Met Phe Gly Ala Arg Ile Ser Gly Val Leu Thr 165 170 175Asn Phe Asp Met His Gly Leu Asp Lys Ser Gly Asn Leu Val Lys Asp 180 185 190Phe Pro Leu Gln Leu Gly Ile Asn Ala Phe Thr Thr Leu Ala Phe Ser 195 200 205Ser Ala Val Gly Lys Pro Ser His Leu Val Ser Asn Gly Asp Ala Tyr 210 215 220Phe Gly Val Leu Val Thr Glu Val Val Pro Pro Arg Pro Arg Thr Leu225 230 235 240Glu Glu Ser Arg Ser Ile Leu Thr Glu Glu Trp Lys Ser Ala Leu Arg 245 250 255Met Lys Lys Ile Arg Glu Phe Ala Val Glu Leu Arg Ser Lys Leu Gln 260 265 270Asn Gly Thr Glu Leu Ser Val Val Asn Gly Val Ser Phe Lys Lys Asn 275 280 285Val Thr Val Lys Lys Ser Asp Gly Ser Thr Asp Asn Asp Ser Lys Tyr 290 295 300Pro Glu Arg Leu Val Asp Glu Ile Phe Ala Ile Asn Ile Gly Gly Val305 310 315 320Thr Lys Glu Val Ile Asp Ser Glu Ser Glu Thr Val Tyr Ile 325 330 175 amino acids amino acid single linear protein Ehrlichia 29Ile Phe Ile Gln His Ser Asp Glu Ile Arg Glu Ile Leu Arg Ser Gln1 5 10 15Pro Lys His Ala Ala Asn Ile Val Glu Lys Thr Gly Val Asn Thr Glu 20 25 30Asn Leu Arg Val Leu Leu Ser Ser Ile Leu Ser Asn Ser Ser Gly Ser 35 40 45Ser Leu Pro Val Glu Leu Ala Ala His Tyr Val Ala His Glu Gly Val 50 55 60Val Ala Asp Asn Gly Asp Ser Ala Arg Arg Leu Pro Val Asn Gln His65 70 75 80Val Leu Glu Glu His Leu Val Tyr Arg Val Thr Ser Val Ser Gly Ile 85 90 95His Ile His Ala Cys Val Asp Tyr Val Val Glu Asp Ile Asp Thr Pro 100 105 110Gly Ser Val Lys Asp Leu Gly Leu Cys Ile Arg Asp Val Arg Ile Gly 115 120 125Thr Arg Val Ala Ser Ser Ala Glu Glu Val Cys Ser Ala Ile Gln Glu 130 135 140Lys Glu Gly Arg Ile Asp Arg Asn Asp Phe Ala Trp Phe Asn Val Asp145 150 155 160Gln Ser Leu Val Glu Thr Ser Arg Ala Glu Phe Arg Ala Ala Ile 165 170 175 41 amino acids amino acid single linear peptide Ehrlichia Modified-site /note= “Where Xaa is either a Met or Thr” 30Leu Gly Ser Ala Ala Gly Xaa Gly Ser Gln Gln Ala Ser His Ile Pro1 5 10 15Pro His Asp Pro Gly Met Met Pro Tyr Ser Tyr Ala Gln Pro Ser Thr 20 25 30Ser Trp Asp Gln Pro Ser Thr Ser Gly 35 40 860 base pairs nucleic acid single linear DNA (genomic) Ehrlichia 31AAAAGCTTAA GGAAGATGTG GCTTCTATGT CGGATGAGGC TTTGCTGAAG TTTGCCAATA 60GGCTCAGAAG AGGTGTTCCT ATGGCTGCTC CGGTGTTTGA GGGTCCGAAG GATGCGCAGA 120TTTCCCGGCT TTTGGAATTA GCGGATGTTG ATCCGTCTGG GCAGGTGGAT CTTTATGATG 180GGCGTTCAGG GCAGAAGTTT GATCGCAAGG TAACTGTTGG ATACATTTAC ATGTTGAAGC 240TCCATCACTT GGTGGATGAC AAGATACATG CTAGGTCTGT TGGTCCGTAT GGTCTGGTTA 300CTCAGCAACC TCTTGGAGGA AAGTCGCACT TTGGTGGGCA GAGATTTGGG GAAATGGAAT 360GCTGGGCATT GCAGGCCTAT GGTGCTGCTT ATACTTTGCA GGAAATGCTA ACTGTCAAAT 420CTGACGATAT CGTAGGTAGG GTAACAATCT ATGAATCCAT AATTAAGGGG GATAGCAACT 480TCGAGTGTGG TATTCCTGAG TCGTTTAATG TCATGGTCAA GGAGTTACGC TCGCTGTGCC 540TTGATGTTGT TCTAAAGCAG GATAAAGAGT TTACTAGTAG CAAGGTGGAG TAGGGATTTA 600CAATTATGAA GACGTTGGAT TTGTATGGCT ATACCAGTAT AGCACAGTCG TTCGATAACA 660TTTGCATATC CATATCTAGT CCACAAAGTA TAAGGGCTAT GTCCTATGGA GAAATCAAGG 720ATATCTCTAC TACTATCTAT CGTACCTTTA AGGTGGAGAA GGGGGGGCTA TTCTGTCCTA 780AGATCTTTGG TCCGGTTAAT GATGACGAGT GTCTTTGTGG TAAGTATAGG AAAAAGCGCT 840ACAGGGGCAT TGTCTGTGAA 860 196 amino acids amino acid single linear protein Ehrlichia 32Lys Leu Lys Glu Asp Val Ala Ser Met Ser Asp Glu Ala Leu Leu Lys1 5 10 15Phe Ala Asn Arg Leu Arg Arg Gly Val Pro Met Ala Ala Pro Val Phe 20 25 30Glu Gly Pro Lys Asp Ala Gln Ile Ser Arg Leu Leu Glu Leu Ala Asp 35 40 45Val Asp Pro Ser Gly Gln Val Asp Leu Tyr Asp Gly Arg Ser Gly Gln 50 55 60Lys Phe Asp Arg Lys Val Thr Val Gly Tyr Ile Tyr Met Leu Lys Leu65 70 75 80His His Leu Val Asp Asp Lys Ile His Ala Arg Ser Val Gly Pro Tyr 85 90 95Gly Leu Val Thr Gln Gln Pro Leu Gly Gly Lys Ser His Phe Gly Gly 100 105 110Gln Arg Phe Gly Glu Met Glu Cys Trp Ala Leu Gln Ala Tyr Gly Ala 115 120 125Ala Tyr Thr Leu Gln Glu Met Leu Thr Val Lys Ser Asp Asp Ile Val 130 135 140Gly Arg Val Thr Ile Tyr Glu Ser Ile Ile Lys Gly Asp Ser Asn Phe145 150 155 160Glu Cys Gly Ile Pro Glu Ser Phe Asn Val Met Val Lys Glu Leu Arg 165 170 175Ser Leu Cys Leu Asp Val Val Leu Lys Gln Asp Lys Glu Phe Thr Ser 180 185 190Ser Lys Val Glu 195 89 amino acids amino acid single linear protein Ehrlichia 33Gly Phe Thr Ile Met Lys Thr Leu Asp Leu Tyr Gly Tyr Thr Ser Ile1 5 10 15Ala Gln Ser Phe Asp Asn Ile Cys Ile Ser Ile Ser Ser Pro Gln Ser 20 25 30Ile Arg Ala Met Ser Tyr Gly Glu Ile Lys Asp Ile Ser Thr Thr Ile 35 40 45Tyr Arg Thr Phe Lys Val Glu Lys Gly Gly Leu Phe Cys Pro Lys Ile 50 55 60Phe Gly Pro Val Asn Asp Asp Glu Cys Leu Cys Gly Lys Tyr Arg Lys65 70 75 80Lys Arg Tyr Arg Gly Ile Val Cys Glu 85 484 base pairs nucleic acid single linear DNA (genomic) Ehrlichia 34ATCATAAGCT TTACATGTCC TATCCAGGCG ATTATCCCTA TCCATAGCAT AGTAACGCCC 60TGCAACAGTA GCAATTTCGG CATTTAAGTG CTCAATTTTA GCGTTCAGCA TACCGATATA 120CTTCTCAGCA GAACGCGGTG GAACATCCCT ACCATCTAGA ATTACATGTA TAAAAACCTT 180GATGCCAAAT CCGGTGATAA CCTCAATAAT GGTTTCCATG TGCGCCTGAA GAGAATGCAC 240TCCACCATCA GAAAGCAGAC CAATCATGTG GCATACCCCA CCCTTCGCCT GTATATCGCG 300CACAAAGTCC AACAATTTAG GATTCTTGTG AACCTCATTA ATCTCAAGAT TAATTCTCAA 360CAGATCCTGA AGCACTATCC TGCCGCATCC TATACTTATG TGCCCTACTT CTGAATTCCC 420GAACTGACCT GAAGGCAATC CGACATCCGT TCCACTAGCA GACAAACTAC TCATAGGACA 480GCAT 484 161 amino acids amino acid single linear protein Ehrlichia 35Cys Cys Pro Met Ser Ser Leu Ser Ala Ser Gly Thr Asp Val Gly Leu1 5 10 15Pro Ser Gly Gln Phe Gly Asn Ser Glu Val Gly His Ile Ser Ile Gly 20 25 30Cys Gly Arg Ile Val Leu Gln Asp Leu Leu Arg Ile Asn Leu Glu Ile 35 40 45Asn Glu Val His Lys Asn Pro Lys Leu Leu Asp Phe Val Arg Asp Ile 50 55 60Gln Ala Lys Gly Gly Val Cys His Met Ile Gly Leu Leu Ser Asp Gly65 70 75 80Gly Val His Ser Leu Gln Ala His Met Glu Thr Ile Ile Glu Val Ile 85 90 95Thr Gly Phe Gly Ile Lys Val Phe Ile His Val Ile Leu Asp Gly Arg 100 105 110Asp Val Pro Pro Arg Ser Ala Glu Lys Tyr Ile Gly Met Leu Asn Ala 115 120 125Lys Ile Glu His Leu Asn Ala Glu Ile Ala Thr Val Ala Gly Arg Tyr 130 135 140Tyr Ala Met Asp Arg Asp Asn Arg Leu Asp Arg Thr Cys Lys Ala Tyr145 150 155 160Asp 1039 base pairs nucleic acid single linear DNA (genomic) Ehrlichia 36TTAATCAGAG CGGTTGTGCT AGTCCTTTCC GAAATTCCTG TGCTGAATGC GGAGATTTCA 60GGCGATGATA TAGTCTACAG GGACTATTGT AACATTGGAG TCGCGGTAGG TACCGATAAG 120GGGTTAGTGG TGCCTGTTAT CAGAAGAGCG GAAACTATGT CACTTGCTGA AATGGAGCAA 180GCACTTGTTG ACTTAAGTAC AAAAGCAAGA AGTGGCAAGC TCTCTGTTTC TGATATGTCT 240GGTGCAACCT TTACTATTAC CAATGGTGGT GTGTATGGGT CGCTATTGTC TACCCCTATA 300ATCAACCCTC CTCAATCTGG AATCTTGGGT ATGCATGCTA TACAGCAGCG TCCTGTGGCA 360GTAGATGGTA AGGTAGAGAT AAGGCCTATG ATGTATTTGG CGCTATCATA TGATCATAGA 420ATAGTTGACG GGCAAGGTGC TGTGACGTTT TTGGTAAGAG TGAAGCAGTA CATAGAAGAT 480CCTAACAGAT TGGCTCTAGG AATTTAGGGG GTTTTTATGG GGCGGGGTAC AATAACCATC 540CACTCCAAAG AGGATTTTGC CTGTATGAGA AGGGCTGGGA TGCTTGCAGC TAAGGTGCTT 600GATTTTATAA CGCCGCATGT TGTTCCTGGT GTGACTACTA ATGCTCTGAA TGATCTATGT 660CACGATTTCA TCATTTCTGC CGGGGCTATT CCAGCGCCTT TGGGCTATAG AGGGTATCCT 720AAGTCTATTT GTACTTCGAA GAATTTTGTG GTTTGCCATG GCATTCCAGA TGATATTGCA 780TTAAAAAACG GCGATATAGT TAACATAGAC GTTACTGTGA TCCTCGATGG TTGGCACGGG 840GATACTAATA GGATGTATTG GGTTGGTGAT AACGTCTCTA TTAAGGCTAA GCGCATTTGT 900GAGGCAAGTT ATAAGGCATT GATGGCGGCG ATTGGTGTAA TACAGCCAGG TAAGAAGCTC 960AATAGCATAG GGTTAGCTAT AGAGGAAGAA ATCAGAGGTT ATGGATACTC CATTGTTAGA 1020GATTACTGCG GACATGGGA 1039 168 amino acids amino acid single linear protein Ehrlichia 37Leu Ile Arg Ala Val Val Leu Val Leu Ser Glu Ile Pro Val Leu Asn1 5 10 15Ala Glu Ile Ser Gly Asp Asp Ile Val Tyr Arg Asp Tyr Cys Asn Ile 20 25 30Gly Val Ala Val Gly Thr Asp Lys Gly Leu Val Val Pro Val Ile Arg 35 40 45Arg Ala Glu Thr Met Ser Leu Ala Glu Met Glu Gln Ala Leu Val Asp 50 55 60Leu Ser Thr Lys Ala Arg Ser Gly Lys Leu Ser Val Ser Asp Met Ser65 70 75 80Gly Ala Thr Phe Thr Ile Thr Asn Gly Gly Val Tyr Gly Ser Leu Leu 85 90 95Ser Thr Pro Ile Ile Asn Pro Pro Gln Ser Gly Ile Leu Gly Met His 100 105 110Ala Ile Gln Gln Arg Pro Val Ala Val Asp Gly Lys Val Glu Ile Arg 115 120 125Pro Met Met Tyr Leu Ala Leu Ser Tyr Asp His Arg Ile Val Asp Gly 130 135 140Gln Gly Ala Val Thr Phe Leu Val Arg Val Lys Gln Tyr Ile Glu Asp145 150 155 160Pro Asn Arg Leu Ala Leu Gly Ile 165 177 amino acids amino acid single linear protein Ehrlichia 38Gly Val Phe Met Gly Arg Gly Thr Ile Thr Ile His Ser Lys Glu Asp1 5 10 15Phe Ala Cys Met Arg Arg Ala Gly Met Leu Ala Ala Lys Val Leu Asp 20 25 30Phe Ile Thr Pro His Val Val Pro Gly Val Thr Thr Asn Ala Leu Asn 35 40 45Asp Leu Cys His Asp Phe Ile Ile Ser Ala Gly Ala Ile Pro Ala Pro 50 55 60Leu Gly Tyr Arg Gly Tyr Pro Lys Ser Ile Cys Thr Ser Lys Asn Phe65 70 75 80Val Val Cys His Gly Ile Pro Asp Asp Ile Ala Leu Lys Asn Gly Asp 85 90 95Ile Val Asn Ile Asp Val Thr Val Ile Leu Asp Gly Trp His Gly Asp 100 105 110Thr Asn Arg Met Tyr Trp Val Gly Asp Asn Val Ser Ile Lys Ala Lys 115 120 125Arg Ile Cys Glu Ala Ser Tyr Lys Ala Leu Met Ala Ala Ile Gly Val 130 135 140Ile Gln Pro Gly Lys Lys Leu Asn Ser Ile Gly Leu Ala Ile Glu Glu145 150 155 160Glu Ile Arg Gly Tyr Gly Tyr Ser Ile Val Arg Asp Tyr Cys Gly His 165 170 175Gly 2129 base pairs nucleic acid single linear DNA (genomic) 39TTTACCTCTT TTTGAAGAAA TCTTAAAGAA AAAGCATGGG GCACGGTCCA ACACATCGAA 60CCTTCCCCAT ACTTTTCACG AGAAAGATAT CCTAATAACT TAGAACATCT TCATCGTCAG 120GATCCTTTAA CGGCAAAGCA GTCGGAACAT CTACTAACTC TTGCTGCATA CCAGCATCAG 180CTTCTACAGA TACTTCAACC TTCTCAACTT CTTCAGTTGC TTGTGTCTCT TGATCAGAGA 240TTCCTGCTTC TTGCTGCATA CCAGCATCAG CTTCTACAGA TACTTCAGAC TTCAGATCAC 300CTTCAGTAAC ACCAAGAACT GTAGACTCAG GTTGTACTGG CGCAGAAACT TCAGGAGCTG 360ATTCTAGTTG TTGCGCTTCT GGAGCAACTA CCACTTCTTG AAGCTTATTT TCTTCTAGTG 420ATGGTACAAT CGCTTCTGCA GCTTCAACAC CAGGTAATTC TGCTTCAGCT ACTACAGGTA 480CTTGCGCTAC AGGTTGCTCA AGATCTATCA AAGTACCTTC TTCTAGAATA ACTTCTGGCT 540CTTCCGTTTT TGTTTCTACA GATACTTCAA CCTTTTCAAC TTCTTCAGTT GCTTGTGTCT 600CTTGATCAGA GATTCCTGCT TCTTGCTGCA TACCAGCATC AGCTTCTACA GATACTTCAG 660ACTTCAGATC ACCTTCAGTA ACACCAAGAA CTGTAGACTC AGGTTGTGCT GGTGCAGAAA 720CTTCAGGAGC TGATTCTAGT TGTTGCGCTT CTGGAGCAAC TACCACTTCT TGAAGCTTAT 780TTTCTTCTAG TGATGGTACA ATCGCTTCTG CAGCTTCAAC ACCAGGTAAT TCTGCTTCAG 840CTACTACAGG TACTTGTGCT ACAGGTTGCT CAAGATCTAT CAAAGTATCT TCCTTTAGAA 900GAACTTCTGT TTCTTCTTTT ACTTCTACAG GAGCTTCAGT TCCCTCTAGT GCTTCTGCAA 960TTTCTTGCTC TTGTTGACCA GAGATTACTT CTTTTTGCGC TACATCAGCA TTAGCTTCTA 1020CAGATACTTC AGACTTTAGA TCACCTTCAG CAACACCAAG AACTGTAGAC TCAGGTTGTG 1080CTGGCGCAGA AACTTCAGGA GCTGATTCTA GTTGTTGCGC TTCTGGAGCA ACTACCACTT 1140CTTGAAGCTT ATTTTCTTCT AGTGATGGTA CAATCGCTTC TGCAGCTTCA ACACCAGGTA 1200ATTCTGCTTC AGCTACTACA GGTACTTGCG CTACAGGTTG CTCAAGATCT ATCAAAGTAC 1260CTTCTTCCAG AATAACTTCT TGCTCTTCTG TCTCAACTTC TTCAATTGCT GGTGCTTCTT 1320GATCTATTTC TTGTTCTTCT TGCGTATCTA CACCCGACCC TGTTGCTGAC TCAACTACAC 1380TAGGATCTAC TGTTTGAGGT TCCTCTGCTG CACTCTTTTC TATCTTGAAA AACCTTACGA 1440CCGCTTTTTC TGGTGCGTTT ATCAAGTACA TACCTGTACC CTCTTCCTCT TGCACCAGCG 1500ATAATGCCTC CACAACGGTA GTATAAACAC CACCTTCAGC AGTAGCAGCT CTGCCCGCTT 1560CTGCCTCTAT AAAATACACC TTCCCTGGCA AATTACCATG ATGCATACCC GAAGCAACAT 1620CTCTACATGC CACATGCTCA TCACCAACAT ATAAAACCAG TTCGCTCGGT CTCCACGTTC 1680CCCGTACTAC CCTACACTTG TCATACGAGT ACGCATTAGT GCTGGCATCT TTGTCACAAG 1740CACATCCTTC GTAGTAGCCA TCATCTCCAC TGGAAATGGT TTCACTACCA ATTCTGTAAT 1800CACTTAGCTC TATATCTATA CCATACATAT ACGCAAATCC TCCTTTAATC CCTCTACGTT 1860CACCAGCATT TGTTTAAGTG CTACACGATA CACCTAAAGA GATGATATCT TGCACACCTA 1920TACATACAAT ATGCATATTT TACAACAACT TGCACAAATA TCCGACCAAC TAAGCACAAA 1980TAAGGACGAT GATAACAAGT ATGCGAAGAA ATCCCCTAAA CCATATTGCC TACTATCCTC 2040TAAAATACTA TCAAGCTTTA TCATGAGTGC TTTAGTTGCA AATTAGCAAA TTGTTCAACG 2100AAATCTAGCA ATGCTGTTTC CTCGTGCCG 2129 1919 base pairs nucleic acid single linear DNA (genomic) 40ATGCTGTGAA AATTACTAAC TCCACTATCG ATGGGAAGGT TTGTAATGGT AGTAGAGAGA 60AGGGGAATAG TGCTGGGAAC AACAACAGTG CTGTGGCTAC CTACGCGCAG ACTCACACAG 120CGAATACATC AACGTCACAG TGTAGCGGTC TAGGGACCAC TGTTGTCAAA CAAGGTTATG 180GAAGTTTGAA TAAGTTTGTT AGCCTGACGG GGGTTGGTGA AGGTAAAAAT TGGCCTACAG 240GTAAGATACA CGACGGTAGT AGTGGTGTCA AAGATGGTGA ACAGAACGGG AATGCCAAAG 300CCGTAGCTAA AGACCTAGTA GATCTTAATC GTGACGAAAA AACCATAGTA GCAGGATTAC 360TAGCTAAAAC TATTGAAGGG GGTGAAGTTG TTGAGATCAG GGCGGTTTCT TCTACTTCTG 420TGATGGTTAA TGCTTGTTAT GATCTTCTTA GTGAAGGTTT AGGCGTTGTT CCTTACGCTT 480GTGTCGGTCT CGGAGGTAAC TTCGTGGGCG TTGTTGATGG GCATATCACT CCTAAGCTTG 540CTTATAGATT AAAGGCTGGC TTGAGTTATC AGCTCTCTCC TGAAATCTCT GCTTTTGCTG 600GGGGTTTCTA CCATCGTGTT GTGGGAGATG GTGTTTATGA TGATCTGCCA GCTCAACGTC 660TTGTAGATGA TACTAGTCCG GCGGGCCGTA CTAAGGATAC TGCTGTTGCT AACTTCTCCA 720TGGCTTATGT CGGTGGGGAA TTTGGTGTTA GGTTTGCTTT TTAAGGTGGT TTGTTGGAAG 780CGGGGTAAGT CAAACTTACC CCGCTTCTAT TAGGGAGTTA GTATATGAGA TCTAGAAGTA 840AGCTATTATT AGGAAGCGTA ATGATGTCGA TGGCTATAGT CATGGCTGGG AATGATGTCA 900GGGCTCATGA TGACGTTAGC GCTTTGGAGA CTGGTGGTGC GGGATATTTC TATGTTGGTT 960TGGATTACAG TCCAGCGTTT AGCAAGATAA GAGATTTTAG TATAAGGGAG AGTAACGGAG 1020AGACTAAGGC AGTATATCCA TACTTAAAGG ATGGAAAGAG TGTAAAGCTA GAGTCACACA 1080AGTTTGACTG GAACACTCCT GATCCTCGGA TTGGGTTTAA GGACAACATG CTTGTAGCTA 1140TGGAAGGCAG TGTTGGTTAT GGTATTGGTG GTGCCAGGGT TGAGCTTGAG ATTGGTTACG 1200AGCGCTTCAA GACCAAGGGT ATTAGAGATA GTGGTAGTAA GGAAGATGAA GCTGATACAG 1260TATATCTACT AGCTAAGGAG TTAGCTTATG ATGTTGTTAC TGGACAGACT GATAACCTTG 1320CTGCTGCTCT TGCCAAGACC TCTGGAAAAG ATATCGTTCA GTTTGCCAAT GCTGTTAAAA 1380TTACTAACTC CGCTATCGAT GGGAAGATTT GTAATAGGGG TAAGGCTAGT GGCGGCAGCA 1440AAGGCCTGTC TAGTAGCAAA GCAGGTTCAT GTGATAGCAT AGATAAGCAG AGTGGAAGCT 1500TGGAACAGAG TTTAACAGCG GCTTTAGGTG ATAAAGGTGC TGAAAAGTGG CCTAAAATTA 1560ATAATGGCAC TAGCGACACG ACACTGAATG GAAACGACAC TAGTAGTACA CCGTACACTA 1620AAGATGCCTC TGCTACTGTA GCTAAAGACC TCGTAGCTCT TAATCATGAC GAAAAAACCA 1680TAGTAGCAGG GTTACTAGCT AAAACTATTG AAGGGGGTGA GGTTGTTGAG ATTAGGGCGG 1740TTTCTTCTAC TTCTGTAATG GTCAATGCTT GTTATGATCT TCTTAGTGAA GGTCTAGGCG 1800TTGTTCCTTA CGCTTGTGTC GGTCTTGGAG GTAACTTCGT GGGCGTTGTT GATGGGCATA 1860TCACTCCTAA GCTTGCTTAT AGATTAAAGG CTGGCTTGAG TTATCAGCTC TCTCCTGAA 1919 3073 base pairs nucleic acid single linear DNA (genomic) 41TCCCATGTCC GCAGTAATCT CTAACAATGG AGTATCCATA ACCTCTGATT TCTTCCTCTA 60TAGCTAACCC TATGCTATTG AGCTTCTTAC CTGGCTGTAT TACACCAATC GCCGCCATCA 120ATGCCTTATA ACTTGCCTCA CAAATGCGCT TAGCCTTAAT AGAGACGTTA TCACCAACCC 180AATACATCCT ATTAGTATCC CCGTGCCAAC CATCGAGGAT CACAGTAACG TCTATGTTAA 240CTATATCGCC GTTTTTTAAT GCAATATCAT CTGGAATGCC ATGGCAAACC ACAAAATTCT 300TCGAAGTACA AATAGACTTA GGATACCCTC TATAGCCCAA AGGCGCTGGA ATAGCCCCGG 360CAGAAATGAT GAAATCGTGA CATAGATCAT TCAGAGCATT AGTAGTCACA CCAGGAACAA 420CATGCGGCGT TATAAAATCA AGCACCTTAG CTGCAAGCAT CCCAGCCCTT CTCATACAGG 480CAAAATCCTC TTTGGAGTGG ATGGTTATTG TACCCCGCCC CATAAAAACC CCCTAAATTC 540CTAGAGCCAA TCTGTTAGGA TCTTCTATGT ACTGCTTCAC TCTTACCAAA AACGTCACAG 600CACCTTGCCC GTCAACTATT CTATGATCAT ATGATAGCGC CAAATACATC ATAGGCCTTA 660TCTCTACCTT ACCATCTACT GCCACAGGAC GCTGCTGTAT AGCATGCATA CCCAAGATTC 720CAGATTGAGG AGGGTTGATT ATAGGGGTAG ACAATAGCGA CCCATACACA CCACCATTGG 780TAATAGTAAA GGTTGCACCA GACATATCAG AAACAGAGAG CTTGCCACTT CTTGCTTTTG 840TACTTAAGTC AACAAGTGCT TGCTCCATTT CAGCAAGTGA CATAGTTTCC GCTCTTCTGA 900TAACAGGCAC CACTAACCCC TTATCGGTAC CTACCGCGAC TCCAATGTTA CAATAGTCCC 960TGTAGACTAT ATCATCGCCT GAAATCTCCG CATTCAGCAC AGGAATTTCG GAAAGGACTA 1020GCACAACCGC TCTGATAAAG AAGGACATAA ACCCAAGCTT AACATCATAC CTCTTCACAA 1080AGGCATCTTT GTACTTAGCT CTGAGCTCCA TCACTTTGCT CATATCAACT TCATTAAAGG 1140TGCTGAGTGT AGCAGAGGTA TTTTGTGACT CCTTAAGCCT AGCAGCTATA ACTTGGCGGA 1200TTTTGCTCAT CTTCACGCGT CTTTCACCCA CCACGTCGCC ATGGCAACTC ATCAGATCCT 1260TAGACGGCTG GCTAGCAACT ATCTTCTTGT CTTGTTCACT CTTAGCACTC ATACCCAAAG 1320CTCTAGAAGT AGGAGTTGTG TTGATTCCTG CAACAAAATC TTCTACAGTA GGAGTTACTA 1380GACCTTTGCC TTCAATAATT GTCTTTTCCT GCGGTTTTTG AGTGCTCACT GCCTGTGCAA 1440CAACGGGTTG AGCAAGCACC TCCTCCTTGC TCTCTGGCTC CTTATTAACA CCCTCTGCAG 1500TAGCCTCACC CTGTGGCCGT ATGATAGCCA AGACCTGCCC TTGGTAATCA CTTCTTCATC 1560TGCAACTCTC AACTCTGTGA GAACACCAGC AACAGGGGCT GATATTTCAA GAGAAGTCTT 1620GTCTGTTTCA ACAATGAAGA GCACATCTTC TGCAGATACA GTATCTCCCA CCTTTTTCAT 1680TACCCGAATC GGAGCTTCTA GAATGGATTC GCCACCAAGA TTCTCAGCCC TAACTTCTAC 1740AGCATCACCC ATAAATACAA ACCAGAACTA AAACAAAAAA CACAGATTGA AAGGCAGTGT 1800AATCACCAAA AGACACTAAT GTCAAACCAT AGATGAATAC CTTGTTATAA GTATCCACGC 1860GATAACGCTA TGTAATTTTC AGCAGATTTT TGTAGGTATA AAATCTCCTC TTCAGTCATC 1920ATACGTAGAA ATTTTGCAGG CCTACCTGCC CATAACTCTC CAGATTTTAC AATCTTACCC 1980CTAGTGAGCA GTGAACCTGC AGCTAACATG CTGCCCTCTT CCATCACTGC ACGATCCATA 2040ACGATTGATC CCATACCCAC AAAGGCGTTA TTCCCAAGAG TACAAGCATG CAATATGCAG 2100CTATGGCCAA TAGTAACGAA TTTACCTATT ACAGTATCAC CATGCATGCT ATCTGTATGT 2160ACTACTGTAT TATCTTGAAT GTTTGTACCT TCACCCACTT CAATTTTATC CACATCGCCC 2220CTGAGTACGG TTCCATACCA TATGCTGGCA TTCTTACCTA TACAAACATC TCCTATGATA 2280CGGGCATAAC CTGCGATAAA TGCAGTGCTA TCTACAGACG GTGATACTCC TGCATAAGGC 2340ACCAGAACTT CCCTCATAAC TTCACAACCT CCAGTGTTCT TTAAACGGCA CAGCATGATA 2400GTGTTTTTAG CACACCATAA CGGAGTACAC CACCACTCTT AACAGATTTG GCTCTGGCAC 2460ACTAGATGCA CACATATCTT GTATAGGACT TATATATTGT TGTTCATGAA ACGTGCGTAA 2520TGCTATGGGA GATTACTATT CTTATGTATG TAAATTAAGC AAATTTAGCA CGTGCTACTG 2580CACCCAGCAT GTTCTCATTT TCTTTAAAAG GCAGACCTTC CTTTTTCGAA ATAGCCTTTT 2640CTTTAGGAAG CGTAATGATG TCTATGGCTA TAGTCATGGC TGGGAATGAT GTCAGGGCTC 2700ATGATGACGT TAGCGCTTTG GAGACTGGTG GTGCGGGATA TTTCTATGTT GGTTTGGATT 2760ACAGTCCAGC GTTTAGCAAG ATAAGAGATT TTAGTATAAG GGAGAGTAAC GGAGAGACTA 2820AGGCAGTATA TCCATACTTA AAGGATGGAA AGAGTGTAAA GCTAGAGTCT AACAAGTTTG 2880ACTGGAACAC TCCTGATCCT CGGATTGGGT TTAAGGACAA CATGCTTGTA GCTATGGAAG 2940GCAGTGTTGG TTATGGTATT GGTGGTGCCA GGGTTGAGCT TGAGATTGGT TACGAGCGCT 3000TCAAGACCAA GGGTATTAGA GATAGTGGTA GTAAGGAAGA TGAAGCTGAT ACAGTATATC 3060TACTAGCTAA GGA 3073 3786 base pairs nucleic acid single linear DNA (genomic) 42AAAAGCTTAA GGAAGATGTG GCTTCTATGT CGGATGAGGC TTTGCTGAAG TTTGCCAATA 60GGCTCAGAAG AGGTGTTCCT ATGGCTGCTC CGGTGTTTGA GGGTCCGAAG GATGCGCAGA 120TTTCCCGGCT TTTGGAATTA GCGGATGTTG ATCCGTCTGG GCAGGTGGAT CTTTATGATG 180GGCGTTCAGG GCAGAAGTTT GATCGCAAGG TAACTGTTGG ATACATTTAC ATGTTGAAGC 240TCCATCACTT GGTGGATGAC AAGATACATG CTAGGTCTGT TGGTCCGTAT GGTCTGGTTA 300CTCAGCAACC TCTTGGAGGA AAGTCGCACT TTGGTGGGCA GAGATTTGGG GAAATGGAAT 360GCTGGGCATT GCAGGCCTAT GGTGCTGCTT ATACTTTGCA GGAAATGCTA ACTGTCAAAT 420CTGACGATAT CGTAGGTAGG GTAACAATCT ATGAATCCAT AATTAAGGGG GATAGCAACT 480TCGAGTGTGG TATTCCTGAG TCGTTTAATG TCATGGTCAA GGAGTTACGC TCGCTGTGCC 540TTGATGTTGT TCTAAAGCAG GATAAAGAGT TTACTAGTAG CAAGGTGGAG TAGGGATTTA 600CAATTATGAA GACGTTGGAT TTGTATGGCT ATACCAGTAT AGCACAGTCG TTCGATAACA 660TTTGCATATC CATATCTAGT CCACAAAGTA TAAGGGCTAT GTCCTATGGA GAAATCAAGG 720ATATCTCTAC TACTATCTAT CGTACCTTTA AGGTGGAGAA GGGGGGGCTA TTCTGTCCTA 780AGATCTTTGG TCCGGTTAAT GATGACGAGT GTCTTTGTGG TAAGTATAGG AAAAAGCGCT 840ACAGGGGCAT TGTCTGTGAG AAATGCGGAG TGGAGGTAAC TTCTTCTAAA GTTAGAAGAG 900AGAGAATGGG GCACATAGAG TTGGTCTCAC CTGTTGCTCA TATTTGGTTT CTTAAATCCC 960TGCCGTCACG TATAGGTGCT CTGCTAGACA TGCCTTTAAA GGCTATAGAG AATATACTAT 1020ATAGTGGAGA TTTTGTAGTA ATTGATCCGG TAGCTACTCC TTTTGCTAAG GGGGAAGTAA 1080TCAGTGAGGT AGTTTATAAT CAGGCGCGGG ATGCCTATGG TGAGGATGGA TTTTTTGCGC 1140TCACTGGTGT TGAAGCTATA AAGGAGTTGC TAACTCGCCT TGATTTGGAG GCTATCAGGG 1200CTACTTTGAG GAATGAGCTT GAGTCAACTT CTTCGGAAAT GAAGCGTAAG AAGGTTGTTA 1260AGAGGCTCAG GCTTGTTGAG AATTTTATTA AGTCTGGTAA TAGGCCGGAG TGGATGATCT 1320TGACTGTAAT TCCTGTTCTT CCACCGGATT TGAGGCCGTT GGTATCACTG GAAAATGGTA 1380GACCTGCGGT ATCAGATTTA AATCACCATT ACAGGACTAT AATAAACCGT AATAACAGAT 1440TGGAAAAGCT ACTCAAGCTG AATCCTCCTG CGATCATGAT ACGCAATGAA AAGAGGATGT 1500TGCAAGAAGC GGTAGATGCT CTGTTTGACA GCAGTCGGCG TAGTTACGTT TCCAGTAGAG 1560TTGGAAGCAT GGGCTATAAG AAGTCTCTTA GCGACATGCT AAAGGGTAAG CAGGGTAGGT 1620TTAGGCAGAA CTTGCTTGGT AAAAGGGTTG ACTATTCTGG TAGGTCAGTA ATAGTTGTGG 1680GCCCTAGTTT GAAGCTGCAT CAGTGTGGTT TGCCCAAGAA GATGGCTCTT GAGCTGTTCA 1740AGCCGTTCAT TTGTTCTAAG CTGAAGATGT ACGGTATTGC TCCGACTGTG AAGTTGGCTA 1800ACAAGATGAT TCAGAGTGAG AAGCCTGATG TTTGGGATGT TTTGGATGAA GTGATTAAAG 1860AGCATCCTAT TCTCCTTAAT AGGGCTCCTA CACTGCATAG ATTGGGTCTT CAGGCGTTTG 1920ATCCTGTATT GATAGAAGGT AAGGCAATAC AGTTGCATCC GTTGGTATGT AGTGCGTTTA 1980ATGCCGATTT CGATGGTGAT CAGATGGCGG TACACGTGCC ATTGTCTCAA GAGGCGCAGC 2040TTGAGGCGCG CGTGTTGATG ATGTCTACAA ATAACATCTT GAGTCCTTCT AACGGTAGGC 2100CAATTATAGT TCCGTCTAAG GATATCGTTC TTGGGATATA CTATTTAACG TTGTTGGAAG 2160AAGATCCTGA AGTGCGTGAA GTGCAGACTT TTGCGGAGTT CAGCCACGTG GAGTACGCAT 2220TGCATGAGGG GATTGTGCAT ACGTGCTCAA GGATAAAGTA CAGAATGCAG AAGAGTGCAG 2280CTGATGGTAC TGTATCTAGC GAAATAGTTG AGACTACGCC TGGTAGGTTG ATATTGTGGC 2340AGATATTCCC GCAGCATAAG GATTTGACTT TTGACTTGAT CAACCAAGTG CTTACGGTTA 2400AGGAAATCAC CTCCATTGTG GATCTTGTCT ATAGAAGTTG TGGTCAGAGG GAGACGGTAG 2460AGTTCTCTGA CAAACTGATG TATTGGGGAT TCAAGTATGC TTCGCAATCA GGTATTTCTT 2520TTGGTTGTAA GGATATGATT ATTCCTGATA CTAAGGCTGC GCACGTTGAA GATGCTAGCG 2580AAAAGATCAG GGAATTCTCT ATACAGTATC AGGATGGTTT GATAACCAAG AGCGAGCGCT 2640ATAACAAAGT GGTTGATGAG TGGTCTAAGT GTACCGATTT GATTGCTAGG GATATGATGA 2700AGGCTATATC TTTATGTGAT GAGCCAGCGC GTTCAGGCGC TCCTGATACG TAACCTTGTC 2760GCCAAGTGCA ACTTTTCCTA AACTAAAGCC TCAAATCTTT ATTATATTCT GTTAATGACT 2820CAGTGGACTT TTGGCAGAAA GAGCTAGTTT CCTTTGGTAC AAACACTTTT ATAGAGGGTT 2880CTGATTAATC TATCCGATGG TCTAAAATCA AAATAACATA TGCAATCGTT GGCTGAAAAA 2940GCTCACCCGT GGTGTTATAA CAATAATTCC TCTCCTTGTT TTCATATATA ACCTTTTGGA 3000AACATTCCTG TTGGAGCCAA AATTTCTATA TTTTGGAAAC TTGGCATATG GATGGATGAT 3060GGCTGAAGTA TGCCATTTAT TTTCCTTTTG GGGAGGACTA GAGAAAGCAG AATAGTTGTT 3120ACACTACTTT TGAAAGTAAA GTTTGTAGGA CAACCCAGTT TAATGTGGAA TAAAGCCCTG 3180TTCTTTAGTT TTCATGTCAT AACACATATT CATTTCTAAA CATTTTTCCT GACCACCCAA 3240TTTAAAGTAG TTGACATCCC CAGAAGTCAC TTTCTCTAAC AGAGGTCAAC ACACTTTTCT 3300GTGTACTGCC AGACAGTAAA CATTTTGGAC TTTGTATGTT ATATGGTCTC TTTCTGTTGC 3360AACTACTGAA CTCTTCCATT GTAGCACGAA GGCGGCTGCA GACAATATGT AAACAGATGA 3420GCATGACTCT GATCCATTAC AGCTCTATTT ATGGACACTG AAATTTAAAT TTGCTAAAAT 3480TTTCACATCA CAAAATATTA TCCTACTTTT GATATTTTTC TAACACTTAA AAAATGTAAA 3540AAACAATTCC TAACTCACAG ACCAAACACA ACCAGGCAGT AGACAGAATT TGACCAGTGA 3600GCTATCATTT GAGACCCTCA GTTCCACATT ACTTTTAGAG AGGTTTTTTA AATGTCACTT 3660CTTAGCATCT AAACAAATCT ATTTACATAT TTATATTACT TCTATAGTGT CATGTGCTAA 3720AATTTAAGCT CTTGTATTAG TCCGTTCTCA CACTGCTATA AAGACATACC TGAGACTGGG 3780TTTCAC 3786 3735 base pairs nucleic acid single linear DNA (genomic) 43AATGCGCTCC ACATAACTAG CATAACGTTT TCAGCAACGG CAGATCTTCA TATATAAGCA 60CTGAACACCT ACGTTCCAAG ATCATGCTCT TCGCGCCTGT TTACTTGGTG GCTCAGAGTC 120ATCATCACTA GGAGTTCGTG GTCTGTGAGA GCTAACTTGT GCTTCTTCCA GCGTATAACT 180AGCACCTCCC AATCCTGATG CTGAAGGTTG ATCCCACGAA TAAGGCATAA TCCCTTGATC 240CTGAGGTGGC ACATAGGGAG CTTGTGATCT TCCCATTCCA GTACTAGTAC CTCCTAGCCC 300AGATGTTGAG AATTGGCTAG ATGGATAAGG AACATTCTCT AGGACACGTA GTATAATATG 360AGGGGGGGGG GGAACGAGTT GAGCTCCCTG TCCGGCAGTA CCTCCCAATC CTGATGTTGA 420GGGTTGATCC CATGATGTTG AGGGTTGATC CCACGATGTT GAAGGTTGTG CATACGAATA 480GGGCATCATC CCTGGATCAT GTGGTGGAAT ATGCGAAGCT TGTTGACTTC CCATTCCAGC 540GGCACTTCCT AACCCTGATG TTGAGGGTTG ATCCCACGAT GTTGAAGGTT GTGCATACGA 600ATAGGGCATC ATCCCTGGAT CATGTGGTGG AATATGCGAA GCTTGTTGAC TTCCCATTCC 660AGCGGCACTT CCTAACCCTG ATGTTGAGGG TTGATCCCAC GATGTTGAAG GTTGTGCATA 720CGAATAGGGC ATCATCCCTG GATCATGTGG TGGAATATGC GAAGCTTGTT GACTTCCCGT 780TCCAGCGGCA CTTCCTAACC CTGATGTTGA GGGTTGATCC CACAATGTTG AAGGTTGTGC 840ATACGAATAG GGCATCATCC CTGGATCATG TGGTGGAATA TGCGAAGCTT GTTGACTTCC 900CGTTCCAGCA GTACCCCCCA TTCCTGATGT TGAGGGTTGA TCCCACGGCG CACCATAGGG 960TATGGGTATA CGCTCAAGAA CACGTAGTGG GACACTGATA GCTTGTGCTC CTTCCACTCC 1020AGCACTAGTA CTCCCTAATC CTGATGTCGA GGGTTGACTA GGTGCAGCAC CGGTCTGCTC 1080AACAGCATTG AAATATCTTC CGTATTTCTT GTCACAAATA TTCATCATTA CTGAAAGATA 1140CCGCAATGCT GTATTGCGCC ACTTGACTTC TATCTGTGGA ATTAATAGCG CATCTTCCGT 1200AATATGCTCA TTGATCTCCT CATAGACATG GCACATGTCT AAAAATGATT TGCGAGCCCT 1260GTATGCCCCG AGCTCCCTTC TTCTGCTATA TAAAGCACAC AAAATCTGGA GACAATGCCC 1320AATCCTACCT GCAACAACAT GATCTACATT ACCGGTGGAA GCGTATACTC TATACATCAA 1380GAACAAACCA CCTACTGCAT GCACTAAAGC ACCACCCCGA TACCTTTCTC GCTTGAGTCG 1440TAAATCAAAA CTGTGAACTC CTAAACCTTC AACATATGCC TCTAAATAGT AGAGAAAATT 1500TGCCATCGCT CTTCTAGAGA GTCCTAGACG CAGGCGTGCA CTTTCATTAT TACGTACCAT 1560CGCTTCACAT GCAGCTGCAC TAGTCTCAAT AGCATCAATA ACACTGTCCA AGCAAGCCTC 1620TGTACGATGA CGGAAAAAAC GCGGTGTATT AGGCTCAACT AACTCAGCAA CCTTACTGCA 1680AAGCTCTATG TTATGCCGCA CTACGCGCAA AATCGCCTTT ATATTCTCTG TTTCCTCAGA 1740ATCCAAAGAA GAATTTAAGC ATCTACTTAA GGCTGAAAAT TTTACATAGC AGTATGCACT 1800TAAAGCTGTC ACTGTATGAG ATGCACTACC ATCTCTACGC TCACTACTCA CTGCACCAGT 1860AAACCTCGTG GCAATAGTTC TGGCACAGCA GTTCACTATA GCAATAACAT TCACTATGAT 1920AGCACATGCC TTGCCTATTT GTAGGTGTGC CTTACGCTTA ATAAAGTCTT GATCCATGAA 1980CAGCGGCACT TCTTTGTTGC ACTGCGCCGT GATGCAGTCC TGCAACGCGT CGTACAACCG 2040ATTGATCAAA CTATACAACA CCCCCGGTTC TGCGCTTGAA GCACCTTCTG CAGCAGTTAT 2100ACAGCTGTTA ATACTGTCTA TCTTATCAGC TGCCGCAAAC ACGACATCTA CACCCCGGAG 2160CTTGACAAAC GTATCGCGCA ATTCCAGCAT ACATTGACGT ATAGCCTGCA GGCATGCAGC 2220ATATGGCCTG GAATTAGTCA TTATTGAATT ACATACAGTT TCTTTATATT CCGCAGAAGA 2280GCAACCACTG TAGGCATATC CAGACATAAC TGGAGTAGTG AATATACGAG GCATATGCAT 2340CTAATTAACC ACTGGAACAA CTTCACACCT TGAAAGTGTA GCATACCGGT GTGACGCAGC 2400TCAATATTAA AGATTATGCA CTTCGTGATC GTCTACTAGG AGGCTCAAGT TCATCATCAC 2460TAGGAGTTTG TGATCTAGGA GAGACTACCT GTGCTCCTTC CAGCGTAGAA CTAGCACCTC 2520CTAATCCTGA TGTTGAGGGT TGTGCATACG AATAATCTTG CAACGGACCA CAAGGTGCCT 2580GAGCTTGCAG TGCTCCCTGT CCAGCAGGAT TACCTCCCAA TCCCGATGTT GAGGGTTGAC 2640TAGGTGAAGA GGGCATATGC CCTGGATCAT GAGGTAGCGT ATAGGAAGCT TGTGATCCTC 2700CTATTCCAGC CCCAGCACTT CCTAGTCTAG ATGTTGAGGG TTGACTAGGC GAACCCTCAG 2760TCTGCCTAAT ATTATTGAAA TATCTCTCGT ACTTCTTTTC CCAAATACCA ATCATTGCCG 2820AAAGATACCC CAACATAGCA CTACAGAACC CAACTTCTGT CTGGGGATTT AATAGTAGAC 2880CTCGCGTAAC GCATTCCTGA ATCTCATCAT AGACAGTACA CATGTCCAAA TATAATTCTT 2940GTGCCGTATA TTCTGAAGCT CCCGCTCTTC TGACCTTATA TTTATAGAGA GTAAGCAACA 3000TTTGAAGACA ATGCTCAATT TTACTCGCAA CAACATGCCC TGTATTACCC GTGGAAGCAT 3060ATACTCTGTG CATTGAGAAT AAACTACCAA TTGCATACAC TAAAGCTTGC ACATACTTGT 3120CATGCCTGAA ACTTTTAAAA GCAACGCTCA GTCCTAAACT TTTATATGTC TTGAAATGGT 3180GTAAAAAACC TGTTCTCGCT TTTTTAGCGA GAGCTAGGCG GTTCTTTGCA CTATCGTTAT 3240CACTCACCAT CTCTTCGCAT TCAGCCGAGG TAGACCCAAC TGCATCAAGC ATACTGTTTA 3300AGCAACTCAC CGTACGATCA CGGAAACAAT ATGGAATCTC CGGATCAACT AGCTCAGCAA 3360CCTTATTACA AAGCTCTATG TTATGCCTCA CCACACGTAG AATAGCCTTT CTACGCTTAG 3420TTTCCTCAGG ACCCGGAGAA TAATTTAAAC ATCTGCTTAA AGCTGAAAAT TTTGCATTTA 3480CGTATGCACT TAAAGCCATG TTGGCATGAT ACGCACTATG CTCATCAGCC TCACCTATTG 3540CACTGTCAGA CGCCTCGGTT AAGGTTGTGA CAAAGCAGCT TGCCATGGTA ATAGCATTCA 3600CCAGGATAGC ACATACCTTA GCGATTTGTA GGTGTACTTC ACGCCTCGTG AAGTCTGGAT 3660CCATGAACCG CGGCACTTCT TTGTTGCACT GCGCCGTGGC ACAGTCATGC AGCATATTAT 3720ATGCACTATG GATTA 3735 2322 base pairs nucleic acid single linear DNA (genomic) 44AATGTATACA GTCTCAGATT CAGAATCTAT AACTTCTTTC GTTACTCCAC CAATGTTAAT 60GGCGAATATC TCATCGACTA AGCGTTCAGG ATACTTGCTA TCATTGTCGG TAGAGCCATC 120TGACTTTTTT ACCGTGACAT TCTTTTTAAA AGAAACTCCA TTTACAACGG ACAATTCAGT 180GCCATTTTGT AGCTTCGAGC GCAACTCCAC AGCAAATTCA CGTATTTTCT TCATACGTAA 240TGCACTCTTC CATTCTTCAG TAAGAATAGA CCTGCTTTCT TCAAGTGTCC TTGGTCTTGG 300AGGCACTACT TCAGTAACAA GAACGCCGAA ATAAGCGTCA CCATTGCTAA CCAGATGAGA 360CGGTTTTCCT ACGGCAGATG AAAACGCCAA AGTAGTAAAG GCGTTTATAC CAAGCTGCAA 420CGGAAAGTCT TTCACTAAGT TGCCAGATTT ATCGAGCCCA TGCATATCAA AATTCGTCAA 480AACACCACTG ATCCGCGCAC CAAACATATC CTTTAGTTCA TTCAGCAATG CCCCGCGGCT 540GATCATATCG TTTGCTTTTT TCACATTGCT AACTAGCAAC TCACCTGCCT TTTGCCTTCT 600AATATTTGAA GATATCTTCT CTTTCAGCTT TTCTAGGTCT TCCTTAGTGA TCTCATGCTT 660CCTTATTACC TTCATGATAT GCCAGCCGAC AACGCTACGG AACATTTCAC TGACTTCTCC 720TTCATTTAGT GCAAACACCA CATTTCGCAC ACCTACCGGA AGAACATCCT TAGAGATATT 780ATTGAGTGCA ATATCCTCTA TGGTGTAGCC AGCATCACTA ACCAATTCCT CAAAAGACTT 840ACCCTCTTGG TAAGCTTTGT AAGCTAGCTC AGCTTCATTT TTGTCTGTAA ATACTAAATT 900TAGAACATCT CTTTGATCAT GTAGTTCACT GTTTTTAATC TCAACGTCTA CCTCTTGATC 960CGAAACAATG ACATCAGCAA GCAAGTCGTC TTCTGCCATG ATTATATAAT CAGCACTGCG 1020ATATTCAGGG AAATTTAGAG AATTCTTGTA CTGCTCCTCA AACAATTTTT GCAATTCATC 1080ATCAGATATA TCACTTCCTG AAATGTCTAC GGCATCAGAA GATATTTCCA CTATGTCTGC 1140CACACGATGC TGCAGCAATC CCAACACAAC ATCTTTTGCT AATGCATCAT AATAAGGAAT 1200ATGTAATTCC GCCCTATTAG GGAATAAACA CTCCATTAGA ATAGTAGAAG GTAAAGCATT 1260GCGAATTTTA TTCACATAGG ACGACTCAGT CATTCCGCTG TCAGCCAATA CGGCTTCATA 1320TCTCTCCTGG TCGAAGACAC CATTAGCATC CTGAAATATT CTTATATTTT TGATCAGACT 1380CCGTAAGCTA TTTGAGCCAA CACGTATGCC TAAGTCATGA GCAAACTTTT CAACGACCAT 1440GTCGGCTATC ATGTTCTTGA GGACAACTTC CTTAATACCA AACTGATTAA TTTGAGCATC 1500AGACAATTTG TGTTGTAACA TCTTCTCTAG TTCTGCCAAC TCGTTGCGGT ACATTATACG 1560GTAATCCCGC AATGGTAGAC ATTTATTACC CAACATTGCA ACGCACTGTC CGTTGCCAGA 1620ATTAGACAAC TTACCCATTG GTATCATGCT TCCAAAAGTG ACAAAAGCCA TGGCACCTAA 1680AACCGTTGCC ATGACCACCC AAACATAAAT CTTCCTTGAT CGCATAACAG AACGCCCATA 1740GCTGGTCAGA TTCCCGAAGG AATATAGTAA TCAGAAAAAA TCTGCAAGAC TTTTTCTAGT 1800TGTTTATGGG CAATATTCTG AATTTTGCAT AGTAGCCATT ACGTAATGTA TGGATAGACC 1860CGTATTAATT TGTTTCGGTA CGATATATGA AGTTCTAAAA AGCTATAGAA CCTTGCCATG 1920CAAAGCTTAA GAGCCCTTAC CCATCCCATA TACATCCGTG TTAATGAAAG CACCATTCTG 1980CTGCTTGTGC AGAATTCTAC ATAAGCATCT CGTGCCGCTC GTGCCGAATT CGGCACGAGG 2040AATTAGATTT AATAGCAGAA GAGCAGAGGC ACTGTGGTGA CTGAAGCAGC AATTAAAGTA 2100ATGTGGCCAC AGCTAAGTAA TATCAGCAGA CACTGAAGTG GGGGAAGGAA GGAACAGATT 2160GTTACCTGGG CATGATCAAA TTTCTGGATT CAGAAAAGTG TGGATGAAAT CCTGGCTTTA 2220TTATTGATCA GTGCTGTGTG ATACAGCACC TAGTCCTCAA ACTCTTTCTT CTTAAGCATC 2280CACACTTGCA AAATGTGCAA CTTCCAATAT CCATCTCTAA GG 2322 2373 base pairs nucleic acid single linear DNA (genomic) 45GCAAATATTT TTCTTGGTGC CGCCCTAAAA GCCTGAAAAA TTTAAAGAAA TGTTACTGCT 60CTAGTCATTC ATAAAATGCA AATAGCCTAC AGAAGGAGTA TTTACTGCTA TAGGCTTGAA 120AGTGCAATCG TTATTTACTA TTTTTTATAC ATATCGCAGT ACAGAGATTT TACGCGCTAC 180GCCTGTGCAT CATAGCCGTA TTGCATCAAT AAATTGTCGT TGCTACGCGG GAAAGCTGCT 240TAGCGCTTGA CCATTTTTCA TACACATTGT ACCATCATAG CGAGTGTGGT GCTCATGAGA 300GTGCGTAGTG TTGCCGCCGG TTTCTCATGT TATAATCTTG CTGCCGTTTT GTGCAGAAGG 360AGGAGTAGTC TCGTTTTTTT CCAAAAGACA ATGTGCTGGA GTGTCCCGGT GAGCCTCAAG 420GTTCTTGTGG GATTTGTGTG GGCTGTTGTA TAAATACCAC GTTCGAAGCT GTCCTAGTGT 480AATTCAGCAT ATGTTGAGGA AGTTGTTGCT ATGAGGTTGA TGGTATGGCG AAAAGATTCT 540TAAACGACAC AGAAAAGAAA TTACTATCTC TGCTCAAGTC GGTAATGCAG CATTATAAGC 600CTCGTACCGG TTTTGTCAGG GCTTTGCTAA GTGCCCTGCG TTCTATAAGT GTAGGGAATC 660CGAGACAAAC AGCACATGAT CTATCTGTGT TGGTTACACA GGATTTCCTT GTCGAGGTTA 720TTGGCTCTTT CAGTACGCAA GCTATCGCTC CTTCCTTCCT CAACATCATG GCCCTGGTAG 780ATGAGGAGGC ATTAAATCAC TACGACCGCC CTGGGCGTGC TCCAATGTTT GCAGACATGT 840TGAGGTATGC GCAAGAGCAA ATTCGTAGAG GTAATCTGCT TCAGCATAGA TGGAATGAGG 900AGACATTTGC ATCTTTTGCG GATAGTTACC TCAGGAGAAG GCACGAGCGT GTCAGTGCGG 960AGCATCTTCG CCAGGCGATG CAGATCTTGC ATGCACCGGC TAGTTATCGC GTCCTGTCTA 1020CAAATTGGTT TTTGCTGCGT TTGATTGCTG CAGGGTACGT GAGGAATGCA GTTGATGTGG 1080TCGATGCGGA AAGTGCAGGG CTTACTTCTC CTCGGAGCTC CAGTGAGCGT ACTGCTATTG 1140AATCGCTCCT GAAGGATTAT GATGAAGAGG GTCTCAGCGA GATGCTCGAG ACCGAAAAAG 1200GTGTCATGAC GAGCCTCTTC GGTACTGTGT TACTCTCGTG CCGAATTCGG CACGAGTTGA 1260AAAGCAGCCT TTTTAAGGTA GACATCCTGT ATATGATTTA AGTCTCACCT CCCAATGGAA 1320TCATGAAACA GTTAGAAAAA TAATGAACTA CGTCTTATAT AATCTTTATC GCTACTTTAA 1380AAATGAGTAA TATATTCAGA TTTAGTAGAA ACATCCCTGA GGAACAATTT GTTTTCACAA 1440ATTACATTGG TTCCTCACAT GCAAGATTAT TAAGCATTAA GGAGGAGGAT ATTGGACATT 1500GTATACCCTG TAGGAATAGT TTTTTATTTT CAGAAATAAG CTCAGCTTAC TGATTGATGG 1560CAAAGATAGT TGATGATAAA ATAGAAAAAA ACAAAGTTAC TCTTCTTAAT TTTGTACTCT 1620TCTTACCTCC TTTCATTTTT AATTGGTTAT AAGTAGGTGA AAGTTAAAAC TTGGCAATGT 1680TTGCTTTAGG AGTTATTACA ATTACTCAGG TTAGTAGTAT AGTTATACGG TCATCTTTAG 1740TAAAACATCA TTCGGAGTCA TAGTCACACT TATGAATATC ACAGAATGGA TATGTGACTT 1800TGGGGTTTTT TTGTGGGATA TTTTTTGAGA TATTTAAGGC AGAAGTGCCA CCTTTACTTC 1860ATTTATTTTT ATCCGCCCCC CCCCCACCCC ACCGTTTCTC AGAAAGGATA AGGTTTTCAC 1920AGTACCAGAG ACATTTATCT ACTAAAACTT TGAACTAATT AAAATATATA GGGCCGGGTG 1980CAGTGGCTCA CGCCTGTAAT CCCAGCACTT TGGGAGGCCG AGGCGGGCGG ATCACGAGGT 2040CCGGAGATGG AGACCATCCT GGCTAACACG GTGAAACCCC GTCTCTACTA AAAACACAAA 2100AAATTAGCCG GGCGAGGTGG CGGGCACCTG GGGTCCCAGC TACTGGGGAG GCTGAGGCAG 2160AAGAATGGCG TGAACCCAGG AGGCGGATCT TGCAGTGAGC CAAGATCGCG CCACTGCACT 2220CCAGCCTGGG CGACAGAACA AGACTCCATC TCAATAAATA AATAAATAAA TAAAATATTA 2280TTTAATTTAA GAGAGTTGAA ATCATTGAAT TGATTCATTT AAACAAGGTA ATTTGCAATG 2340GGTCTATTTT TAGGCTATTT TCTTTATAGT AGT 2373 7091 base pairs nucleic acid single linear DNA (genomic) 46CCTATGGCAG CTCTAAACTC GGCACGACTG GTTTCTACAA GAGATTGGTC GACATTAAAC 60CATGCGAAAT CATTGCGATC AATTCTTCCT TCTTTTTCCT GTATAGCACT ACAGACTTCC 120TCTGCACTAG AAGCCACTCG TGTCCCGATG CGTACGTCAC GGATGCAAAG CCCCAGGTCT 180TTTACGCTGC CGGGTGTGTC TATATCTTCC ACAACATAAT CAACGCAAGC GTGAATATGG 240ATACCAGAAA CAGAGGTAAC CCTGTATACT AAATGCTCTT CCAAAACATG TTGATTAACA 300GGTAAGCGCC TAGCACTATC ACCATTATCA GCAACAACGC CTTCATGCGC AACGTAATGA 360GCAGCGAGCT CAACTGGCAG AGATGACCCA CTACTGTTAC TCAAGATACT AGATAAGAGT 420ACCCGGAGAT TTTCTGTGTT TACACCAGTT TTCTCCACAA TATTTGCAGC ATGCTTCGGC 480TGTGACCTTA AGATTTCACG TATTTCATCG GAGTGTTGTA TGAAAATACC ACAGTCCCCA 540CGCACAGGTA CAGAGTGAGA TGCCCAGCGA TGGCGCTTCC CCAGATCTTC CCATAGCGAA 600AGGCCGTGAG CTACTATTTC CTCAGCAAGA TTGAAAATGT GGCCTCCGGC AAAATCTGTA 660TCTTTTGCAC TGCCAGCGAG GAAATCTCTA AGTGATATAC CGCCTCCAAG TGTAAGTACA 720TTGCCAAATG TATTCACAGT TACCGCCACA TGACGGAGAA TAGTGGCGCA TGCATCGTGC 780GCCTGAGAGG CCACAAAGGA CATGCAGACC CCCATTTTGG ATACAGCATC CCTGCCATGA 840GAAACAGCGC CCTGCTGTAC TACACTAGAT TTATCGTATC CTACCAGACC AACAACGCCT 900CGTACAACTA CTCGGAATAC ACCGCTCGCT TCTTGACTGA TTACTGTATT ACAAAAAGAA 960AGCTCTAGGA CTTCTAGCGG CATACCGCTA ATAACGCTGT AAGCTCTTAG GATGCATTCA 1020TCAATATCGC TTACATCGTA AAAAACCCTA CGAGCCATGT AACGTGGGTT ATGCCTCTGC 1080AGATTACACG CGCTGTACAA TACATGAGTA GGCTTCTCAG GGACTCTCAC ATAGTGTTTT 1140GCCAGAGCTT TGGGAATATT GTGCCAAGAA CATACAGATC CAGGCTCGCC TTGCCTAACG 1200TCGCGGCAAT CTCTCTCAGT AAGCACGAGC TTTACTTTTT TCACAGCTGT ACGGTAAACA 1260CCCTCCGCCT TTGTCGATGG AGCAATGTCA TACTCTACCC ACATCTTAAC TTTGGCTATG 1320GGTACACCAC TGTTGTCCTG AATACTAAAT ATGCATGATT CGTGTACTGT CAGAGCACCG 1380TTCTTGTAGC TACTAGGTGC TGAAGCCAAT AAAGAATGCA CCCTGGAGAA AGTAGTATAA 1440CTCTGAACTT CAAATGTGGT AGAGTCCTCT TCTCTGACTA TTGTCATATC TTCAGACACC 1500CCATCCAGGC ATCCAAGAAC AAAATTAGTT AAATCCTCTT CCTGGTTTTT TCCTGGCAAG 1560CTGTTATAGG CAAGTGCAAG GGCATGCCAC AGCTGGAAAG GTACTTGTTG GAAGGCAGTA 1620CTGTTACTCG CTGTCTTATG CAGAGCTCTT GCTAATAAAT CTGGGGAAGT TAGATTCTCA 1680TGTATGAGTG CAGGAGGTAC CGCACTGCCC TCACGTAGAG TAAACCCCTC TGCTAAGAGT 1740ATGACCATTC TGCGTCGTGC AGGATGACTG TTCCGATCAC GACATAAAAA GAAATCTATC 1800GCGCTACCAA GCAGTGCAAC GGACGCTTTC GATGGGTTTT GCTTAAGCAG CAGAGTCATG 1860GGTGCCTCAT CTTAGTTACT TCTAGTGACA AAGCGGTACT TTTATTCCTG TAAGGACAGA 1920AAGGCCTGTT TTTTTCCAGA AATCTACGCC TTACATGTAT GGAAACCTGC GCATCCAGCT 1980ATAGATATCG CAAGGCATAG TGTGCAGAAT ACGGAGCTGT AGCAGGCGCT CTTACCCCCC 2040AGCAAAGTAC GCAAACCTAG CGACGACTCG TTCTCACACG TTGTGAACAT ACGTAGTAAC 2100ACACCTTGAC GTACCTAGCC TACACCACTA GACATATAGT GTAAAACAAA AAGTACCAGA 2160TCCCCGTCTC AGGGGTTGTA AAAGTAGCAC ATTGGAAACG GACTGTTAAG TATTTATATT 2220ACTACTTAGG TTCAGAATAA ACATTCGAAT TGTAATGCAC CATAGGTTAG TAATGCACTA 2280TGAGTGAGAA ATTACGCGAA TTGGTACTGT GCGATGATCT TGAAATTTAC AGTTGTAGAC 2340ACGGCGCATG CGGAAGATAT AACCTCTCAA ACCCTGCAGA GGTTTTACTA ATCATATGTT 2400TTGTCTAATA CCTGCCCACA AAAAACATAT GAAAGCCTTC GTAGCTCAGG TCGGTTCTCT 2460GGCTGTTTTC ATCTCTAGGT TTTAATTCCC AAGAATTCGA CTTTTCGCGC TACCTAAGCA 2520TTTTTAATCA CCGTTGACTA TTAGAGACGA TATAATAAGC TACATTGATT ATCTGAAATA 2580TGTGATCCTT CTAAAAATCT TTAGGTGCTT TAGAAGAAGT ACATATTACC CTCTATGGCA 2640ACAACATTGA TAATTTAGGT GAAGTGTCAC AGCGTTTCAT TATGAAAAAA AGGGATACTT 2700ATTTATGGGG AATGGCACCT TATGCAATAT GAGCCTTAGG GATTGCCACA GTGTTTTGGT 2760TTCACAGCAT GAGTAAGGAC GTGGTTTTTT AGCAAGTATT TATTGTGCTA TGTGTGTAAA 2820AAGTAACATA TGAAGATCGC TAAAGAATTC ACACTAGAAA TAAGTTGATA CCTGATGATG 2880TAGTATAAAG GTTGAGCAAT AGTCTTTTTT TGACTGTAAA TCCCGCATGC AGCTTTATGT 2940GTGTTTATCG CAAAAAGTGG GCGTTTGTTG CAATAAAAAT TGAAATGCCA ACTATTATTG 3000CACATACCGT GCTCATACCC TTAATCTTGT AGATGCGCTG TAATCACAAT TCGCATGTGC 3060AGCAAAACTG TAATAGATAG CTTAGCACAG GGACGAATAA TCCCTAGATT CTACGCTGCG 3120GGCTAGTGCT TTTTTTAGCA TCTATACGGG AGTATCTTTG ATATGATAAA CACACAACAG 3180CATGATGCTG TGCTTATATA GCATTGGTAT ATATTCTGCG ATGCGGACTA ATCAATGTTG 3240TAATCAAGTA AAAAATGCTT TTTTGAACCG TATATTGTTC GTAAGGCATG TATTACTCAG 3300TTGTCGTACT ACAAATTCCT CTTCCTCTAG AGCATGCAAG TATGAATACA GCTTATGTGT 3360GCGATGCGTA GATTACTAAT GCATGATTAG TGTAGGGTAT GCTGTATTTT TTGCATGCGT 3420TTTAGATATG TTACGCAACA CATGTTTTTC AAGGACGCTG TGGCTATCAC GGATATGATA 3480GCCACAATGC GCTGCTCTTA GGTCAACTAG GATGGGCTGT GGGTTTATGC ATATTAAGCA 3540GTGGCTCCTG CATTCAAAGC TATTCTTTGT TGTGGTTAAC AATCAAAAAT AGAGAGTAGT 3600TTGTTTATAA GAAGATATGC AAAAAACCTT TTTATCCACA GTAAGCCCCA GGCGTATCGA 3660TGCACAAGGA TCCACCATGG CTATGTCTTA AGGATGTACC CAGAATATGA TCGTATCTCA 3720TTGGCTAAGC AGAGCGTCCT CCAGTTTCTG ATTCTACAGA TAGTACATCC TGTAATGAAG 3780AAATGGATCC TTCATCAAGT GTCGTTGATG GAGCATCATC CGGACAGTAC TTTGTAGTAG 3840TGCTCTCGGA GTTCAGATCA TCGCTTGTAC TTACATCATC ATATGACGAA GAAACATCAA 3900TCGTAGCATG TTCGGGTTGA GGCTCTGCCA GATGCACTTC CTGAGAGAGG AGGTCATGAT 3960ATAAATCCCA CAGATAGTGC TGTTTTTAAC CAGGTCCCTG AAAAACTCTT CTGGAGAAAC 4020TGGCAGAGGA GCCATTGCGT ACTGCAGTTT GGTAATATTC ATGCCTATGC AAGGGATGCG 4080TTGAACGCGA ACAAGTGTAG GATCTGGTAC GCGCGTATCT TGAGGAGTAA AGACTTTCCG 4140TTTATAGAAC CGATGCTTCA ATCTGAGTAG AAGACGTCCT AACGGAGGAC ATACTCTAAA 4200CAGTAATGGT GGTGAGGTCT TTATATTGCA GTCTGGTGGA GTGATGATTG TCAGGTTTAA 4260TGAACAGTTA TCATAGAGAA CTCGTCCCTC TCCTTGTATA GAGATCTCGT ATTTCAGTGC 4320TGTGTTTACT TTGAACGCAG GAGTCTTTTC TCCCTCTGTA GACTGCGGCA CTTTCAGGAG 4380AAAGTCCAAA TTCTCGCAGA CTGCAATACG CTCTGGTGTT ATTGCATCTA CCTGTTTTAT 4440ATTGCTACAC GCTGATACAT AGATGCGATT TAGTAGATTT AGCGTGGCAC CTGCATCGCT 4500AAAGAAGTAT TCTTTATCCA AAGCATGTTT TATAGGCCAA ATTACATCGA AACATACCCA 4560GGCTGACAGC CCTCCTTGAT GGCAATGGCT TGCTATTTCA TCAAGCAGTC TAATGTCTGG 4620GACGACCCCA TGACGATCAT CTCGGAACAT TTTTTGCAGC ATGGCTATCG CGAGACTTCT 4680TTCACGATAG CGGCGCAAAA ATACCCCTCT ACTTACTCCA TATGTTCTCT GACATACAAG 4740ATTAAGGTTA GTGATGCTCG ACGATTTTAT GCTCCTTTCT AGTCTTGCAA TATGAGCACT 4800TACATTTTGT CTAGGGTAAA ATGTTTTATT GATGCACCAG TCACATCTAT GCATATCGAT 4860TAGAAACTGA TGGCCGTACA AGTTAGACTT GTTTTTATAC GAATCGCAAA GTGCGCTGTG 4920GAAGGAAAAC CCCGATGCAC CTTCCAGCCA TTTTTTCTTT TGAGAATACT TTAAACTTAC 4980ATCTATAGAA GGGCGATGAT CCTTATGCTT AGCTTTACTA TCCTTACTTG CGTCAGAGCT 5040ATTGTGTGTG CAGATATGTA CTGAATTAGC CTCATCTTCT GCCTTAGAGA CAGCACTACT 5100AGATGTTGAA AAAATTGAGA TTATCCTAAA AAACAGTGCT CTCAAATAGT TCAGGATACC 5160ACTGACAGTT CTTCTAGATC CATTGTGAGT ATTCTTTTTA CGCAACTTAA ACCTCCATGT 5220TACACAATAT GCAGCTTTGC TATTTTCCTT TCTCATGTGG ATGCGCTAAT CTGCGTTTGA 5280TCAGTAGTAA CGACGCGCGC TGTAGTGTAG TTGTTCCAAC AATGAACATG CAAAATTGCT 5340GCAATACTTA ACTTCCTCCT TCTGAAATGC ATTTCCCACA TTTCAGGCTT TTACTATTTC 5400ATGCTTTACA TCGTGTAGCG CATTTTTGAA AAAACAAGAT ATTAGTACAG CATTTCTGGT 5460AAACCAGTAA TTGTTCCTAT TCAAGGTCTC TGAATCATGA CGACCACTTT CTTTGCGGCA 5520ATTGAGAAAT TCCTCACATA TTTGATATAC ACCGCACTTT TTGTTTTTGC TCCATGAATG 5580GATTACCGGA TCCAAGGGCA TTGCTATACT TCACTGTGCA ACACTACTGT AAGTGTCGTT 5640AGCATATCAT GAAATTATTA AATAATATGT AGAATATGTT GTGCAAAAGA CGCTTATAAC 5700AACTTAATAG TGAATTTCAT GAAATTTGTG AGTAGTTTTC TATCGGAATA CGTGTTTTAG 5760CAACGCTATA GATGGGGTAA GATCGCTTTT ATGTTCAGAA ATTCGCAACC ATACTATTTT 5820CTCTGTATGC GAAGACATGT CTTAGCGTCA AGCCACATAT GTGGGGTACT TAAGCGTTGC 5880CTTGCACGCA ACAGCTCCAC ATTGCCTGGA TTTTTCTTAA CATCAGCTAA TTATATACCA 5940GACTCACAGA TATACTACGC GTAACCAGTC ATATTATGCA GCACCTGTAC ATGTTCTCTG 6000GGGAGTTCCT TTATGAAACG AGACATTTTC ATGGATTGGC TCCAGTTATT GATTTCTCTC 6060ATTGCAGCAC ATGATATGTA TAGCTGCTCT CTAGCTCTTG TTATGCCAAC ATAGGCTAAG 6120CGCCTCTCTT CTTCCAGAGC GTTTCCAGTT ATGTCATTCA TGGATTTTTC GTGTGGGAAG 6180ACTCCTTCCT CCCATCCGGG GAGGAAAACC AACGGGAACT CCAACCCCTT TGCGGCATGT 6240AATGTCATAA CGTGTACGTA GTTATTGTCT TCTTCTAAAG AATCATTTTC TGCCACTAAG 6300CTAATGTGTT CTAAAAACTT CGACACATCA TCGAATCCTG ATACGGCTGA GAAGAGTTCC 6360TTTATGTTCT CTATTCTTGA TAGACCTGAT TCCCCGTCTT TTTTTAGAGA TTCTATATAT 6420CCAGAGTCAT GAGCAATAGC TTTTAGTACA TTGACGGATG AATCTCTACT TAACATTTCT 6480CTCCAATCAT CAAACTGCTT GAGAAGATCT TGCAGAATGT TGGATGTATT ATCAGATAGT 6540AATCCATCTT TTATCATTGA GTGTCCGGCT TCAGTTAGGG AAATACTGTG CTTTCTCCCA 6600TATGCACGAA GCTTATTGAC AGTAGAAGTT CCGAGCTTGC GTTTGGGCTT ATTTATAATT 6660TTCTCAAACG CTATGTCGTT ATTGGGGTTG ACTACTACTT TGAGATATGC AACAAGATCG 6720CGGATTTCTA CCCTATCATA GAACTTGGTT CCGCCGATAA TTTTGTAAGG TATACCATAT 6780CTTACGAAGA ACTCCTCGAA GACTCTAGTC TGAAAGCTGG CTCTTACTAG AACAGCAGTT 6840TCACTAAATT TATAATCGTA AGAGCTCTTA ATATGCTCAC TAATGTATTG AGCTTCGAGC 6900CGTCCATCGA AGAACTTCAT TAAACCAACT TTTTGTCCTG CCTGATTGTG CGTCCATAAT 6960GTTTTTTTAA GGCGGGATTT ATTATTATCA ATTATCGCTG ATGCTGAGGC TAATATGTTA 7020GACGTTGACC TATAATTACA TTCCAGCCTT ATTACTTTAG CGTCTGGGAA ATCATCTGAA 7080AATCTGAGTA T 7091 3947 base pairs nucleic acid single linear DNA (genomic) 47GGTATATCGA TAGCCTACGT AGTCACTCCT TATTATTAAA AAGGAAGACC AAGGGTATTA 60GAGATAGTGG AAGTAAGGAA GATGAAGCAG ATACAGTATA TCTACTAGCT AAGGAGTTAG 120CTTATGATGT TGTTACTGGG CAGACTGATA ACCTTGCCGC TGCTCTTGCC AAAACCTCCG 180GTAAGGACTT TGTTAAATTT GCCAATGCTG TTGTTGGAAT TTCTCACCCC GATGTTAATA 240AGAAGGTTTG TGCGACGAGG AAGGACAGTG GTGGTACTAG ATATGCGAAG TATGCTGCCA 300CGACTAATAA GAGCAGCAAC CCTGAAACCT CACTGTGTGG AGACGAAGGT GGCTCGAGCG 360GCACGAATAA TACACAAGAG TTTCTTAAGG AATTTGTAGC CAAAACCCTA GTAGAAAATG 420AAAGTAAAAA CTGGCCTACT TCAAGCGGGA CTGGGTTGAA GACTAACGAC AACGCCAAAG 480CCGTAGCCAC GGACCTAGTA GCGCTTAATC GTGACGAAAA AACCATAGTA GCTGGGCTAC 540TAGCTAAAAC TATTGAAGGG GGTGAGGTTG TTGAAATAAG GGCAGTTTCT TCTACTTCTG 600TGATGGCGCT TGAACTCCGG GTATGCTGGT GATTTTGAGG TATTGGGAGT TATACCGCAA 660GTATATAACT TAAATACTGC ATCGTAAGGA TATCCTTCTG TTTCTGAGAC ACTGGTAAGT 720ATGCCCATTA CCTATGAATC TCTATGTAGA TGTAATAAGA GCATACACAG TAACTCTTAT 780TATTAAAAAC AAGACCAATG GTATAAGGGA TAGAAGAAGA GTATTATTAG AGAGGATGAA 840GTAGATACAG TATATCTACT AGCTAAGGAG TTAGCTTATG ATGTTGTTAC TGGACAGACT 900GATAAGCTTA CTGCTGCTCT TGCCAAAACC TCCGGTAAAG ACATCGTTCA GTTTGCTAAG 960GCGGTTGGGG TTTCTCATCC CAGTATTGAT GGGAAGGTTT GTAGGACGAA GCGGAAGGCT 1020GGTGACAGTA GCGGCACCTA TGCCAAGTAT GGGGAAGAAA CGGATAATAA TACTAGCGGT 1080CAAAGTACGG TTGCGGTTTG TGGAGAGAAG GCTGGACACA ACGCCAATGG GTCGGGTACC 1140GTGCAGTCTT TAAAAGACTT TGTAAGAGAG ACGCTAAAAG CGGATGGTAA TAGGAATTGG 1200CCTACTTCAA GGGAGAAATC GGGAAATACT AACACAAAGC CTCAACCTAA CGACAACGCC 1260AAAGCTGTAG CTAAAGACCT AGTACAAGAG CTTAATCATG ATGAAAAAAC CATAGTAGCT 1320GGGTTACTAG CTAAAACTAT TGAAGGTGGG GAAGTGGTTG AGATTAGGGC GGTTTCTTCT 1380ACTTCTGTGA TGGTCAATGC TTGTTATGAT CTTCTTAGTG AAGGTTTAGG TGTTGTTCCT 1440TATGCTTGCG TCGGGCTCGG TGGTAACTTC GTGGGCGTGG TTGATGGGCA TATCACAATC 1500CGTTGGGCTT CGACCCTATA TGCTCACAGC AAGTCACTAG GCAAAATTGG AGCTGCATCA 1560CTCCGAAACA GACTACGATC AGCGATTCTC CATACCTAGT AGATCAGTAC AGTGGCTTTA 1620TACTCTTACC CAGCATGAAA TACTTGCTAT CTAAGAATCT CCTCTAAAAC TTTCCAGAGG 1680TTATCTGTAC TTCGAGAGGA AGCTAATCTG CGACTAATAC GGATGGTGTT TATAATATCA 1740CTCCTAAACT TGCTTATAGG TTAAAAGCTG GGTTGAGTTA TCAGCTTTCT CATGAAATCT 1800CGGCTTTTGC GGGTGGCTTC TACCATCGTG TTGTTGGTGA TGGTGTTTAT GATGATCTTC 1860CGGCTCAACT ACCTACAAAT TGATAGGTAC ACTAAAAGCC CACGTAATAA CTCTCATTAT 1920TAAAATGAGG AAGATGAAGC AGATACAGTA TATCTACTAG CTAAGGAGTT AGCTTATGAT 1980GTTGTTACTG GGCAGACTGA TAACCTTGCT GCTGCTCTTG CCAAAACTTC CGGTAAAGAC 2040TTTGTTCAGT TTGCGAATGC TGTGAAAATT TCTGCCCCTA ATACTCGTGC CGAATTCGGC 2100ACGAGCGGCA CGAGCTATAT TTAACTTATA AGAAATCAGC AGACTATTTT TCAAATTGAT 2160TGTACAATTT ACCTTACCTG GGAATATATG TGAGAACCCT GGCTTCTCTA CCTTTTAACA 2220ATATTTGCTA TTATTATTTT TAAAGTATTA GCTATTGTGG TTATGTGGAA TTAAATATCA 2280ACTTGGTTTC AATTTGCATT TTCCTAATGA GGAATGCTGT TGACTACGTT TTGCATGTGC 2340TTGTGGGCCA TTTATGTATC TTCATTACAT TTGTTAAGGG ATCGTGTGAG ACATTCATTC 2400ATTTTTATTT TATTGTCATT CCATTACTTG TTAACTCTTT CTACTAGTCT TTTAAAATAA 2460TGTTTAATTT ATCACCTTTT TATTTATGGC TTTCTTTTCT TGGCCTTGTT GGACAGATAT 2520TTTTCCTACC CCACATCATG AAGACAGTCC CCTATGTTCT TGTTTGTTTG ATAAAATACG 2580TAGACTTTAA CTCTTGAATG AGATGCATAA CTTACCTCAA ATTAAGTTTG TGAATGTTAG 2640TAGGTAGAGG GCAACATACA AATTGTATAT GAATATATTG TTGTTCCATC ATCATTGGTT 2700TAAAAAATTC TTAATTCTCC TGATGAAATT ACTTGGGATG TCTGTCAAAT AAATCTTAAA 2760ATACTTTTTG TTAATTTTTA TTAAGTAGTG TACTGAAATT AAATTGGAAC TGGTTAAATC 2820TATAGATTGT TAAATTGAAT ATATAAAGGT TAAATTGAAA TTCATTCAAT TCATGTACTT 2880CTTAAATTTC TATCAGCTAA CTTTTATAAT TTTTGGTATA GAAATCATAC ACAACATAAA 2940AAAATACTAA GTATTTTATC TATTTTTGAT ACAAATGTAA ATTAAAATTT AATTTTTTAC 3000TGCTAATATT ACTTATTTAA AATTTTAACT CTTAATCATT AAATATCTCT AATATCACAT 3060ATATATTTCA ATGTATATAA TTATAAAGTA ACACTTCTTC CTTGTCAATT TGTGTGGCTT 3120GTACTAAATT GTATTAATTT TTCTTTATTT AAGATGTCTT TATTTCCTCT TTATTCTTCA 3180ATAATATGTT CTCTGGAATC AAAATCAAGA TTTACATTTC TTTTATTTCT ACACTTGAGA 3240GATATGGTGT CAGTTCTTCC TGGTTTCCAT GATTTCCATA GTTCCCACTG TTTTCATGAA 3300ATCCACTGTT AAGCAATTTA TCCCCTTTAT ATAAAGTGTC ATTTTTTTGT TGTTACTTTC 3360TTTGTTGTAT TTAGTTTTTA GAAATTTGAT TATGATATGT TGTAGTGTAG ATTTCCCAGG 3420TGTTTTCTTG TTTGATGTTC TCTAGTTTGG TGGCTACCTT GTTGAATCTA TAGGTTTTTT 3480TATTTACACT TAACTAAATT TGAGAAGTTG TCAGCCATTA TTTTCTTAAA TTACTTTTGA 3540CTTTTTTAGC CTCTACTATT TCTATTTCTT TTTTTGAGGC TCTGATGACA TGGATATGAG 3600GTCTTTTGTT TTAGTTCCAC AACTCGTGCC GCTCGTGCCG AATTCGGCAC GAGAAAAGGA 3660CAAATGTTGT ACAGTTTCAC TTACATGAGA TACCTAGCAC AGGCCTTTTC ATAGGGAAAG 3720TGGAATAGAG GTTACCAGAG CTCAGGGCAT TGGGAAATGG GGAGTATTGT TTAATGGGCA 3780CGGAGTTTCT GTTTGAGATG AGGAAAAAGT TCTGGAAATG TGCAGTATTG TACAAGCTCA 3840CAAATTGTAC TAAGCTCATC AATTTAATGT TAATGCCACT GAATTGTCTA CTTAAAAATT 3900GTTAAAATGT TAATTTTCAT ATTGTGTATA TTTGACCACA GTTTAAA 3947 5521 base pairs nucleic acid single linear DNA (genomic) 48TTCACCTGGC CAAATCTTAT TGGATCTTCA GGACAAAGAC CAAGAATCTG CTTCTCCAAG 60AAGCATTCTC TGACCCCCAC CTACCTATCT GACTCTTAGC TTAGATTCCT AATGGTGTGA 120GTGTGTCAGA GCCTTTACTT AGTCTAAGCG TAACTGTAAA AACATCTTTT CAAAAGTCTC 180TGCATGACTG TCTAGGTCTC ACCTATCACA CTGTAAGCAT CTGGAAAACA AAGCCACTGA 240GTCTTCCTTT TACCAAAAAG GCCTAGCCTT GTTTTTGACA AATGGCAAGA ACACATTAGA 300TGTTTGTTGA GAGAACAAAA GGAGAGAACT CATTATGAAA CTCTGGACAA CATTTATATA 360CCTCTCTACA TTTTTTGTGT TGGAGGTTAG TTTTCTTTTC TAATAATTTG ATTTCTTTGG 420ATACATCGAG GCAATACACT TAAGAAGCAA GAAGATTGGG GCCAGCCTTC TAGACTGTTC 480AAAGGGTTAC ACCCAACAGA AGGGAAATAT TCCCGAGATG ACCTTGGTGC CTGTTGGGGT 540GATCAAGCCC AACACCAGGC CGTCGGGGCT ACAAAGTCCA GTGGGGTCAA AGGAATGAGA 600AAAGACAAGT TAAGAGTGCA TAAAGTGTAT CCAGGGGGCT AACGCTAGAT TGGAGGCTGT 660GAAGGCCCGG AGCTCTGGGA GCCCACACTA TTTATTGCTG GAGTAGAAAG GTAGCAGTGC 720ATCAAGTGTA GCTGTGACAG TTTAGCATTT TCTTTGACAC ATATAGAATA TGCTCTGCTG 780CTTGATATAA TGGAGAGCAT GTTTATGAGC CTGGGAGAGC AACCAACAAG TCTGTGCACA 840TTCCAGAGGC TACGAGGGGC TTTATGCCCT GAGCCCTGGA TTCCATCCAA GCCGCAAGGG 900GTTTTATGCC CTGGGCTTAG ATTTGTGGCG TGGCAGTGCA GCCTTCCACC CTTTGGCACA 960GAGCTTGGTG TTCCAAAGGC CACGAGGGGT TTTAGACCCT GGACCCCGGA CATCCTCCAA 1020GGATCTTTTA TATTACGACA AACAAGCCAG TCCTGCCTCA GCTCTTCTAC CAACAGGTAC 1080CTTTGGCCAA ATGTCTGAAA TAGGGTTACA GATTCTATAA CTGATGGATC TCCTAACAGG 1140ATAATTGAGT GTCTTATAGG GAAGTTGACA TTTTTTTGGT TACTCTACTC CAAGGCATTG 1200AATTGTTTAC AGTTTTTATT TGTTCATGGT GGAAACTGTG GCTGTATATT ATTTCTTATT 1260GGTGTAGGCT AGTATGATAA ACTTTGCTTA TCTTTTAGTT TGTTATCAAC CCATAGTAGC 1320ACATCAAACT GAATCTACAA AAAAAACTAT GGAAAACCCT TATGTATGTG TTTCATGAGC 1380AAAATTACCT TTGCTTCAAA TTCCAACCTT GGAAATGTTT CTTGAGTTTC TACAGGTAGT 1440CTAATACCAG ATTCTATGTA CCTTGTTGTA ACCTCGTGCC GAATTCGGCA CGAGCTCGTG 1500CCGTGCTGAG TCATTATTTC CTCTCATAGA TATAGTGCTT TCTGAAGGAG GAATATCCTA 1560CCAAAATTTA ACTGACATTG CAGTAATAAT AGGCCCTGGA AGCTTTACTG GGTTAAGAGT 1620ATCTCTGGCA ACAGCACAAG GTTTTGAGCT TGCTTCTAGT GTTGCTGTTC ATGGGATCAG 1680TCTTCTTGAA CTACAAGCAT ATTCAATTTT GTGTGCTTCT GAACAAACTG AAGAAGATAT 1740AGTTGCTGTG ATAGAATCTA CAAAAGCCGA TTTTGTCTAT TATCAAATGT TCAATAACTC 1800CCTCATTCCC CTAACAGGTG TGCATTTAGT GCCTCTAAAT GAAGTGCCTC AAGGCAAAAT 1860ATTGAAGGGC TCCCCTGCTA TAGCTTTGGA TACCAAGTCT ATTGGGTTGT ACCTTATTTA 1920TAAACTATCA AATCGACTTC CGAAAACTAC ACTTGCCCCC ATTTATTCGC GCTTTTACCA 1980CTAGAGTGTC CATGATAATT TAACTGATAA CATCAATCGG GCTAGATATG TGTCTAGCTT 2040TTGTGCGTAA GCTCTTATGG AAATAAGTGT GATATTTTGC GAGCACATGG TGATGGAGAG 2100CTCATCTAAG GCAGCCTCAG TAACATGCCC CGCGTCTATG AATTGTGATT GTAATGCGTA 2160TTAAGGATTC CACAATTTCC TGTGACAACC ACTAAAAGTA GTCTACAAGC TATAAACTCT 2220TAAATCTATA GATTGCTAGG GCTGATAAAG AACCTTTAGC ATTAGAAGCG TAGAGAGACA 2280CTGATGGGTT AGAATTTGAT ACAAAAACAT GACCTTATTA CTACAATAGT TTACTTGTGA 2340GCAGTGCACA CCAAGAATAT AACATTAAGC TTCTGAGAGG ATACACTCAC TGAGACTCTG 2400TGAGATCTGA CGTACCCTTA CCCAATCTAC TACACTCTAC CTCTGGCAAC GCATTCTACA 2460GAGCACGTTT TAGCGTGAAA ATCTTCACAC GAAGATACCG TTGTATTGTG GCTCCAGTTA 2520GCGTCACTAA GTATTGAGCT AGCAGTTCCA CCTTGATTAA AAGGTACTGC ATCTTATACA 2580GACTTTAGCA GTCCCATTAC ATACTCACCT TGATCTAGAA AACAATGATC TAGCCGCACC 2640TAACATTTCT ATCTTCAAAA AACCACTTAT AGCGTTTTTC TCTCCAACTT CTAAAACATA 2700CTCTATATAC TTTAAAGGTT TTATTGAGGA AATCAGAAAA GATTTTTCAA GTAACACTGA 2760GCTTTCTTTT AAACATCTGG TGCAGAGATA TGTACTACAC AAACTGAAAT ATAAACGTTT 2820TGGAAAATAT CTATAAATAT GAAACATTAA GTTTTAAGCA TAATATGCTT TAAAACTAGC 2880AGAATATATT GCAACACATA TTCTATACAT TCTTGCTTGC ATTAGAATAA AAATAGATTG 2940CTCAAGGAAA CTGCTAGGTA TACATATACC TTTTCACCAA ATTAGCAGTG TATACCTTCT 3000GGAATACTCA TAAGCGTCTT GTGAATACGA TGTTTTTCTA CACTGCAGGT AAGATGACGT 3060TTGGCCTATT TTTCGTATCA GCAGGGCTCA GGTAAATGAT GTATGTGCGG TGTTATTATC 3120TATCAACAAA TGCGTATGGT GTATTTTTGA TGCCGAAAAT TGTCTCCATC TCACAGGCAG 3180CATATCTTAC TCTTGTAAGC ATATAAAATT TTAGTTCACA GTGTTAAGAA ACACTGTTAT 3240TTGATCCCTT GAAGGTATGC TTAAACGGTT TGAAAATGCA CGTCCTGCAG TGTGTTTGTA 3300ATACCTGTTC TAACAACCAA GAGCTTTAAG CATCTCGAAA AAGCTTTTAA GAAATTGATG 3360CGTCCCCTAG TAGTGCCGCG GTAAGCATTA TTATGAACGC TCAAAGGTAT AGTATTTTGG 3420CATATTGAAT ATTACAGTAC AGCATCAATA TACAGTTTAA AACTCAAGTA TCACATCTCC 3480TACTGCTATC ATCTATGCTG GAAAAACTCA TTTATACCCT GTGATGCGCT TTTAAGAGTG 3540TTACACTGTT AATTCTTTCC TCTGTTTAAA TGTTATGCAG AACATGAGTA ATAAAACTAA 3600TAGAAGATAT GTGAGAAGAG GCATTCAGCC CATTACTTAC TCATGGATTA GATAAGAAAC 3660TAGAGCCACG TTTGCTTCTG TTTTTCGTGA CATGCTTATG TAGAATTCTG CACAAGCAGC 3720AGAATGGTGC TTTCATTAAC ACGGATGTAT ATGGGATGGG TAAGGGCTCT TAAGCTTTGC 3780ATGGCAAGGT TCTATAGCTT TTTAGAACTT CATATATCGT ACCGAAACAA ATTAATACGG 3840GTCTATCCAT ACATTACGTA ATGGCTACTA TGCAAAATTC AGAATATTGC CCATAAACAA 3900CTAGAAAAAG TCTTGCAGAT TTTTTCTGAT TACTATATTC CTTCGGGAAT CTGACCAGCT 3960ATGGGCGTTC TGTTATGCGA TCAAGGAAGA TTTATGTTTG GGTGGTCATG GCAACGGTTT 4020TAGGTGCCAT GGCTTTTGTC ACTTTTGGAA GCATGATACC AATGGGTAAG TTGTCTAATT 4080CTGGCAACGG ACAGTGCGTT GCAATGTTGG GTAATAAATG TCTACCATTG CGGGATTACC 4140GTATAATGTA CCGCAACGAG TTGGCAGAAC TAGAGAAGAT GTTACAACAC AAATTGTCTG 4200ATGCTCAAAT TAATCAGTTT GGTATTAAGG AAGTTGTCCT CAAGAACATG ATAGCCGACA 4260TGGTCGTTGA AAAGTTTGCT CATGACTTAG GCATACGTGT TGGCTCAAAT AGCTTACGGA 4320GTCTGATCAA AAATATAAGA ATATTTCAGG ATGCTAATGG TGTCTTCGAC CAGGAGAGAT 4380ATGAAGCCGT ATTGGCTGAC AGCGGAATGA CTGAGTCGTC CTATGTGAAT AAAATTCGCA 4440ATGCTTTACC TTCTACTATT CTAATGGAGT GTTTATTCCC TAATAGGGCG GAATTACATA 4500TTCCTTATTA TGATGCATTA GCAAAAGATG TTGTGTTGGG ATTGCTGCAG CATCGTGTGG 4560CAGACATAGT GGAAATATCT TCTGATGCCG TAGACATTTC AGGAAGTGAT ATATCTGATG 4620ATGAATTGCA AAAATTGTTT GAGGAGCAGT ACAAGAATTC TCTAAATTTC CCTGAATATC 4680GCAGTGCTGA TTATATAATC ATGGCAGAAG ACGACTTGCT TGCTGATGTC ATTGTTTCGG 4740ATCAAGAGGT AGACGTTGAG ATTAAAAACA GTGAACTACA TGATCAAAGA GATGTTCTAA 4800ATTTAGTATT TACAGACAAA AATGAAGCTG AGCTAGCTTA CAAAGCTTAC CAAGAGGGTA 4860AGTCTTTTGA GGAATTGGTT AGTGATGCTG GCTACACCAT AGAGGATATT GCACTCAATA 4920ATATCTCTAA GGATGTTCTT CCGGTAGGTG TGCGAAATGT GGTGTTTGCA CTAAATGAAG 4980GAGAAGTCAG TGAAATGTTC CGTAGCGTTG TCGGCTGGCA TATCATGAAG GTAATAAGGA 5040AGCATGAGAT CACTAAGGAA GACCTAGAAA AGCTGAAAGA GAAGATATCT TCAAATATTA 5100GAAGGCAAAA GGCAGGTGAG TTGCTAGTTA GCAATGTGAA AAAAGCAAAC GATATGATCA 5160GCCGCGGGGC ATTGCTGAAT GAACTAAAGG ATATGTTTGG TGCGCGGATC AGTGGTGTTT 5220TGACGAATTT TGATATGCAT GGGCTCGATA AATCTGGCAA CTTAGTGAAA GACTTTCCGT 5280TGCAGCTTGG TATAAACGCC TTTACTACTT TGGCGTTTTC ATCTGCCGTA GGAAAACCGT 5340CTCATCTGGT TAGCAATGGT GACGCTTATT TCGGCGTTCT TGTTACTGAA GTAGTGCCTC 5400CAAGACCAAG GACACTTGAA GAAAGCAGGT CTATTCTTAC TGAAGAATGG AAGAGTGCAT 5460TACGTATGAA GAAAATACGT GAATTTGCTG TGGAGTTGCG CTCGAAGCTA CAAAATGGCA 5520C 5521 1938 base pairs nucleic acid single linear DNA (genomic) 49TTGAGGAGTA TTAAGCAAGT CTCCGAAAGA TGAGTTTGAC AAATGCTTTC GAGACTCTTT 60AAGCATCTTT AAAAAGCATT TTTCTGTAAC CTTATCAGAA TATAAAGCCT CATGTAACGC 120TGTATCTCCC ATATGAGAAA GGAGTGCTTG ACAGCTATCT GGGCATTTTT TCGCAATTTA 180CTTATATAGC TTACCGTCAC CATTAGCAGC TGCTATATGT AAAGCCGTCT TACCATAAGC 240ATCTCTCTGC GTTGCTGGAG CCCCTTTATC CAAGAGCAAC CTAGCAGTCT TCTGGTTGCC 300AGCAGCTGTT GCTAAATGCA AGGCTGGAGT TCCAGTGTGA TCCGTAGACG AAAGATCTGC 360ACCCCTCTGT AAAAGGAAAT TTACAATCCT ATTAGCCTCT TTAAGGTTAC TTGCCTCATT 420TGCCACTTGA ACTGCAGCAG CTAAAGGGCT CATAGATCCG GTAGGAGTAT TTATATGTGC 480CCCAGCTTCT ACAACACGCT TTAAATGCTT TATAGCTTTA CCCCCCTGAA AGCACCCTCC 540TTGTATACCC ACAGAAATAG CTGGTTCTGG AGACGCATTT ACATCAGCAC TGTTTTTAAT 600TAACGTCTTC ACTGCAGCAT ATTGACCACT AGTTAGTGCT TCAGCGGTCA AAGTTGTCTT 660TTTTCCTTCA GGAGTTGTAA TTTCTTCATT TACACTAATC ACTTCAGTGG TAATAAGATG 720CCTCAATACA TCTGCTGCAC CTTTTCTTAC TGCCTCGACA GCAACATGCT GCGGGTAAGG 780CTCATATCTC ATTAACATGT CAAGTGCTGG TAGCGATACT TTTCCACCAC TTGCTTCACG 840AATCGCATAT ACACCTGGAG TAGGAACACC ATCCTTTACA GGAAACTTAG AATAACTACT 900CTTCCTTCCA AGAGCCTGCT GCAATATCTC TAAATTTCCA TCCTTTGCTG CGTAATGTAT 960TATAGTTCCA CCATCATGTG ACCGAGCATC TACGTCCATG CTATTACAGC GTAACATAGT 1020CTTAACACCC TCAGTGTTGC CCCCTTTATA CGCAGCTACC ACAGGCGTTT CACCTGTCAC 1080TGGAGATGGT ACATTGATTG ATGGAATATT ACGCACATTC TCAATCAACA TCTGCAATTT 1140AACGCTTACG CCTTTATGGC TTGGCTCATC CTCAACTATC ATGTGAATAG GCGCTTTGCC 1200ATTCGGTGCT AATTGATTTA CAACAGACTC AGGAGTGCAT CTTACCACCT GCTCAAAAAC 1260CCCCACTGTT GATTTTTGTG CTGCAGCATG TATAGGTGCA TTACCTGCAA TATCTAAATT 1320AGTAAAAGGT TCCTCTCCAT ACCTATGATA TGCTTCCTCC AATACCCTTT TCGCAAGAGG 1380ATCAAAATTT GGGGTCCCAT TAGAAGATAC AAAATGCACC AGCGTTGATG CGTCCTCTGG 1440ATTAGGACAT GTAAAGAGAG ATTTTACTTC TGAAGAAGCT GAGCCATACA CTTTATCTGC 1500AATGTTCATG GCCTTCTCGA AGATCTTCTC AGCCTCCGGT ATAGCCTTCT AATAGCATAC 1560TGTACTGCAC TCATCCCTTT TTTATCCGGG AATATTAGTG CCTCTGCACA CTGCGATTGC 1620CCTCAATATT TGACGACACC GCTTCTTGCA TCTTGTCAAT GTATGATAAA ACATCCCGCC 1680TTGGCCATTG CTTTGCAACA ATGTGGCAAA CGGTTTCACC AGCATCATTT GCAACGCTAA 1740TATCACTTAA CCTTGAGAGA AGATGCTTTA CTTTCTGGTG ATCCATACGC TCCGTAGCAA 1800TATGAAGCGG AGTGTTTCCA CCCGGTCCCT TAGCATTAAC ATCTGCTATA AGAGCTTTGT 1860CGCATAGTAC ATCAAGATTG CCTAAAGCAT TTTTGCCTAC TGAAGATGCA GCTGTATGTA 1920ATGGCGTATT ACCATCTA 1938 578 amino acids amino acid linear protein 50Met Tyr Gly Ile Asp Ile Glu Leu Ser Asp Tyr Arg Ile Gly Ser Glu1 5 10 15Thr Ile Ser Ser Gly Asp Asp Gly Tyr Tyr Glu Gly Cys Ala Cys Asp 20 25 30Lys Asp Ala Ser Thr Asn Ala Tyr Ser Tyr Asp Lys Cys Arg Val Val 35 40 45Arg Gly Thr Trp Arg Pro Ser Glu Leu Val Leu Tyr Val Gly Asp Glu 50 55 60His Val Ala Cys Arg Asp Val Ala Ser Gly Met His His Gly Asn Leu65 70 75 80Pro Gly Lys Val Tyr Phe Ile Glu Ala Glu Ala Gly Arg Ala Ala Thr 85 90 95Ala Glu Gly Gly Val Tyr Thr Thr Val Val Glu Ala Leu Ser Leu Val 100 105 110Gln Glu Glu Glu Gly Thr Gly Met Tyr Leu Ile Asn Ala Pro Glu Lys 115 120 125Ala Val Val Arg Phe Phe Lys Ile Glu Lys Ser Ala Ala Glu Glu Pro 130 135 140Gln Thr Val Asp Pro Ser Val Val Glu Ser Ala Thr Gly Ser Gly Val145 150 155 160Asp Thr Gln Glu Glu Gln Glu Ile Asp Gln Glu Ala Pro Ala Ile Glu 165 170 175Glu Val Glu Thr Glu Glu Gln Glu Val Ile Leu Glu Glu Gly Thr Leu 180 185 190Ile Asp Leu Glu Gln Pro Val Ala Gln Val Pro Val Val Ala Glu Ala 195 200 205Glu Leu Pro Gly Val Glu Ala Ala Glu Ala Ile Val Pro Ser Leu Glu 210 215 220Glu Asn Lys Leu Gln Glu Val Val Val Ala Pro Glu Ala Gln Gln Leu225 230 235 240Glu Ser Ala Pro Glu Val Ser Ala Pro Ala Gln Pro Glu Ser Thr Val 245 250 255Leu Gly Val Ala Glu Gly Asp Leu Lys Ser Glu Val Ser Val Glu Ala 260 265 270Asn Ala Asp Val Ala Gln Lys Glu Val Ile Ser Gly Gln Gln Glu Gln 275 280 285Glu Ile Ala Glu Ala Leu Glu Gly Thr Glu Ala Pro Val Glu Val Lys 290 295 300Glu Glu Thr Glu Val Leu Leu Lys Glu Asp Thr Leu Ile Asp Leu Glu305 310 315 320Gln Pro Val Ala Gln Val Pro Val Val Ala Glu Ala Glu Leu Pro Gly 325 330 335Val Glu Ala Ala Glu Ala Ile Val Pro Ser Leu Glu Glu Asn Lys Leu 340 345 350Gln Glu Val Val Val Ala Pro Glu Ala Gln Gln Leu Glu Ser Ala Pro 355 360 365Glu Val Ser Ala Pro Ala Gln Pro Glu Ser Thr Val Leu Gly Val Thr 370 375 380Glu Gly Asp Leu Lys Ser Glu Val Ser Val Glu Ala Asp Ala Gly Met385 390 395 400Gln Gln Glu Ala Gly Ile Ser Asp Gln Glu Thr Gln Ala Thr Glu Glu 405 410 415Val Glu Lys Val Glu Val Ser Val Glu Thr Lys Thr Glu Glu Pro Glu 420 425 430Val Ile Leu Glu Glu Gly Thr Leu Ile Asp Leu Glu Gln Pro Val Ala 435 440 445Gln Val Pro Val Val Ala Glu Ala Glu Leu Pro Gly Val Glu Ala Ala 450 455 460Glu Ala Ile Val Pro Ser Leu Glu Glu Asn Lys Leu Gln Glu Val Val465 470 475 480Val Ala Pro Glu Ala Gln Gln Leu Glu Ser Ala Pro Glu Val Ser Ala 485 490 495Pro Val Gln Pro Glu Ser Thr Val Leu Gly Val Thr Glu Gly Asp Leu 500 505 510Lys Ser Glu Val Ser Val Glu Ala Asp Ala Gly Met Gln Gln Glu Ala 515 520 525Gly Ile Ser Asp Gln Glu Thr Gln Ala Thr Glu Glu Val Glu Lys Val 530 535 540Glu Val Ser Val Glu Ala Asp Ala Gly Met Gln Gln Glu Leu Val Asp545 550 555 560Val Pro Thr Ala Leu Pro Leu Lys Asp Pro Asp Asp Glu Asp Val Leu 565 570 575Ser Tyr 125 amino acids amino acid linear protein Modified-site /note= “Residue can be either Thr or Lys” Modified-site /note= “Residue can be Gln, Thr or Pro” Modified-site /note= “Residue can be either Ile or Leu” Modified-site /note= “Residue can be either Glu or Lys” Modified-site 11 /note= “Residue can be either Gly or Asp” Modified-site 71 /note= “Residue can be either Ala or Val” Modified-site 81 /note= “Residue can be either Ala or Thr” Modified-site 94 /note= “Residue can be either Asn or Asp” Modified-site 96 /note= “Residue can be either Asp or Gly” Modified-site 97 /note= “Residue can be either Val or Met” Modified-site 98 /note= “Residue can be either Ala or Gln” Modified-site 100 /note= “Residue can be either Lys or Glu” Modified-site 101 /note= “Residue can be either Glu or Ala” Modified-site 102 /note= “Residue can be either Val or Gly” Modified-site 105 /note= “Residue can be either Gly or Asp” Modified-site 107 /note= “Residue can be either Gln or Glu” Modified-site 108 /note= “Residue can be either Glu or Thr” Modified-site 110 /note= “Residue can be either Glu or Ala” Modified-site 112 /note= “Residue can be either Ala or Thr” Modified-site 114 /note= “Residue can be either Ala or Glu” Modified-site 115 /note= “Residue can be either Leu or Val” Modified-site 117 /note= “Residue can be either Gly or Lys” Modified-site 118 /note= “Residue can be either Thr or Val” Modified-site 120 /note= “Residue can be either Ala or Val” Modified-site 121 /note= “Residue can be either Pro or Ser” Modified-site 124 /note= “Residue can be Val, Thr or Ala” 51Xaa Glu Glu Xaa Glu Val Xaa Leu Xaa Glu Xaa Thr Leu Ile Asp Leu1 5 10 15Glu Gln Pro Val Ala Gln Val Pro Val Val Ala Glu Ala Glu Leu Pro 20 25 30Gly Val Glu Ala Ala Glu Ala Ile Val Pro Ser Leu Glu Glu Asn Lys 35 40 45Leu Gln Glu Val Val Val Ala Pro Glu Ala Gln Gln Leu Glu Ser Ala 50 55 60Pro Glu Val Ser Ala Pro Xaa Gln Pro Glu Ser Thr Val Leu Gly Val65 70 75 80Xaa Glu Gly Asp Leu Lys Ser Glu Val Ser Val Glu Ala Xaa Ala Xaa 85 90 95Xaa Xaa Gln Xaa Xaa Xaa Ile Ser Xaa Xaa Gln Glu Xaa Xaa Xaa Xaa 100 105 110Glu Xaa Xaa Glu Xaa Xaa Glu Xaa Xaa Val Glu Xaa Xaa 115 120 125 253 amino acids amino acid linear protein 52Ala Val Lys Ile Thr Asn Ser Thr Ile Asp Gly Lys Val Cys Asn Gly1 5 10 15Ser Arg Glu Lys Gly Asn Ser Ala Gly Asn Asn Asn Ser Ala Val Ala 20 25 30Thr Tyr Ala Gln Thr His Thr Ala Asn Thr Ser Thr Ser Gln Cys Ser 35 40 45Gly Leu Gly Thr Thr Val Val Lys Gln Gly Tyr Gly Ser Leu Asn Lys 50 55 60Phe Val Ser Leu Thr Gly Val Gly Glu Gly Lys Asn Trp Pro Thr Gly65 70 75 80Lys Ile His Asp Gly Ser Ser Gly Val Lys Asp Gly Glu Gln Asn Gly 85 90 95Asn Ala Lys Ala Val Ala Lys Asp Leu Val Asp Leu Asn Arg Asp Glu 100 105 110Lys Thr Ile Val Ala Gly Leu Leu Ala Lys Thr Ile Glu Gly Gly Glu 115 120 125Val Val Glu Ile Arg Ala Val Ser Ser Thr Ser Val Met Val Asn Ala 130 135 140Cys Tyr Asp Leu Leu Ser Glu Gly Leu Gly Val Val Pro Tyr Ala Cys145 150 155 160Val Gly Leu Gly Gly Asn Phe Val Gly Val Val Asp Gly His Ile Thr 165 170 175Pro Lys Leu Ala Tyr Arg Leu Lys Ala Gly Leu Ser Tyr Gln Leu Ser 180 185 190Pro Glu Ile Ser Ala Phe Ala Gly Gly Phe Tyr His Arg Val Val Gly 195 200 205Asp Gly Val Tyr Asp Asp Leu Pro Ala Gln Arg Leu Val Asp Asp Thr 210 215 220Ser Pro Ala Gly Arg Thr Lys Asp Thr Ala Val Ala Asn Phe Ser Met225 230 235 240Ala Tyr Val Gly Gly Glu Phe Gly Val Arg Phe Ala Phe 245 250 366 amino acids amino acid linear protein 53Tyr Met Arg Ser Arg Ser Lys Leu Leu Leu Gly Ser Val Met Met Ser1 5 10 15Met Ala Ile Val Met Ala Gly Asn Asp Val Arg Ala His Asp Asp Val 20 25 30Ser Ala Leu Glu Thr Gly Gly Ala Gly Tyr Phe Tyr Val Gly Leu Asp 35 40 45Tyr Ser Pro Ala Phe Ser Lys Ile Arg Asp Phe Ser Ile Arg Glu Ser 50 55 60Asn Gly Glu Thr Lys Ala Val Tyr Pro Tyr Leu Lys Asp Gly Lys Ser65 70 75 80Val Lys Leu Glu Ser His Lys Phe Asp Trp Asn Thr Pro Asp Pro Arg 85 90 95Ile Gly Phe Lys Asp Asn Met Leu Val Ala Met Glu Gly Ser Val Gly 100 105 110Tyr Gly Ile Gly Gly Ala Arg Val Glu Leu Glu Ile Gly Tyr Glu Arg 115 120 125Phe Lys Thr Lys Gly Ile Arg Asp Ser Gly Ser Lys Glu Asp Glu Ala 130 135 140Asp Thr Val Tyr Leu Leu Ala Lys Glu Leu Ala Tyr Asp Val Val Thr145 150 155 160Gly Gln Thr Asp Asn Leu Ala Ala Ala Leu Ala Lys Thr Ser Gly Lys 165 170 175Asp Ile Val Gln Phe Ala Asn Ala Val Lys Ile Thr Asn Ser Ala Ile 180 185 190Asp Gly Lys Ile Cys Asn Arg Gly Lys Ala Ser Gly Gly Ser Lys Gly 195 200 205Leu Ser Ser Ser Lys Ala Gly Ser Cys Asp Ser Ile Asp Lys Gln Ser 210 215 220Gly Ser Leu Glu Gln Ser Leu Thr Ala Ala Leu Gly Asp Lys Gly Ala225 230 235 240Glu Lys Trp Pro Lys Ile Asn Asn Gly Thr Ser Asp Thr Thr Leu Asn 245 250 255Gly Asn Asp Thr Ser Ser Thr Pro Tyr Thr Lys Asp Ala Ser Ala Thr 260 265 270Val Ala Lys Asp Leu Val Ala Leu Asn His Asp Glu Lys Thr Ile Val 275 280 285Ala Gly Leu Leu Ala Lys Thr Ile Glu Gly Gly Glu Val Val Glu Ile 290 295 300Arg Ala Val Ser Ser Thr Ser Val Met Val Asn Ala Cys Tyr Asp Leu305 310 315 320Leu Ser Glu Gly Leu Gly Val Val Pro Tyr Ala Cys Val Gly Leu Gly 325 330 335Gly Asn Phe Val Gly Val Val Asp Gly His Ile Thr Pro Lys Leu Ala 340 345 350Tyr Arg Leu Lys Ala Gly Leu Ser Tyr Gln Leu Ser Pro Glu 355 360 365 340 amino acids amino acid linear protein 54Arg Ser Asp Tyr Gln Gly Gln Val Leu Ala Ile Ile Arg Pro Gln Gly1 5 10 15Glu Ala Thr Ala Glu Gly Val Asn Lys Glu Pro Glu Ser Lys Glu Glu 20 25 30Val Leu Ala Gln Pro Val Val Ala Gln Ala Val Ser Thr Gln Lys Pro 35 40 45Gln Glu Lys Thr Ile Ile Glu Gly Lys Gly Leu Val Thr Pro Thr Val 50 55 60Glu Asp Phe Val Ala Gly Ile Asn Thr Thr Pro Thr Ser Arg Ala Leu65 70 75 80Gly Met Ser Ala Lys Ser Glu Gln Asp Lys Lys Ile Val Ala Ser Gln 85 90 95Pro Ser Lys Asp Leu Met Ser Cys His Gly Asp Val Val Gly Glu Arg 100 105 110Arg Val Lys Met Ser Lys Ile Arg Gln Val Ile Ala Ala Arg Leu Lys 115 120 125Glu Ser Gln Asn Thr Ser Ala Thr Leu Ser Thr Phe Asn Glu Val Asp 130 135 140Met Ser Lys Val Met Glu Leu Arg Ala Lys Tyr Lys Asp Ala Phe Val145 150 155 160Lys Arg Tyr Asp Val Lys Leu Gly Phe Met Ser Phe Phe Ile Arg Ala 165 170 175Val Val Leu Val Leu Ser Glu Ile Pro Val Leu Asn Ala Glu Ile Ser 180 185 190Gly Asp Asp Ile Val Tyr Arg Asp Tyr Cys Asn Ile Gly Val Ala Val 195 200 205Gly Thr Asp Lys Gly Leu Val Val Pro Val Ile Arg Arg Ala Glu Thr 210 215 220Met Ser Leu Ala Glu Met Glu Gln Ala Leu Val Asp Leu Ser Thr Lys225 230 235 240Ala Arg Ser Gly Lys Leu Ser Val Ser Asp Met Ser Gly Ala Thr Phe 245 250 255Thr Ile Thr Asn Gly Gly Val Tyr Gly Ser Leu Leu Ser Thr Pro Ile 260 265 270Ile Asn Pro Pro Gln Ser Gly Ile Leu Gly Met His Ala Ile Gln Gln 275 280 285Arg Pro Val Ala Val Asp Gly Lys Val Glu Ile Arg Pro Met Met Tyr 290 295 300Leu Ala Leu Ser Tyr Asp His Arg Ile Val Asp Gly Gln Gly Ala Val305 310 315 320Thr Phe Leu Val Arg Val Lys Gln Tyr Ile Glu Asp Pro Asn Arg Leu 325 330 335Ala Leu Gly Ile 340 177 amino acids amino acid linear protein 55Gly Val Phe Met Gly Arg Gly Thr Ile Thr Ile His Ser Lys Glu Asp1 5 10 15Phe Ala Cys Met Arg Arg Ala Gly Met Leu Ala Ala Lys Val Leu Asp 20 25 30Phe Ile Thr Pro His Val Val Pro Gly Val Thr Thr Asn Ala Leu Asn 35 40 45Asp Leu Cys His Asp Phe Ile Ile Ser Ala Gly Ala Ile Pro Ala Pro 50 55 60Leu Gly Tyr Arg Gly Tyr Pro Lys Ser Ile Cys Thr Ser Lys Asn Phe65 70 75 80Val Val Cys His Gly Ile Pro Asp Asp Ile Ala Leu Lys Asn Gly Asp 85 90 95Ile Val Asn Ile Asp Val Thr Val Ile Leu Asp Gly Trp His Gly Asp 100 105 110Thr Asn Arg Met Tyr Trp Val Gly Asp Asn Val Ser Ile Lys Ala Lys 115 120 125Arg Ile Cys Glu Ala Ser Tyr Lys Ala Leu Met Ala Ala Ile Gly Val 130 135 140Ile Gln Pro Gly Lys Lys Leu Asn Ser Ile Gly Leu Ala Ile Glu Glu145 150 155 160Glu Ile Arg Gly Tyr Gly Tyr Ser Ile Val Arg Asp Tyr Cys Gly His 165 170 175Gly 197 amino acids amino acid linear protein 56Glu Trp Trp Cys Thr Pro Leu Trp Cys Ala Lys Asn Thr Ile Met Leu1 5 10 15Cys Arg Leu Lys Asn Thr Gly Gly Cys Glu Val Met Arg Glu Val Leu 20 25 30Val Pro Tyr Ala Gly Val Ser Pro Ser Val Asp Ser Thr Ala Phe Ile 35 40 45Ala Gly Tyr Ala Arg Ile Ile Gly Asp Val Cys Ile Gly Lys Asn Ala 50 55 60Ser Ile Trp Tyr Gly Thr Val Leu Arg Gly Asp Val Asp Lys Ile Glu65 70 75 80Val Gly Glu Gly Thr Asn Ile Gln Asp Asn Thr Val Val His Thr Asp 85 90 95Ser Met His Gly Asp Thr Val Ile Gly Lys Phe Val Thr Ile Gly His 100 105 110Ser Cys Ile Leu His Ala Cys Thr Leu Gly Asn Asn Ala Phe Val Gly 115 120 125Met Gly Ser Ile Val Met Asp Arg Ala Val Met Glu Glu Gly Ser Met 130 135 140Leu Ala Ala Gly Ser Leu Leu Thr Arg Gly Lys Ile Val Lys Ser Gly145 150 155 160Glu Leu Trp Ala Gly Arg Pro Ala Lys Phe Leu Arg Met Met Thr Glu 165 170 175Glu Glu Ile Leu Tyr Leu Gln Lys Ser Ala Glu Asn Tyr Ile Ala Leu 180 185 190Ser Arg Gly Tyr Leu 195 172 amino acids amino acid linear protein 57Ala Asn Leu Ala Arg Ala Thr Ala Pro Ser Met Phe Ser Phe Ser Leu1 5 10 15Lys Gly Arg Pro Ser Phe Phe Glu Ile Ala Phe Ser Leu Gly Ser Val 20 25 30Met Met Ser Met Ala Ile Val Met Ala Gly Asn Asp Val Arg Ala His 35 40 45Asp Asp Val Ser Ala Leu Glu Thr Gly Gly Ala Gly Tyr Phe Tyr Val 50 55 60Gly Leu Asp Tyr Ser Pro Ala Phe Ser Lys Ile Arg Asp Phe Ser Ile65 70 75 80Arg Glu Ser Asn Gly Glu Thr Lys Ala Val Tyr Pro Tyr Leu Lys Asp 85 90 95Gly Lys Ser Val Lys Leu Glu Ser Asn Lys Phe Asp Trp Asn Thr Pro 100 105 110Asp Pro Arg Ile Gly Phe Lys Asp Asn Met Leu Val Ala Met Glu Gly 115 120 125Ser Val Gly Tyr Gly Ile Gly Gly Ala Arg Val Glu Leu Glu Ile Gly 130 135 140Tyr Glu Arg Phe Lys Thr Lys Gly Ile Arg Asp Ser Gly Ser Lys Glu145 150 155 160Asp Glu Ala Asp Thr Val Tyr Leu Leu Ala Lys Glu 165 170 196 amino acids amino acid linear protein 58Lys Leu Lys Glu Asp Val Ala Ser Met Ser Asp Glu Ala Leu Leu Lys1 5 10 15Phe Ala Asn Arg Leu Arg Arg Gly Val Pro Met Ala Ala Pro Val Phe 20 25 30Glu Gly Pro Lys Asp Ala Gln Ile Ser Arg Leu Leu Glu Leu Ala Asp 35 40 45Val Asp Pro Ser Gly Gln Val Asp Leu Tyr Asp Gly Arg Ser Gly Gln 50 55 60Lys Phe Asp Arg Lys Val Thr Val Gly Tyr Ile Tyr Met Leu Lys Leu65 70 75 80His His Leu Val Asp Asp Lys Ile His Ala Arg Ser Val Gly Pro Tyr 85 90 95Gly Leu Val Thr Gln Gln Pro Leu Gly Gly Lys Ser His Phe Gly Gly 100 105 110Gln Arg Phe Gly Glu Met Glu Cys Trp Ala Leu Gln Ala Tyr Gly Ala 115 120 125Ala Tyr Thr Leu Gln Glu Met Leu Thr Val Lys Ser Asp Asp Ile Val 130 135 140Gly Arg Val Thr Ile Tyr Glu Ser Ile Ile Lys Gly Asp Ser Asn Phe145 150 155 160Glu Cys Gly Ile Pro Glu Ser Phe Asn Val Met Val Lys Glu Leu Arg 165 170 175Ser Leu Cys Leu Asp Val Val Leu Lys Gln Asp Lys Glu Phe Thr Ser 180 185 190Ser Lys Val Glu 195 719 amino acids amino acid linear protein 59Gly Phe Thr Ile Met Lys Thr Leu Asp Leu Tyr Gly Tyr Thr Ser Ile1 5 10 15Ala Gln Ser Phe Asp Asn Ile Cys Ile Ser Ile Ser Ser Pro Gln Ser 20 25 30Ile Arg Ala Met Ser Tyr Gly Glu Ile Lys Asp Ile Ser Thr Thr Ile 35 40 45Tyr Arg Thr Phe Lys Val Glu Lys Gly Gly Leu Phe Cys Pro Lys Ile 50 55 60Phe Gly Pro Val Asn Asp Asp Glu Cys Leu Cys Gly Lys Tyr Arg Lys65 70 75 80Lys Arg Tyr Arg Gly Ile Val Cys Glu Lys Cys Gly Val Glu Val Thr 85 90 95Ser Ser Lys Val Arg Arg Glu Arg Met Gly His Ile Glu Leu Val Ser 100 105 110Pro Val Ala His Ile Trp Phe Leu Lys Ser Leu Pro Ser Arg Ile Gly 115 120 125Ala Leu Leu Asp Met Pro Leu Lys Ala Ile Glu Asn Ile Leu Tyr Ser 130 135 140Gly Asp Phe Val Val Ile Asp Pro Val Ala Thr Pro Phe Ala Lys Gly145 150 155 160Glu Val Ile Ser Glu Val Val Tyr Asn Gln Ala Arg Asp Ala Tyr Gly 165 170 175Glu Asp Gly Phe Phe Ala Leu Thr Gly Val Glu Ala Ile Lys Glu Leu 180 185 190Leu Thr Arg Leu Asp Leu Glu Ala Ile Arg Ala Thr Leu Arg Asn Glu 195 200 205Leu Glu Ser Thr Ser Ser Glu Met Lys Arg Lys Lys Val Val Lys Arg 210 215 220Leu Arg Leu Val Glu Asn Phe Ile Lys Ser Gly Asn Arg Pro Glu Trp225 230 235 240Met Ile Leu Thr Val Ile Pro Val Leu Pro Pro Asp Leu Arg Pro Leu 245 250 255Val Ser Leu Glu Asn Gly Arg Pro Ala Val Ser Asp Leu Asn His His 260 265 270Tyr Arg Thr Ile Ile Asn Arg Asn Asn Arg Leu Glu Lys Leu Leu Lys 275 280 285Leu Asn Pro Pro Ala Ile Met Ile Arg Asn Glu Lys Arg Met Leu Gln 290 295 300Glu Ala Val Asp Ala Leu Phe Asp Ser Ser Arg Arg Ser Tyr Val Ser305 310 315 320Ser Arg Val Gly Ser Met Gly Tyr Lys Lys Ser Leu Ser Asp Met Leu 325 330 335Lys Gly Lys Gln Gly Arg Phe Arg Gln Asn Leu Leu Gly Lys Arg Val 340 345 350Asp Tyr Ser Gly Arg Ser Val Ile Val Val Gly Pro Ser Leu Lys Leu 355 360 365His Gln Cys Gly Leu Pro Lys Lys Met Ala Leu Glu Leu Phe Lys Pro 370 375 380Phe Ile Cys Ser Lys Leu Lys Met Tyr Gly Ile Ala Pro Thr Val Lys385 390 395 400Leu Ala Asn Lys Met Ile Gln Ser Glu Lys Pro Asp Val Trp Asp Val 405 410 415Leu Asp Glu Val Ile Lys Glu His Pro Ile Leu Leu Asn Arg Ala Pro 420 425 430Thr Leu His Arg Leu Gly Leu Gln Ala Phe Asp Pro Val Leu Ile Glu 435 440 445Gly Lys Ala Ile Gln Leu His Pro Leu Val Cys Ser Ala Phe Asn Ala 450 455 460Asp Phe Asp Gly Asp Gln Met Ala Val His Val Pro Leu Ser Gln Glu465 470 475 480Ala Gln Leu Glu Ala Arg Val Leu Met Met Ser Thr Asn Asn Ile Leu 485 490 495Ser Pro Ser Asn Gly Arg Pro Ile Ile Val Pro Ser Lys Asp Ile Val 500 505 510Leu Gly Ile Tyr Tyr Leu Thr Leu Leu Glu Glu Asp Pro Glu Val Arg 515 520 525Glu Val Gln Thr Phe Ala Glu Phe Ser His Val Glu Tyr Ala Leu His 530 535 540Glu Gly Ile Val His Thr Cys Ser Arg Ile Lys Tyr Arg Met Gln Lys545 550 555 560Ser Ala Ala Asp Gly Thr Val Ser Ser Glu Ile Val Glu Thr Thr Pro 565 570 575Gly Arg Leu Ile Leu Trp Gln Ile Phe Pro Gln His Lys Asp Leu Thr 580 585 590Phe Asp Leu Ile Asn Gln Val Leu Thr Val Lys Glu Ile Thr Ser Ile 595 600 605Val Asp Leu Val Tyr Arg Ser Cys Gly Gln Arg Glu Thr Val Glu Phe 610 615 620Ser Asp Lys Leu Met Tyr Trp Gly Phe Lys Tyr Ala Ser Gln Ser Gly625 630 635 640Ile Ser Phe Gly Cys Lys Asp Met Ile Ile Pro Asp Thr Lys Ala Ala 645 650 655His Val Glu Asp Ala Ser Glu Lys Ile Arg Glu Phe Ser Ile Gln Tyr 660 665 670Gln Asp Gly Leu Ile Thr Lys Ser Glu Arg Tyr Asn Lys Val Val Asp 675 680 685Glu Trp Ser Lys Cys Thr Asp Leu Ile Ala Arg Asp Met Met Lys Ala 690 695 700Ile Ser Leu Cys Asp Glu Pro Ala Arg Ser Gly Ala Pro Asp Thr705 710 715 439 amino acids amino acid linear protein 60Ile His Ser Ala Tyr Asn Met Leu His Asp Cys Ala Thr Ala Gln Cys1 5 10 15Asn Lys Glu Val Pro Arg Phe Met Asp Pro Asp Phe Thr Arg Arg Glu 20 25 30Val His Leu Gln Ile Ala Lys Val Cys Ala Ile Leu Val Asn Ala Ile 35 40 45Thr Met Ala Ser Cys Phe Val Thr Thr Leu Thr Glu Ala Ser Asp Ser 50 55 60Ala Ile Gly Glu Ala Asp Glu His Ser Ala Tyr His Ala Asn Met Ala65 70 75 80Leu Ser Ala Tyr Val Asn Ala Lys Phe Ser Ala Leu Ser Arg Cys Leu 85 90 95Asn Tyr Ser Pro Gly Pro Glu Glu Thr Lys Arg Arg Lys Ala Ile Leu 100 105 110Arg Val Val Arg His Asn Ile Glu Leu Cys Asn Lys Val Ala Glu Leu 115 120 125Val Asp Pro Glu Ile Pro Tyr Cys Phe Arg Asp Arg Thr Val Ser Cys 130 135 140Leu Asn Ser Met Leu Asp Ala Val Gly Ser Thr Ser Ala Glu Cys Glu145 150 155 160Glu Met Val Ser Asp Asn Asp Ser Ala Lys Asn Arg Leu Ala Leu Ala 165 170 175Lys Lys Ala Arg Thr Gly Phe Leu His His Phe Lys Thr Tyr Lys Ser 180 185 190Leu Gly Leu Ser Val Ala Phe Lys Ser Phe Arg His Asp Lys Tyr Val 195 200 205Gln Ala Leu Val Tyr Ala Ile Gly Ser Leu Phe Ser Met His Arg Val 210 215 220Tyr Ala Ser Thr Gly Asn Thr Gly His Val Val Ala Ser Lys Ile Glu225 230 235 240His Cys Leu Gln Met Leu Leu Thr Leu Tyr Lys Tyr Lys Val Arg Arg 245 250 255Ala Gly Ala Ser Glu Tyr Thr Ala Gln Glu Leu Tyr Leu Asp Met Cys 260 265 270Thr Val Tyr Asp Glu Ile Gln Glu Cys Val Thr Arg Gly Leu Leu Leu 275 280 285Asn Pro Gln Thr Glu Val Gly Phe Cys Ser Ala Met Leu Gly Tyr Leu 290 295 300Ser Ala Met Ile Gly Ile Trp Glu Lys Lys Tyr Glu Arg Tyr Phe Asn305 310 315 320Asn Ile Arg Gln Thr Glu Gly Ser Pro Ser Gln Pro Ser Thr Ser Arg 325 330 335Leu Gly Ser Ala Gly Ala Gly Ile Gly Gly Ser Gln Ala Ser Tyr Thr 340 345 350Leu Pro His Asp Pro Gly His Met Pro Ser Ser Pro Ser Gln Pro Ser 355 360 365Thr Ser Gly Leu Gly Gly Asn Pro Ala Gly Gln Gly Ala Leu Gln Ala 370 375 380Gln Ala Pro Cys Gly Pro Leu Gln Asp Tyr Ser Tyr Ala Gln Pro Ser385 390 395 400Thr Ser Gly Leu Gly Gly Ala Ser Ser Thr Leu Glu Gly Ala Gln Val 405 410 415Val Ser Pro Arg Ser Gln Thr Pro Ser Asp Asp Glu Leu Glu Pro Pro 420 425 430Ser Arg Arg Ser Arg Ser Ala 435 752 amino acids amino acid linear protein 61Met His Met Pro Arg Ile Phe Thr Thr Pro Val Met Ser Gly Tyr Ala1 5 10 15Tyr Ser Gly Cys Ser Ser Ala Glu Tyr Lys Glu Thr Val Cys Asn Ser 20 25 30Ile Met Thr Asn Ser Arg Pro Tyr Ala Ala Cys Leu Gln Ala Ile Arg 35 40 45Gln Cys Met Leu Glu Leu Arg Asp Thr Phe Val Lys Leu Arg Gly Val 50 55 60Asp Val Val Phe Ala Ala Ala Asp Lys Ile Asp Ser Ile Asn Ser Cys65 70 75 80Ile Thr Ala Ala Glu Gly Ala Ser Ser Ala Glu Pro Gly Val Leu Tyr 85 90 95Ser Leu Ile Asn Arg Leu Tyr Asp Ala Leu Gln Asp Cys Ile Thr Ala 100 105 110Gln Cys Asn Lys Glu Val Pro Leu Phe Met Asp Gln Asp Phe Ile Lys 115 120 125Arg Lys Ala His Leu Gln Ile Gly Lys Ala Cys Ala Ile Ile Val Asn 130 135 140Val Ile Ala Ile Val Asn Cys Cys Ala Arg Thr Ile Ala Thr Arg Phe145 150 155 160Thr Gly Ala Val Ser Ser Glu Arg Arg Asp Gly Ser Ala Ser His Thr 165 170 175Val Thr Ala Leu Ser Ala Tyr Cys Tyr Val Lys Phe Ser Ala Leu Ser 180 185 190Arg Cys Leu Asn Ser Ser Leu Asp Ser Glu Glu Thr Glu Asn Ile Lys 195 200 205Ala Ile Leu Arg Val Val Arg His Asn Ile Glu Leu Cys Ser Lys Val 210 215 220Ala Glu Leu Val Glu Pro Asn Thr Pro Arg Phe Phe Arg His Arg Thr225 230 235 240Glu Ala Cys Leu Asp Ser Val Ile Asp Ala Ile Glu Thr Ser Ala Ala 245 250 255Ala Cys Glu Ala Met Val Arg Asn Asn Glu Ser Ala Arg Leu Arg Leu 260 265 270Gly Leu Ser Arg Arg Ala Met Ala Asn Phe Leu Tyr Tyr Leu Glu Ala 275 280 285Tyr Val Glu Gly Leu Gly Val His Ser Phe Asp Leu Arg Leu Lys Arg 290 295 300Glu Arg Tyr Arg Gly Gly Ala Leu Val His Ala Val Gly Gly Leu Phe305 310 315 320Leu Met Tyr Arg Val Tyr Ala Ser Thr Gly Asn Val Asp His Val Val 325 330 335Ala Gly Arg Ile Gly His Cys Leu Gln Ile Leu Cys Ala Leu Tyr Ser 340 345 350Arg Arg Arg Glu Leu Gly Ala Tyr Arg Ala Arg Lys Ser Phe Leu Asp 355 360 365Met Cys His Val Tyr Glu Glu Ile Asn Glu His Ile Thr Glu Asp Ala 370 375 380Leu Leu Ile Pro Gln Ile Glu Val Lys Trp Arg Asn Thr Ala Leu Arg385 390 395 400Tyr Leu Ser Val Met Met Asn Ile Cys Asp Lys Lys Tyr Gly Arg Tyr 405 410 415Phe Asn Ala Val Glu Gln Thr Gly Ala Ala Pro Ser Gln Pro Ser Thr 420 425 430Ser Gly Leu Gly Ser Thr Ser Ala Gly Val Glu Gly Ala Gln Ala Ile 435 440 445Ser Val Pro Leu Arg Val Leu Glu Arg Ile Pro Ile Pro Tyr Gly Ala 450 455 460Pro Trp Asp Gln Pro Ser Thr Ser Gly Met Gly Gly Thr Ala Gly Thr465 470 475 480Gly Ser Gln Gln Ala Ser His Ile Pro Pro His Asp Pro Gly Met Met 485 490 495Pro Tyr Ser Tyr Ala Gln Pro Ser Thr Leu Trp Asp Gln Pro Ser Thr 500 505 510Ser Gly Leu Gly Ser Ala Ala Gly Thr Gly Ser Gln Gln Ala Ser His 515 520 525Ile Pro Pro His Asp Pro Gly Met Met Pro Tyr Ser Tyr Ala Gln Pro 530 535 540Ser Thr Ser Trp Asp Gln Pro Ser Thr Ser Gly Leu Gly Ser Ala Ala545 550 555 560Gly Met Gly Ser Gln Gln Ala Ser His Ile Pro Pro His Asp Pro Gly 565 570 575Met Met Pro Tyr Ser Tyr Ala Gln Pro Ser Thr Ser Trp Asp Gln Pro 580 585 590Ser Thr Ser Gly Leu Gly Ser Ala Ala Gly Met Gly Ser Gln Gln Ala 595 600 605Ser His Ile Pro Pro His Asp Pro Gly Met Met Pro Tyr Ser Tyr Ala 610 615 620Gln Pro Ser Thr Ser Trp Asp Gln Pro Ser Thr Ser Trp Asp Gln Pro625 630 635 640Ser Thr Ser Gly Leu Gly Gly Thr Ala Gly Gln Gly Ala Gln Leu Val 645 650 655Pro Pro Pro Pro His Ile Ile Leu Arg Val Leu Glu Asn Val Pro Tyr 660 665 670Pro Ser Ser Gln Phe Ser Thr Ser Gly Leu Gly Gly Thr Ser Thr Gly 675 680 685Met Gly Arg Ser Gln Ala Pro Tyr Val Pro Pro Gln Asp Gln Gly Ile 690 695 700Met Pro Tyr Ser Trp Asp Gln Pro Ser Ala Ser Gly Leu Gly Gly Ala705 710 715 720Ser Tyr Thr Leu Glu Glu Ala Gln Val Ser Ser His Arg Pro Arg Thr 725 730 735Pro Ser Asp Asp Asp Ser Glu Pro Pro Ser Lys Gln Ala Arg Arg Ala 740 745 750 110 amino acids amino acid linear protein 62Met Tyr Thr Val Ser Asp Ser Glu Ser Ile Thr Ser Phe Val Thr Pro1 5 10 15Pro Met Leu Met Ala Asn Ile Ser Ser Thr Lys Arg Ser Gly Tyr Leu 20 25 30Leu Ser Leu Ser Val Glu Pro Ser Asp Phe Phe Thr Val Thr Phe Phe 35 40 45Leu Lys Glu Thr Pro Phe Thr Thr Asp Asn Ser Val Pro Phe Cys Ser 50 55 60Phe Glu Arg Asn Ser Thr Ala Asn Ser Arg Ile Phe Phe Ile Arg Asn65 70 75 80Ala Leu Phe His Ser Ser Val Arg Ile Asp Leu Leu Ser Ser Ser Val 85 90 95Leu Gly Leu Gly Gly Thr Thr Ser Val Thr Arg Thr Pro Lys 100 105 110 149 amino acids amino acid linear protein 63Asp Gly Phe Pro Thr Ala Asp Glu Asn Ala Lys Val Val Lys Ala Phe1 5 10 15Ile Pro Ser Cys Asn Gly Lys Ser Phe Thr Lys Leu Pro Asp Leu Ser 20 25 30Ser Pro Cys Ile Ser Lys Phe Val Lys Thr Pro Leu Ile Arg Ala Pro 35 40 45Asn Ile Ser Phe Ser Ser Phe Ser Asn Ala Pro Arg Leu Ile Ile Ser 50 55 60Phe Ala Phe Phe Thr Leu Leu Thr Ser Asn Ser Pro Ala Phe Cys Leu65 70 75 80Leu Ile Phe Glu Asp Ile Phe Ser Phe Ser Phe Ser Arg Ser Ser Leu 85 90 95Val Ile Ser Cys Phe Leu Ile Thr Phe Met Ile Cys Gln Pro Thr Thr 100 105 110Leu Arg Asn Ile Ser Leu Thr Ser Pro Ser Phe Ser Ala Asn Thr Thr 115 120 125Phe Arg Thr Pro Thr Gly Arg Thr Ser Leu Glu Ile Leu Leu Ser Ala 130 135 140Ile Ser Ser Met Val145 590 amino acids amino acid linear protein 64Leu Leu Tyr Ser Phe Gly Asn Leu Thr Ser Tyr Gly Arg Ser Val Met1 5 10 15Arg Ser Arg Lys Ile Tyr Val Trp Val Val Met Ala Thr Val Leu Gly 20 25 30Ala Met Ala Phe Val Thr Phe Gly Ser Met Ile Pro Met Gly Lys Leu 35 40 45Ser Asn Ser Gly Asn Gly Gln Cys Val Ala Met Leu Gly Asn Lys Cys 50 55 60Leu Pro Leu Arg Asp Tyr Arg Ile Met Tyr Arg Asn Glu Leu Ala Glu65 70 75 80Leu Glu Lys Met Leu Gln His Lys Leu Ser Asp Ala Gln Ile Asn Gln 85 90 95Phe Gly Ile Lys Glu Val Val Leu Lys Asn Met Ile Ala Asp Met Val 100 105 110Val Glu Lys Phe Ala His Asp Leu Gly Ile Arg Val Gly Ser Asn Ser 115 120 125Leu Arg Ser Leu Ile Lys Asn Ile Arg Ile Phe Gln Asp Ala Asn Gly 130 135 140Val Phe Asp Gln Glu Arg Tyr Glu Ala Val Leu Ala Asp Ser Gly Met145 150 155 160Thr Glu Ser Ser Tyr Val Asn Lys Ile Arg Asn Ala Leu Pro Ser Thr 165 170 175Ile Leu Met Glu Cys Leu Phe Pro Asn Arg Ala Glu Leu His Ile Pro 180 185 190Tyr Tyr Asp Ala Leu Ala Lys Asp Val Val Leu Gly Leu Leu Gln His 195 200 205Arg Val Ala Asp Ile Val Glu Ile Ser Ser Asp Ala Val Asp Ile Ser 210 215 220Gly Ser Asp Ile Ser Asp Asp Glu Leu Gln Lys Leu Phe Glu Glu Gln225 230 235 240Tyr Lys Asn Ser Leu Asn Phe Pro Glu Tyr Arg Ser Ala Asp Tyr Ile 245 250 255Ile Met Ala Glu Asp Asp Leu Leu Ala Asp Val Ile Val Ser Asp Gln 260 265 270Glu Val Asp Val Glu Ile Lys Asn Ser Glu Leu His Asp Gln Arg Asp 275 280 285Val Leu Asn Leu Val Phe Thr Asp Lys Asn Glu Ala Glu Leu Ala Tyr 290 295 300Lys Ala Tyr Gln Glu Gly Lys Ser Phe Glu Glu Leu Val Ser Asp Ala305 310 315 320Gly Tyr Thr Ile Glu Asp Ile Ala Leu Asn Asn Ile Ser Lys Asp Val 325 330 335Leu Pro Val Gly Val Arg Asn Val Val Phe Ala Leu Asn Glu Gly Glu 340 345 350Val Ser Glu Met Phe Arg Ser Val Val Gly Trp His Ile Met Lys Val 355 360 365Ile Arg Lys His Glu Ile Thr Lys Glu Asp Leu Glu Lys Leu Lys Glu 370 375 380Lys Ile Ser Ser Asn Ile Arg Arg Gln Lys Ala Gly Glu Leu Leu Val385 390 395 400Ser Asn Val Lys Lys Ala Asn Asp Met Ile Ser Arg Gly Ala Leu Leu 405 410 415Asn Glu Leu Lys Asp Met Phe Gly Ala Arg Ile Ser Gly Val Leu Thr 420 425 430Asn Phe Asp Met His Gly Leu Asp Lys Ser Gly Asn Leu Val Lys Asp 435 440 445Phe Pro Leu Gln Leu Gly Ile Asn Ala Phe Thr Thr Leu Ala Phe Ser 450 455 460Ser Ala Val Gly Lys Pro Ser His Leu Val Ser Asn Gly Asp Ala Tyr465 470 475 480Phe Gly Val Leu Val Thr Glu Val Val Pro Pro Arg Pro Arg Thr Leu 485 490 495Glu Glu Ser Arg Ser Ile Leu Thr Glu Glu Trp Lys Ser Ala Leu Arg 500 505 510Met Lys Lys Ile Arg Glu Phe Ala Val Glu Leu Arg Ser Lys Leu Gln 515 520 525Asn Gly Thr Glu Leu Ser Val Val Asn Gly Val Ser Phe Lys Lys Asn 530 535 540Val Thr Val Lys Lys Ser Asp Gly Ser Thr Asp Asn Asp Ser Lys Tyr545 550 555 560Pro Glu Arg Leu Val Asp Glu Ile Phe Ala Ile Asn Ile Gly Gly Val 565 570 575Thr Lys Glu Val Ile Asp Ser Glu Ser Glu Thr Val Tyr Ile 580 585 590 245 amino acids amino acid linear protein 65Gly Ser Cys Cys Tyr Glu Val Asp Gly Met Ala Lys Arg Phe Leu Asn1 5 10 15Asp Thr Glu Lys Lys Leu Leu Ser Leu Leu Lys Ser Val Met Gln His 20 25 30Tyr Lys Pro Arg Thr Gly Phe Val Arg Ala Leu Leu Ser Ala Leu Arg 35 40 45Ser Ile Ser Val Gly Asn Pro Arg Gln Thr Ala His Asp Leu Ser Val 50 55 60Leu Val Thr Gln Asp Phe Leu Val Glu Val Ile Gly Ser Phe Ser Thr65 70 75 80Gln Ala Ile Ala Pro Ser Phe Leu Asn Ile Met Ala Leu Val Asp Glu 85 90 95Glu Ala Leu Asn His Tyr Asp Arg Pro Gly Arg Ala Pro Met Phe Ala 100 105 110Asp Met Leu Arg Tyr Ala Gln Glu Gln Ile Arg Arg Gly Asn Leu Leu 115 120 125Gln His Arg Trp Asn Glu Glu Thr Phe Ala Ser Phe Ala Asp Ser Tyr 130 135 140Leu Arg Arg Arg His Glu Arg Val Ser Ala Glu His Leu Arg Gln Ala145 150 155 160Met Gln Ile Leu His Ala Pro Ala Ser Tyr Arg Val Leu Ser Thr Asn 165 170 175Trp Phe Leu Leu Arg Leu Ile Ala Ala Gly Tyr Val Arg Asn Ala Val 180 185 190Asp Val Val Asp Ala Glu Ser Ala Gly Leu Thr Ser Pro Arg Ser Ser 195 200 205Ser Glu Arg Thr Ala Ile Glu Ser Leu Leu Lys Asp Tyr Asp Glu Glu 210 215 220Gly Leu Ser Glu Met Leu Glu Thr Glu Lys Gly Val Met Thr Ser Leu225 230 235 240Phe Gly Thr Val Leu 245 456 amino acids amino acid linear protein 66Lys Ala Ile Pro Glu Ala Glu Lys Ile Phe Glu Lys Ala Met Asn Ile1 5 10 15Ala Asp Lys Val Tyr Gly Ser Ala Ser Ser Glu Val Lys Ser Leu Phe 20 25 30Thr Cys Pro Asn Pro Glu Asp Ala Ser Thr Leu Val His Phe Val Ser 35 40 45Ser Asn Gly Thr Pro Asn Phe Asp Pro Leu Ala Lys Arg Val Leu Glu 50 55 60Glu Ala Tyr His Arg Tyr Gly Glu Glu Pro Phe Thr Asn Leu Asp Ile65 70 75 80Ala Gly Asn Ala Pro Ile His Ala Ala Ala Gln Lys Ser Thr Val Gly 85 90 95Val Phe Glu Gln Val Val Arg Cys Thr Pro Glu Ser Val Val Asn Gln 100 105 110Leu Ala Pro Asn Gly Lys Ala Pro Ile His Met Ile Val Glu Asp Glu 115 120 125Pro Ser His Lys Gly Val Ser Val Lys Leu Gln Met Leu Ile Glu Asn 130 135 140Val Arg Asn Ile Pro Ser Ile Asn Val Pro Ser Pro Val Thr Gly Glu145 150 155 160Thr Pro Val Val Ala Ala Tyr Lys Gly Gly Asn Thr Glu Gly Val Lys 165 170 175Thr Met Leu Arg Cys Asn Ser Met Asp Val Asp Ala Arg Ser His Asp 180 185 190Gly Gly Thr Ile Ile His Tyr Ala Ala Lys Asp Gly Asn Leu Glu Ile 195 200 205Leu Gln Gln Ala Leu Gly Arg Lys Ser Ser Tyr Ser Lys Phe Pro Val 210 215 220Lys Asp Gly Val Pro Thr Pro Gly Val Tyr Ala Ile Arg Glu Ala Ser225 230 235 240Gly Gly Lys Val Ser Leu Pro Ala Leu Asp Met Leu Met Arg Tyr Glu 245 250 255Pro Tyr Pro Gln His Val Ala Val Glu Ala Val Arg Lys Gly Ala Ala 260 265 270Asp Val Leu Arg His Leu Ile Thr Thr Glu Val Ile Ser Val Asn Glu 275 280 285Glu Ile Thr Thr Pro Glu Gly Lys Lys Thr Thr Leu Thr Ala Glu Ala 290 295 300Leu Thr Ser Gly Gln Tyr Ala Ala Val Lys Thr Leu Ile Lys Asn Ser305 310 315 320Ala Asp Val Asn Ala Ser Pro Glu Pro Ala Ile Ser Val Gly Ile Gln 325 330 335Gly Gly Cys Phe Gln Gly Gly Lys Ala Ile Lys His Leu Lys Arg Val 340 345 350Val Glu Ala Gly Ala His Ile Asn Thr Pro Thr Gly Ser Met Ser Pro 355 360 365Leu Ala Ala Ala Val Gln Val Ala Asn Glu Ala Ser Asn Leu Lys Glu 370 375 380Ala Asn Arg Ile Val Asn Phe Leu Leu Gln Arg Gly Ala Asp Leu Ser385 390 395 400Ser Thr Asp His Thr Gly Thr Pro Ala Leu His Leu Ala Thr Ala Ala 405 410 415Gly Asn Gln Lys Thr Ala Arg Leu Leu Leu Asp Lys Gly Ala Pro Ala 420 425 430Thr Gln Arg Asp Ala Tyr Gly Lys Thr Ala Leu His Ile Ala Ala Ala 435 440 445Asn Gly Asp Gly Lys Leu Tyr Lys 450 455 113 amino acids amino acid linear protein 67Asp Gly Asn Thr Pro Leu His Thr Ala Ala Ser Ser Val Gly Lys Asn1 5 10 15Ala Leu Gly Asn Leu Asp Val Leu Cys Asp Lys Ala Leu Ile Ala Asp 20 25 30Val Asn Ala Lys Gly Pro Gly Gly Asn Thr Pro Leu His Ile Ala Thr 35 40 45Glu Arg Met Asp His Gln Lys Val Lys His Leu Leu Ser Arg Leu Ser 50 55 60Asp Ile Ser Val Ala Asn Asp Ala Gly Glu Thr Val Cys His Ile Val65 70 75 80Ala Lys Gln Trp Pro Arg Arg Asp Val Leu Ser Tyr Ile Asp Lys Met 85 90 95Gln Glu Ala Val Ser Ser Asn Ile Glu Gly Asn Arg Ser Val Gln Arg 100 105 110His 623 amino acids amino acid linear protein 68Asp Glu Ala Pro Met Thr Leu Leu Leu Lys Gln Asn Pro Ser Lys Ala1 5 10 15Ser Val Ala Leu Leu Gly Ser Ala Ile Asp Phe Phe Leu Cys Arg Asp 20 25 30Arg Asn Ser His Pro Ala Arg Arg Arg Met Val Ile Leu Leu Ala Glu 35 40 45Gly Phe Thr Leu Arg Glu Gly Ser Ala Val Pro Pro Ala Leu Ile His 50 55 60Glu Asn Leu Thr Ser Pro Asp Leu Leu Ala Arg Ala Leu His Lys Thr65 70 75 80Ala Ser Asn Ser Thr Ala Phe Gln Gln Val Pro Phe Gln Leu Trp His 85 90 95Ala Leu Ala Leu Ala Tyr Asn Ser Leu Pro Gly Lys Asn Gln Glu Glu 100 105 110Asp Leu Thr Asn Phe Val Leu Gly Cys Leu Asp Gly Val Ser Glu Asp 115 120 125Met Thr Ile Val Arg Glu Glu Asp Ser Thr Thr Phe Glu Val Gln Ser 130 135 140Tyr Thr Thr Phe Ser Arg Val His Ser Leu Leu Ala Ser Ala Pro Ser145 150 155 160Ser Tyr Lys Asn Gly Ala Leu Thr Val His Glu Ser Cys Ile Phe Ser 165 170 175Ile Gln Asp Asn Ser Gly Val Pro Ile Ala Lys Val Lys Met Trp Val 180 185 190Glu Tyr Asp Ile Ala Pro Ser Thr Lys Ala Glu Gly Val Tyr Arg Thr 195 200 205Ala Val Lys Lys Val Lys Leu Val Leu Thr Glu Arg Asp Cys Arg Asp 210 215 220Val Arg Gln Gly Glu Pro Gly Ser Val Cys Ser Trp His Asn Ile Pro225 230 235 240Lys Ala Leu Ala Lys His Tyr Val Arg Val Pro Glu Lys Pro Thr His 245 250 255Val Leu Tyr Ser Ala Cys Asn Leu Gln Arg His Asn Pro Arg Tyr Met 260 265 270Ala Arg Arg Val Phe Tyr Asp Val Ser Asp Ile Asp Glu Cys Ile Leu 275 280 285Arg Ala Tyr Ser Val Ile Ser Gly Met Pro Leu Glu Val Leu Glu Leu 290 295 300Ser Phe Cys Asn Thr Val Ile Ser Gln Glu Ala Ser Gly Val Phe Arg305 310 315 320Val Val Val Arg Gly Val Val Gly Leu Val Gly Tyr Asp Lys Ser Ser 325 330 335Val Val Gln Gln Gly Ala Val Ser His Gly Arg Asp Ala Val Ser Lys 340 345 350Met Gly Val Cys Met Ser Phe Val Ala Ser Gln Ala His Asp Ala Cys 355 360 365Ala Thr Ile Leu Arg His Val Ala Val Thr Val Asn Thr Phe Gly Asn 370 375 380Val Leu Thr Leu Gly Gly Gly Ile Ser Leu Arg Asp Phe Leu Ala Gly385 390 395 400Ser Ala Lys Asp Thr Asp Phe Ala Gly Gly His Ile Phe Asn Leu Ala 405 410 415Glu Glu Ile Val Ala His Gly Leu Ser Leu Trp Glu Asp Leu Gly Lys 420 425 430Arg His Arg Trp Ala Ser His Ser Val Pro Val Arg Gly Asp Cys Gly 435 440 445Ile Phe Ile Gln His Ser Asp Glu Ile Arg Glu Ile Leu Arg Ser Gln 450 455 460Pro Lys His Ala Ala Asn Ile Val Glu Lys Thr Gly Val Asn Thr Glu465 470 475 480Asn Leu Arg Val Leu Leu Ser Ser Ile Leu Ser Asn Ser Ser Gly Ser 485 490 495Ser Leu Pro Val Glu Leu Ala Ala His Tyr Val Ala His Glu Gly Val 500 505 510Val Ala Asp Asn Gly Asp Ser Ala Arg Arg Leu Pro Val Asn Gln His 515 520 525Val Leu Glu Glu His Leu Val Tyr Arg Val Thr Ser Val Ser Gly Ile 530 535 540His Ile His Ala Cys Val Asp Tyr Val Val Glu Asp Ile Asp Thr Pro545 550 555 560Gly Ser Val Lys Asp Leu Gly Leu Cys Ile Arg Asp Val Arg Ile Gly 565 570 575Thr Arg Val Ala Ser Ser Ala Glu Glu Val Cys Ser Ala Ile Gln Glu 580 585 590Lys Glu Gly Arg Ile Asp Arg Asn Asp Phe Ala Trp Phe Asn Val Asp 595 600 605Gln Ser Leu Val Glu Thr Ser Arg Ala Glu Phe Arg Ala Ala Ile 610 615 620 464 amino acids amino acid linear protein 69Arg Ile His Met Arg Lys Glu Asn Ser Lys Ala Ala Tyr Cys Val Thr1 5 10 15Trp Arg Phe Lys Leu Arg Lys Lys Asn Thr His Asn Gly Ser Arg Arg 20 25 30Thr Val Ser Gly Ile Leu Asn Tyr Leu Arg Ala Leu Phe Phe Arg Ile 35 40 45Ile Ser Ile Phe Ser Thr Ser Ser Ser Ala Val Ser Lys Ala Glu Asp 50 55 60Glu Ala Asn Ser Val His Ile Cys Thr His Asn Ser Ser Asp Ala Ser65 70 75 80Lys Asp Ser Lys Ala Lys His Lys Asp His Arg Pro Ser Ile Asp Val 85 90 95Ser Leu Lys Tyr Ser Gln Lys Lys Lys Trp Leu Glu Gly Ala Ser Gly 100 105 110Phe Ser Phe His Ser Ala Leu Cys Asp Ser Tyr Lys Asn Lys Ser Asn 115 120 125Leu Tyr Gly His Gln Phe Leu Ile Asp Met His Arg Cys Asp Trp Cys 130 135 140Ile Asn Lys Thr Phe Tyr Pro Arg Gln Asn Val Ser Ala His Ile Ala145 150 155 160Arg Leu Glu Arg Ser Ile Lys Ser Ser Ser Ile Thr Asn Leu Asn Leu 165 170 175Val Cys Gln Arg Thr Tyr Gly Val Ser Arg Gly Val Phe Leu Arg Arg 180 185 190Tyr Arg Glu Arg Ser Leu Ala Ile Ala Met Leu Gln Lys Met Phe Arg 195 200 205Asp Asp Arg His Gly Val Val Pro Asp Ile Arg Leu Leu Asp Glu Ile 210 215 220Ala Ser His Cys His Gln Gly Gly Leu Ser Ala Trp Val Cys Phe Asp225 230 235 240Val Ile Trp Pro Ile Lys His Ala Leu Asp Lys Glu Tyr Phe Phe Ser 245 250 255Asp Ala Gly Ala Thr Leu Asn Leu Leu Asn Arg Ile Tyr Val Ser Ala 260 265 270Cys Ser Asn Ile Lys Gln Val Asp Ala Ile Thr Pro Glu Arg Ile Ala 275 280 285Val Cys Glu Asn Leu Asp Phe Leu Leu Lys Val Pro Gln Ser Thr Glu 290 295 300Gly Glu Lys Thr Pro Ala Phe Lys Val Asn Thr Ala Leu Lys Tyr Glu305 310 315 320Ile Ser Ile Gln Gly Glu Gly Arg Val Leu Tyr Asp Asn Cys Ser Leu 325 330 335Asn Leu Thr Ile Ile Thr Pro Pro Asp Cys Asn Ile Lys Thr Ser Pro 340 345 350Pro Leu Leu Phe Arg Val Cys Pro Pro Leu Gly Arg Leu Leu Leu Arg 355 360 365Leu Lys His Arg Phe Tyr Lys Arg Lys Val Phe Thr Pro Gln Asp Thr 370 375 380Arg Val Pro Asp Pro Thr Leu Val Arg Val Gln Arg Ile Pro Cys Ile385 390 395 400Gly Met Asn Ile Thr Lys Leu Gln Tyr Ala Met Ala Pro Leu Pro Val 405 410 415Ser Pro Glu Glu Phe Phe Arg Asp Leu Val Lys Asn Ser Thr Ile Cys 420 425 430Gly Ile Tyr Ile Met Thr Ser Ser Leu Arg Lys Cys Ile Trp Gln Ser 435 440 445Leu Asn Pro Asn Met Leu Arg Leu Met Phe Leu Arg His Met Met Met 450 455 460 378 amino acids amino acid linear protein 70Ile Leu Arg Phe Ser Asp Asp Phe Pro Asp Ala Lys Val Ile Arg Leu1 5 10 15Glu Cys Asn Tyr Arg Ser Thr Ser Asn Ile Leu Ala Ser Ala Ser Ala 20 25 30Ile Ile Asp Asn Asn Lys Ser Arg Leu Lys Lys Thr Leu Trp Thr His 35 40 45Asn Gln Ala Gly Gln Lys Val Gly Leu Met Lys Phe Phe Asp Gly Arg 50 55 60Leu Glu Ala Gln Tyr Ile Ser Glu His Ile Lys Ser Ser Tyr Asp Tyr65 70 75 80Lys Phe Ser Glu Thr Ala Val Leu Val Arg Ala Ser Phe Gln Thr Arg 85 90 95Val Phe Glu Glu Phe Phe Val Arg Tyr Gly Ile Pro Tyr Lys Ile Ile 100 105 110Gly Gly Thr Lys Phe Tyr Asp Arg Val Glu Ile Arg Asp Leu Val Ala 115 120 125Tyr Leu Lys Val Val Val Asn Pro Asn Asn Asp Ile Ala Phe Glu Lys 130 135 140Ile Ile Asn Lys Pro Lys Arg Lys Leu Gly Thr Ser Thr Val Asn Lys145 150 155 160Leu Arg Ala Tyr Gly Arg Lys His Ser Ile Ser Leu Thr Glu Ala Gly 165 170 175His Ser Met Ile Lys Asp Gly Leu Leu Ser Asp Asn Thr Ser Asn Ile 180 185 190Leu Gln Asp Leu Leu Lys Gln Phe Asp Asp Trp Arg Glu Met Leu Ser 195 200 205Arg Asp Ser Ser Val Asn Val Leu Lys Ala Ile Ala His Asp Ser Gly 210 215 220Tyr Ile Glu Ser Leu Lys Lys Asp Gly Glu Ser Gly Leu Ser Arg Ile225 230 235 240Glu Asn Ile Lys Glu Leu Phe Ser Ala Val Ser Gly Phe Asp Asp Val 245 250 255Ser Lys Phe Leu Glu His Ile Ser Leu Val Ala Glu Asn Asp Ser Leu 260 265 270Glu Glu Asp Asn Asn Tyr Val His Val Met Thr Leu His Ala Ala Lys 275 280 285Gly Leu Glu Phe Pro Leu Val Phe Leu Pro Gly Trp Glu Glu Gly Val 290 295 300Phe Pro His Glu Lys Ser Met Asn Asp Ile Thr Gly Asn Ala Leu Glu305 310 315 320Glu Glu Arg Arg Leu Ala Tyr Val Gly Ile Thr Arg Ala Arg Glu Gln 325 330 335Leu Tyr Ile Ser Cys Ala Ala Met Arg Glu Ile Asn Asn Trp Ser Gln 340 345 350Ser Met Lys Met Ser Arg Phe Ile Lys Glu Leu Pro Arg Glu His Val 355 360 365Gln Val Leu His Asn Met Thr Gly Tyr Ala 370 375 209 amino acids amino acid linear protein 71Tyr Ile Asp Ser Leu Arg Ser His Ser Leu Leu Leu Lys Arg Lys Thr1 5 10 15Lys Gly Ile Arg Asp Ser Gly Ser Lys Glu Asp Glu Ala Asp Thr Val 20 25 30Tyr Leu Leu Ala Lys Glu Leu Ala Tyr Asp Val Val Thr Gly Gln Thr 35 40 45Asp Asn Leu Ala Ala Ala Leu Ala Lys Thr Ser Gly Lys Asp Phe Val 50 55 60Lys Phe Ala Asn Ala Val Val Gly Ile Ser His Pro Asp Val Asn Lys65 70 75 80Lys Val Cys Ala Thr Arg Lys Asp Ser Gly Gly Thr Arg Tyr Ala Lys 85 90 95Tyr Ala Ala Thr Thr Asn Lys Ser Ser Asn Pro Glu Thr Ser Leu Cys 100 105 110Gly Asp Glu Gly Gly Ser Ser Gly Thr Asn Asn Thr Gln Glu Phe Leu 115 120 125Lys Glu Phe Val Ala Lys Thr Leu Val Glu Asn Glu Ser Lys Asn Trp 130 135 140Pro Thr Ser Ser Gly Thr Gly Leu Lys Thr Asn Asp Asn Ala Lys Ala145 150 155 160Val Ala Thr Asp Leu Val Ala Leu Asn Arg Asp Glu Lys Thr Ile Val 165 170 175Ala Gly Leu Leu Ala Lys Thr Ile Glu Gly Gly Glu Val Val Glu Ile 180 185 190Arg Ala Val Ser Ser Thr Ser Val Met Ala Leu Glu Leu Arg Val Cys 195 200 205Trp 261 amino acids amino acid linear protein 72Lys Lys Ser Ile Ile Arg Glu Asp Glu Val Asp Thr Val Tyr Leu Leu1 5 10 15Ala Lys Glu Leu Ala Tyr Asp Val Val Thr Gly Gln Thr Asp Lys Leu 20 25 30Thr Ala Ala Leu Ala Lys Thr Ser Gly Lys Asp Ile Val Gln Phe Ala 35 40 45Lys Ala Val Gly Val Ser His Pro Ser Ile Asp Gly Lys Val Cys Arg 50 55 60Thr Lys Arg Lys Ala Gly Asp Ser Ser Gly Thr Tyr Ala Lys Tyr Gly65 70 75 80Glu Glu Thr Asp Asn Asn Thr Ser Gly Gln Ser Thr Val Ala Val Cys 85 90 95Gly Glu Lys Ala Gly His Asn Ala Asn Gly Ser Gly Thr Val Gln Ser 100 105 110Leu Lys Asp Phe Val Arg Glu Thr Leu Lys Ala Asp Gly Asn Arg Asn 115 120 125Trp Pro Thr Ser Arg Glu Lys Ser Gly Asn Thr Asn Thr Lys Pro Gln 130 135 140Pro Asn Asp Asn Ala Lys Ala Val Ala Lys Asp Leu Val Gln Glu Leu145 150 155 160Asn His Asp Glu Lys Thr Ile Val Ala Gly Leu Leu Ala Lys Thr Ile 165 170 175Glu Gly Gly Glu Val Val Glu Ile Arg Ala Val Ser Ser Thr Ser Val 180 185 190Met Val Asn Ala Cys Tyr Asp Leu Leu Ser Glu Gly Leu Gly Val Val 195 200 205Pro Tyr Ala Cys Val Gly Leu Gly Gly Asn Phe Val Gly Val Val Asp 210 215 220Gly His Ile Thr Ile Arg Trp Ala Ser Thr Leu Tyr Ala His Ser Lys225 230 235 240Ser Leu Gly Lys Ile Gly Ala Ala Ser Leu Arg Asn Arg Leu Arg Ser 245 250 255Ala Ile Leu His Thr 260 530 amino acids amino acid linear protein 73Leu Leu Tyr Ser Phe Gly Asn Leu Thr Ser Tyr Gly Arg Ser Val Met1 5 10 15Arg Ser Arg Lys Ile Tyr Val Trp Val Val Met Ala Thr Val Leu Gly 20 25 30Ala Met Ala Phe Val Thr Phe Gly Ser Met Ile Pro Met Gly Lys Leu 35 40 45Ser Asn Ser Gly Asn Gly Gln Cys Val Ala Met Leu Gly Asn Lys Cys 50 55 60Leu Pro Leu Arg Asp Tyr Arg Ile Met Tyr Arg Asn Glu Leu Ala Glu65 70 75 80Leu Glu Lys Met Leu Gln His Lys Leu Ser Asp Ala Gln Ile Asn Gln 85 90 95Phe Gly Ile Lys Glu Val Val Leu Lys Asn Met Ile Ala Asp Met Val 100 105 110Val Glu Lys Phe Ala His Asp Leu Gly Ile Arg Val Gly Ser Asn Ser 115 120 125Leu Arg Ser Leu Ile Lys Asn Ile Arg Ile Phe Gln Asp Ala Asn Gly 130 135 140Val Phe Asp Gln Glu Arg Tyr Glu Ala Val Leu Ala Asp Ser Gly Met145 150 155 160Thr Glu Ser Ser Tyr Val Asn Lys Ile Arg Asn Ala Leu Pro Ser Thr 165 170 175Ile Leu Met Glu Cys Leu Phe Pro Asn Arg Ala Glu Leu His Ile Pro 180 185 190Tyr Tyr Asp Ala Leu Ala Lys Asp Val Val Leu Gly Leu Leu Gln His 195 200 205Arg Val Ala Asp Ile Val Glu Ile Ser Ser Asp Ala Val Asp Ile Ser 210 215 220Gly Ser Asp Ile Ser Asp Asp Glu Leu Gln Lys Leu Phe Glu Glu Gln225 230 235 240Tyr Lys Asn Ser Leu Asn Phe Pro Glu Tyr Arg Ser Ala Asp Tyr Ile 245 250 255Ile Met Ala Glu Asp Asp Leu Leu Ala Asp Val Ile Val Ser Asp Gln 260 265 270Glu Val Asp Val Glu Ile Lys Asn Ser Glu Leu His Asp Gln Arg Asp 275 280 285Val Leu Asn Leu Val Phe Thr Asp Lys Asn Glu Ala Glu Leu Ala Tyr 290 295 300Lys Ala Tyr Gln Glu Gly Lys Ser Phe Glu Glu Leu Val Ser Asp Ala305 310 315 320Gly Tyr Thr Ile Glu Asp Ile Ala Leu Asn Asn Ile Ser Lys Asp Val 325 330 335Leu Pro Val Gly Val Arg Asn Val Val Phe Ala Leu Asn Glu Gly Glu 340 345 350Val Ser Glu Met Phe Arg Ser Val Val Gly Trp His Ile Met Lys Val 355 360 365Ile Arg Lys His Glu Ile Thr Lys Glu Asp Leu Glu Lys Leu Lys Glu 370 375 380Lys Ile Ser Ser Asn Ile Arg Arg Gln Lys Ala Gly Glu Leu Leu Val385 390 395 400Ser Asn Val Lys Lys Ala Asn Asp Met Ile Ser Arg Gly Ala Leu Leu 405 410 415Asn Glu Leu Lys Asp Met Phe Gly Ala Arg Ile Ser Gly Val Leu Thr 420 425 430Asn Phe Asp Met His Gly Leu Asp Lys Ser Gly Asn Leu Val Lys Asp 435 440 445Phe Pro Leu Gln Leu Gly Ile Asn Ala Phe Thr Thr Leu Ala Phe Ser 450 455 460Ser Ala Val Gly Lys Pro Ser His Leu Val Ser Asn Gly Asp Ala Tyr465 470 475 480Phe Gly Val Leu Val Thr Glu Val Val Pro Pro Arg Pro Arg Thr Leu 485 490 495Glu Glu Ser Arg Ser Ile Leu Thr Glu Glu Trp Lys Ser Ala Leu Arg 500 505 510Met Lys Lys Ile Arg Glu Phe Ala Val Glu Leu Arg Ser Lys Leu Gln 515 520 525Asn Gly 530

Claims

1. A fusion protein comprising at least 10 contiguous amino acids of an amino acid sequence encoded by DNA sequence SEQ ID NO:1.

2. A fusion protein comprising at least 10 contiguous amino acids of SEQ ID NO:8.

3. A diagnostic kit comprising:(a) at least one fusion protein according to any one of claims 1 and 2; and (b) a detection reagent.

4. The kit of claim 3 wherein the fusion protein is immobilized on a solid support.

5. The kit of claim 4 wherein the solid support is selected from the group consisting of nitrocellulose, latex, and plastic materials.

6. The kit of claim 3 wherein the detection reagent comprises a reporter group conjugated to a binding agent.

7. The kit of claim 6 wherein the binding agent is selected from the group consisting of anti-immunoglobulins, Protein G, Protein A and lectins.

8. The kit of claim 6 wherein the reporter group is selected from the group consisting of radioisotopes, fluorescent groups, luminescent groups, enzymes, biotin and dye particles.

9. A diagnostic kit comprising:(a) at least one fusion protein according to any one of claims 1 and 2; (b) a Lyme disease antigen; (c) a B. microti antigen; and (d) a detection reagent.

10. The kit of claim 9, wherein the detection reagent comprises a reporter group conjugated to a binding agent.

11. The kit of claim 10, wherein the binding agent is selected from the group consisting of anti-immunoglobulins, Protein G, Protein A and lectins.

12. The fusion protein of any one of claims 1 and 2 further comprising a Lyme Disease antigen.

13. The fusion protein of any one of claims 12, 1, and 2 further comprising a Babesia microti antigen.

14. A diagnostic kit according to claim 3 further comprising at least one antigen selected from the group consisting of: Lyme disease antigens; and Babesis microti antigens.